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ABSTRACT 
Stacy E. Dixon 
 
GCN5-B IS A NOVEL NUCLEAR HISTONE ACETYLTRANSFERASE THAT IS 
CRUCIAL FOR VIABILITY IN THE PROTOZOAN PARASITE TOXOPLASMA GONDII 
 
Infection with the single-celled parasite Toxoplasma gondii (phylum 
Apicomplexa) is usually benign in normal healthy individuals, but can cause congenital 
birth defects, ocular disease, and also life-threatening infection in immunocompromised 
patients.  Acute infection caused by tachyzoites is controlled by a healthy immune 
response, but the parasite differentiates into a latent cyst form (bradyzoite) leading to 
permanent infection and chronic disease.  Current therapies are effective only against 
tachyzoites, are highly toxic to the patient, and do not eradicate the encysted 
bradyzoites, thus highlighting the need for novel therapeutics.  Inhibitors of histone 
deacetylases have been shown to reduce parasite viability in vitro demonstrating that 
chromatin remodeling enzymes, key mediators in epigenetic regulation, might serve as 
potential drug targets.  Furthermore, epigenetic regulation has been shown to contribute 
to gene expression and differentiation in Toxoplasma.  This dissertation focused on 
investigating the physiological role of a Toxoplasma GCN5-family histone 
acetyltransferase (HAT), termed TgGCN5-B.  It was hypothesized that TgGCN5-B is an 
essential HAT that resides within a unique, multi-subunit complex in the parasite 
nucleus.  Studies of TgGCN5-B have revealed that this HAT possesses a unique nuclear 
localization signal (311RPAENKKRGR320) that is both necessary and sufficient to 
translocate the protein to the parasite nucleus.  Although no other protein motifs have 
been identified in the N-terminal extension of TgGCN5-B, it is likely that this extension 
plays a role in protein-protein interactions.  All GCN5 homologues function within large 
vii 
 
multi-subunit complexes, many being conserved among species, but bioinformatic 
analysis of the Toxoplasma genome revealed a lack of many of these conserved 
components.  Biochemical studies identified several potential TgGCN5-B associating 
proteins, including several novel apicomplexan transcription factors.  Preliminary 
evidence suggested that TgGCN5-B was essential for tachyzoites; therefore, a 
dominant-negative approach was utilized to examine the role of TgGCN5-B in the 
physiology of Toxoplasma.  When catalytically inactive TgGCN5-B protein was over-
expressed in the parasites, there was a significant decrease in tachyzoite growth and 
viability, with initial observations suggesting defects in nuclear division and daughter cell 
budding.  These results demonstrate that TgGCN5-B is important for tachyzoite 
development and indicate that therapeutic targeting of this HAT could be a novel 
approach to treat toxoplasmosis. 
 
 
William J. Sullivan, Jr., Ph.D. – Chairman 
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Chapter 1:  Introduction and Literature Review 
The study of epigenetics has revolutionized the understanding of gene 
expression and regulation in a multitude of organisms including the medically relevant 
pathogen Toxoplasma gondii.  Epigenetics, defined as changes to a genetic locus not 
encoded by the underlying DNA sequence, encompasses a number of coordinated 
cellular phenomena that impact the degree of gene expression [1].  These alterations 
allow for the same genome to give rise to a variety of phenotypes, which is particularly 
important for pathogens such as Toxoplasma that have complex life cycles involving 
multiple stages.  The pharmacological exploitation of epigenetic mechanisms has arisen 
as a promising avenue for new drug discoveries towards several pathogens.  This thesis 
will describe an enzyme involved in the epigenetic regulation of gene expression in the 
parasite Toxoplasma gondii and the potential of that enzyme as a therapeutic target. 
 
I.  Toxoplasma is a successful pathogen 
 
Toxoplasma is one among several human and animal pathogens in the phylum 
Apicomplexa.  The apicomplexans are a large and diverse group of unicellular protozoan 
parasites with an expansive environmental distribution.  The majority of the parasites 
from this phylum are obligate intracellular parasites with complex life cycles that involve 
both asexually reproducing forms and sexual stages.  The name of the phylum is derived 
from a group of unique organelles at the apical end that these parasites possess.  The 
apicoplast is a multiple-membrane bound organelle acquired through a secondary 
endosymbiotic event and thought to be derived from chloroplasts [2,3].  Although no 
longer capable of photosynthesis, this organelle is essential to the apicomplexans, and it 
is believed that its primary function is the synthesis of fatty acids, isoprenoids, and heme 
[2,3].  The apical complex consists of multiple secretory organelles such as micronemes 
and rhoptries that are necessary for interaction and invasion of host cells by 
apicomplexans [4]. 
A.  Toxoplasma is a model apicomplexan parasite 
 The apicomplexan parasites that commonly infect humans cause a variety of 
diseases and affect diverse populations.  The parasites Cystoisospora, Cyclospora, and 
Sarcosystis are all intestinal pathogens that rarely cause disease in the United States.  
Cryptosporidium is another apicomplexan intestinal pathogen that usually infects 
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immunocompromised individuals such as AIDS patients.  However, Cryptosporidium had 
its fifteen minutes of parasitic fame in 1993 when it contaminated the water supply of 
Milwaukee, Wisconsin, causing diarrheal disease in over 400,000 people [5].  Babesia is 
a parasite that is spread by certain species of ticks throughout the northeast United 
States.  Infection is usually asymptomatic although in some cases, babesiosis can result 
in a hemolytic anemia that requires treatment.  By far, the most infamous apicomplexan 
parasite is Plasmodium, the causative agent of malaria. This pathogen is also spread via 
an insect, but in this case it is the mosquito.  About one-half of the world’s population is 
at risk for infection with Plasmodium, and each year there are approximately 250 million 
cases of malaria worldwide, resulting in nearly one million deaths [6].  The countries 
prone to endemic malaria include many of the world’s poorest countries, and those most 
vulnerable to death from the disease are children.  Unfortunately, attempts to control the 
spread of malaria are complicated by the ease with which the parasite has become 
resistant to common treatment options.  This situation has resulted in a substantial 
worldwide health economic burden and necessitates the development for new 
pharmacological agents to combat this pathogenic menace.  Like its cousin Plasmodium, 
Toxoplasma is also present at high concentrations worldwide with approximately one-
third of the world’s population being infected [7].  Although this infection is life-long, most 
affected individuals are asymptomatic.  Toxoplasma is mostly known as an opportunistic 
pathogen causing disease in immunocompromised individuals, although the parasite is 
also associated with congenital infections as well as ocular disease.  The human 
pathogenic members of the phylum Apicomplexa represent a diverse array of clinical 
diseases and account for a significant worldwide health burden. 
In addition, several apicomplexans are animal pathogens.  Toxoplasma can 
infect virtually any warm-blooded vertebrate, making it a pathogen to livestock and 
domestic animals as well as humans.  In particular, infection with Toxoplasma has a 
significant impact on sheep and is a common cause of abortion in ewes, necessitating a 
vaccine to protect herds [8].  Neospora and Theileria are both pathogens of cattle while 
Eimeria is a common infective agent of poultry.  The prominent global prevalence of the 
apicomplexan parasites and their ability to infect a multitude of hosts necessitates the 
need to understand the biology of these ancient protozoans. 
 Toxoplasma is considered a model apicomplexan because the parasites are 
easy to propagate in vitro, there is an established mouse model of infection, and 
Toxoplasma is amenable to genetic manipulation [9,10].  Many of the initial 
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characterization studies of apicomplexan cellular biology such as invasion, motility, and 
function of the apicoplast were first investigated in Toxoplasma [10].  Toxoplasma is an 
experimentally tractable organism, and both classical and reverse genetic techniques 
have been implemented to study a variety of cellular processes.  Additionally, 
Toxoplasma was one of the first apicomplexans to have its genome fully sequenced 
(12X coverage) with a database created to house the information and provide access to 
researchers (http://ToxoDB.org) [11].  Recently, many of the techniques initially 
established in Toxoplasma have been developed for other parasites, and genomic 
sequencing of other apicomplexans has been completed. 
 
 The life cycle of Toxoplasma is complex with sexual reproduction of the parasite 
taking place only within cats and other felids, its definitive hosts.  However, the parasite 
can replicate asexually in a vast range of intermediate hosts, which include virtually all 
warm-blood vertebrates.  With such a broad host range, Toxoplasma is a ubiquitous 
parasite with an expansive geographical distribution.  The parasite is found in both 
temperate and tropical climates alike and does not demonstrate seasonal variation [12]. 
B.  The life cycle of Toxoplasma 
 The three principal stages of Toxoplasma include the tachyzoite, bradyzoite, and 
sporozoite.  Tachyzoites are the rapidly replicating, asexual form of the parasite, capable 
of infecting any nucleated cell.  Tachyzoites divide via a specialized process termed 
endodyogeny, in which two identical daughter cells develop and then consume the 
mother cell after budding.  As the proliferative form of the parasite, tachyzoites are 
responsible for tissue destruction and diseases associated with Toxoplasma infection.  
When under stress, such as from the immune response of the host, tachyzoites have the 
ability to differentiate into a quiescent form termed the bradyzoite.  Bradyzoites are 
slowly developing tissue cysts that have a predilection for muscle tissue and the central 
nervous system.  Bradyzoites are capable of evading the immune response and result in 
a latent, chronic lifelong infection of the host.  The tachyzoite and bradyzoite stages, 
which are both haploid, are the only forms capable of replicating in intermediate hosts. 
 When a cat eats a mouse or any other animal that has a latent infection of 
Toxoplasma (contains bradyzoites), the parasite undergoes a series of differentiating 
events through several additional life stages within the epithelial cells in the small 
intestine of the cat.  This process eventually results in the production of the sexually 
reproducing forms of Toxoplasma, the microgametocytes (males) or macrogametocytes 
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(females).  Upon parasite sexual reproduction, oocysts are formed and shed into the 
environment through the feces of the cat.  Oocysts are highly infectious and resistant to 
environmental insults, allowing them to persist for long periods of time.  Initially, the 
oocysts are unsporulated.  Sporulation, resulting in infectious sporozoites, occurs one to 
five days after excretion of the oocyst from the cat [13].  Once an intermediate host 
becomes infected with an oocyst, sporozoites are released into the intestinal lumen 
where they can then invade and differentiate into tachyzoites, which are able to 
disseminate throughout the body, thus completing the Toxoplasma life cycle.  Figure 1 
summarizes the life cycle and developmental stages of Toxoplasma. 
 The production of oocysts is critical for the propagation of the parasite and 
accounts for the coccidian classification of Toxoplasma.  Typically, a cat will only shed 
oocysts once in its life, after its initial infection [14].  However, it is estimated that even 
after the ingestion of only a few bradyzoites, a cat is capable of shedding millions of 
oocysts, resulting in extensive environmental contamination [15].  Not only are oocysts 
able to withstand environmental conditions and remain viable for months, but they are 
also resistant to disinfectants.  However, oocysts are destroyed at temperatures above 
60o
  
C [16].  Intermediate hosts such as livestock become infected with Toxoplasma when 
they ingest oocysts from the soil or those found on food sources.  Humans become 
infected through the ingestion of oocysts from unwashed fruits, vegetables, or 
contaminated water.  For humans, oocysts are the most infectious form of Toxoplasma, 
more so than bradyzoites or tachyzoites, and a single oocyst can result in an infection 
[17,18].  Humans can also become infected with Toxoplasma through the consumption 
of undercooked meat containing tissue cysts. 
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Figure 1:  Life cycle and transmission of Toxoplasma.  The definitive host of 
Toxoplasma is the cat (or other felids), and it is within the cat’s gut that the sexual cycle 
of the parasites takes place, resulting in the formation of oocysts.  An infected cat will 
shed highly infectious oocysts into the environment.  Intermediate or dead-end hosts will 
consume oocysts, resulting in a chronic infection of Toxoplasma with bradyzoite cysts 
residing in the CNS and muscle tissue.  When a cat eats a chronically infected rodent, 
the parasite’s sexual cycle is completed.  If humans consume oocysts from the 
environment (through contaminated water, on unwashed fruits and vegetables, or after 
eating undercooked meat containing tissue cysts), they become infected.  Tachyzoites 
are the active form of the parasite responsible for tissue destruction and disease 
symptoms.  Tachyzoites can cross the placenta and cause congenital infection of the 
fetus if a woman becomes infected for the first time during pregnancy.  Figure adopted 
from Dubey et al. (1998) and http://www.toxomap.wustl.edu/life_c4.jpg [13]. 
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C.  Clinical toxoplasmosis 
   While the vast majority of the world’s population is at risk for acquiring 
Toxoplasma, very few people will ever experience overt disease.  The leading 
complications associated with infection by Toxoplasma include congenital birth defects 
and opportunistic disease although other complications exist, including ocular disease 
and an association with neurological and psychiatric disorders. 
Many factors contribute to how Toxoplasma will affect its human host, one being 
the strain of the parasite causing the infection.  Toxoplasma is highly clonal.  The three 
strains that cause the vast majority of infections in humans differ from one another 
genetically by only 1% [19,20].  These strains, termed types I, II, or III, appear to have 
shared a common ancestor approximately 10,000 years ago [21].  Types I, II, and III 
strains of Toxoplasma have distinct phenotypic characteristics [19,20,22].  Type I strains 
are extremely virulent, grow faster than the other types in culture, and do not convert to 
bradyzoites in vitro.  Types II and III are avirulent and are capable of in vitro and in vivo 
differentiation.  The majority of human infections are attributed to the type II strain of 
Toxoplasma although any of the strains are capable of infecting humans.  There can 
also be variations and atypical genotypes of Toxoplasma that diverge from the three 
main lineages [23].  The manifestations of toxoplasmosis in humans vary, and this may 
in part be attributed to the strain of Toxoplasma although others factors such as the 
health and genetic background of the host and environmental conditions may also 
contribute. 
 Roughly one-third of the world’s population is infected with Toxoplasma; 
however, the prevalence varies region to region.  For instance, in France, where more 
undercooked meat is eaten, approximately 80% of the population is seropositive for 
Toxoplasma while, in the United States between 16-40% are infected [7].  When humans 
acquire Toxoplasma postnatally, they are usually asymptomatic or develop mild disease.  
Common clinical signs are nonspecific, but can include cervical lymphadenopathy, fever, 
fatigue, and malaise.  The disease is self-limiting and usually resolves without treatment.  
However, due to the life cycle of Toxoplasma, infection is life-long due to bradyzoite 
cysts residing permanently in host tissues. 
 Toxoplasmosis is a disease common to persons with immunosuppression.  
Patients under immunosuppression therapy after transplants and those persons who 
become immunocompromised due to certain malignancies are at risk.  Toxoplasmosis is 
also a serious complication that has arisen with the advent of the HIV/AIDS pandemic.  
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In general, toxoplasmosis in the immunocompromised population results from 
reactivation of disease.  Those persons who are chronically infected with the parasite 
and possess latent bradyzoite cysts are at risk for recrudescence of the bradyzoites into 
the actively destructive tachyzoites upon impairment of immunity.  Because bradyzoites 
tend to reside in the CNS, the most common clinical manifestation for this form of 
toxoplasmosis is encephalitis.  Patients often present with headache, confusion, motor 
weakness, and fever.  Speech abnormalities and hemiparesis are the most common 
neurological findings [24].  If untreated, the disease can progress to seizures, stupor, 
coma, and even death.  The predominant lesion of toxoplasmic encephalitis is cerebral 
necrosis, particularly of the thalamus [25].  Other clinical manifestations include 
chorioretinitis, pneumonia, myocarditis, and disseminated systemic disease. 
 Toxoplasma is capable of vertical transmission through its ability to cross the 
placenta of an infected female, resulting in congenital disease in the fetus.  In the United 
States, 85% of women of childbearing age are susceptible to acute infection with 
Toxoplasma [26].  Congenital transmission occurs if a woman becomes infected with 
Toxoplasma for the first time during pregnancy.  Risk of infection of the fetus is lowest 
during the first trimester and highest in the third trimester.  Overall, the congenital 
infection risk is approximately 20 to 50% [27].  The severity of congenital disease is 
inversely related to the infection risk, with infection acquired during the first trimester 
being the most severe.  If a pregnant woman is confirmed to be infected with 
Toxoplasma as determined by IgG and IgM antibody levels, the fetus can be tested by 
diagnostic PCR screening of the amniotic fluid [28].  Congenital infection can result in 
spontaneous abortion or still birth.  In a live infant, congenital toxoplasmosis can 
manifest as the classic triad of symptoms, which includes chorioretinitis, hydrocephalus, 
and intracranial calcifications.  However, clinical manifestations can be nonspecific and 
include convulsions, growth and mental retardation, learning disabilities, deafness, visual 
impairment, hepatosplenomegaly, and lymphadenopathy to name a few [26].  Most 
children are asymptomatic at birth but can develop sequelae such as ocular or 
neurological disease (learning disabilities) later in life [26,29,30].  It is estimated that 400 
to 4,000 cases of congenital toxoplasmosis occur in the United States each year, 
resulting in a large healthcare economic burden due to the life-long sequelae associated 
with the disease [26]. 
 Toxoplasma infection in humans can also present as ocular disease resulting 
from congenital disease, postnatal acquisition, or reactivation of latent infection.  
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Typically, ocular toxoplasmosis presents as posterior uveitis with the retina being the 
primary site of infection (retinitis).  The choroid, the layer of blood vessels and 
connective tissue in the middle part of the eye, is often affected along with the retina, 
resulting in chorioretinitis.  Other structures that can be infected include the vitreous, 
anterior chamber, or optic nerve [31,32].  Common symptoms include pain, redness, 
photophobia, and decreased vision.  Congenital ocular toxoplasmosis tends to be 
bilateral, with multiple lesions located particularly in the macula, which can result in 
blindness [33].  Postnatally acquired disease is often unilateral and involves a focal area 
[33].  Most postnatally acquired ocular toxoplasmosis is identified in the second through 
fourth decades of life [34].  The major complication of ocular toxoplasmosis is 
recurrence, which can occur at any age [35].  Recurrence not only involves a similar 
pathology, as outlined above, but is also associated with additional complications such 
as neovascularization and retinal detachment [32].  Ocular toxoplasmosis may be more 
common than originally thought; a survey by Lum et al. (2005) estimated that in a 2-year 
period there were over 250,000 visits to ophthalmologists for active or inactive ocular 
toxoplasmosis in the United States [36]. 
For many years, latent toxoplasmosis was considered innocuous; however, 
recent studies suggest that this might not be the case.  Due to its predilection to reside in 
the brain and CNS, Toxoplasma may alter the behavior of its host, a characteristic 
believed to enhance its transmission rate.  This phenomenon has been termed the 
manipulation hypothesis [37].  Rodents chronically infected with Toxoplasma not only 
loose their innate fear of cat odors, but in effect became more attracted to them, thereby 
increasing the likelihood of being devoured by cats, resulting in Toxoplasma completing 
its sexual cycle [38,39,40,41].  In humans, infection with Toxoplasma has been linked to 
schizophrenia.  Several studies, including a meta-analysis, demonstrate that individuals 
with schizophrenia and other psychoses have an increased prevalence of Toxoplasma 
infection based on seroconversion [42,43,44].  Interestingly, the genome of Toxoplasma 
was found to contain two homologues of tyrosine hydrolase, a key enzyme in the 
generation of dopamine [45].  Dopamine is a major neurotransmitter in the brain that is 
involved in many functions, including behavior and the reward system, and is also linked 
to schizophrenia [46].  It has been hypothesized that Toxoplasma might be able to 
manipulate behavior through modulation of dopamine within the brain of the host [45].  
Additionally, serological evidence of Toxoplasma infection has been linked to increased 
tendency to have risk-taking behavior in humans.  Studies show that infected humans 
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have an increased incidence of automobile accidents compared to controls [47,48].  The 
ability of Toxoplasma to manipulate its host is a fascinating subject that deserves further 
research in order to understand the implications of latent toxoplasmosis on humans. 
 In summary, Toxoplasma is a ubiquitous parasite that is responsible for a broad 
spectrum of clinical diseases in humans.  Although approximately one-third of the 
world’s population has been exposed to the parasite, most will not demonstrate clinical 
disease [49].  However, those that are congenitally infected, are immunosuppressed, or 
suffer from ocular toxoplasmic disease represent a significant health burden due to the 
reoccurring nature of the disease.  Additionally, the implied roles of Toxoplasma in 
schizophrenia and host behavior manipulation extend the impact of the parasite on 
human health.  Therefore, toxoplasmosis has a significant impact on the health and 
socio-economic state of the world. 
 
D.  Treatment for toxoplasmosis 
 The standard therapy for toxoplasmosis is a combination of pyrimethamine and 
sulfonamides (such as sulfadiazine or sulfadoxine), which are folate antagonists.  
Pyrimethamine, a competitive inhibitor of dihydrofolate reductase (DHFR), has a narrow 
therapeutic window and is only about six-fold more selective for Toxoplasma DHFR as 
compared to the mammalian enzyme [50].  Therefore, it is necessary to co-administer 
folinic acid as a supplement during treatment to minimize toxicity associated with 
pyrimethamine [51].  Folinic acid cannot by scavenged by the parasites; therefore, it will 
not interfere with therapy [52].  However, even with the administration of folinic acid, 
some patients will still experience adverse side effects of pyrimethamine treatment, 
which include thrombocytopenia and leucopenia [53].  Sulfonamides competitively inhibit 
the parasite enzyme dihydropteroate synthetase (DHPS), an enzyme not found in 
mammalian cells.  An important difficulty with treatments involving sulfonamides is the 
propensity of patients to develop allergic reactions, resulting in rashes or, in extreme 
cases, Stevens-Johnson syndrome.  Sulfonamides can also cause bone marrow 
suppression.  In fact, 40 – 50% of patients treated with pyrimethamine and sulfonamides 
develop adverse effects, thus complicating the long-term prophylactic treatment needed 
for susceptible immunocompromised patients [54].  Alternative treatment options for 
toxoplasmosis include clindamycin, azithromycin, or atovoquone.  Clindamycin and 
azithromycin both are antibiotics that inhibit protein synthesis and result in the loss of the 
apicoplast of Toxoplasma [55,56].  Atovoquone, a hydroxynaphthoquinone, is presumed 
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to inhibit the electron transport chain within the mitochondria.  Often, corticosteroids are 
co-administered with Toxoplasma treatment regimes to reduce inflammation, particularly 
in ocular toxoplasmosis. 
Special consideration for treatment of toxoplasmosis must be implemented in 
pregnant females.  If the woman is infected but not the fetus, then spiramycin should be 
administered since this drug is unable to cross the placenta.  If the fetus has acquired 
congenital toxoplasmosis, then the standard treatment of pyrimethamine, sulfadiazine, 
and folinic acid should be administered to the mother.  However, pyrimethamine should 
not be given in the first 14 – 16 weeks of pregnancy due to the teratogenic nature of the 
drug during early fetal development [57]. 
Interestingly, drug resistance is rarely a complication of treating toxoplasmosis, 
because if resistance arises during clinical treatment, it cannot be readily transmitted.  
Humans are dead-end hosts for Toxoplasma and therefore do not contribute to the 
propagation of the parasite. 
Aside from the mentioned side effects of each treatment regimen, the major 
caveat with current therapies is that none are capable of eliminating bradyzoite cysts, 
the latent form of toxoplasmosis.  Bradyzoite cysts are quiescent and metabolically 
inactive; therefore, the current regimens that target active metabolic processes such as 
folate and protein synthesis are ineffective.  This limitation is a significant disadvantage, 
making infection with Toxoplasma impossible to clear.  Therefore, in susceptible 
populations such as immunocompromised human patients, reoccurrence of active 
disease is always a threat.  This disadvantage necessitates the need to develop novel 
therapies that not only reduce toxicity but also eliminate or inhibit the recrudescence of 
latent bradyzoite cysts. 
 
II.  Epigenetics and chromatin remodeling 
 
A.  Definition of epigenetics 
All nucleated cells in a human body contain the exact same genetic material.  
The DNA code or genetic sequence does not vary from hepatocyte to astrocyte, yet 
these two cell types are extremely different.  How can an identical genetic code be read 
and interpreted in such variant manners as to produce such diverse cell types?  The 
same question can be applied to protozoan parasites such as Toxoplasma.  How can 
the same genetic code give rise to both a tachyzoite and a bradyzoite, two very distinct 
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life stages?  Something beyond or above the genetic code must be contributing to the 
phenotype of individual cells, something epigenetic.  Hence, the field of epigenetics was 
born. 
Epigenetics is most basically defined as changes to a genetic locus not encoded 
by the underlying DNA sequence [1].  These changes account for a number of cellular 
phenomena that alter the degree of gene expression.  By regulating the level of gene 
expression, the same genetic code can give rise to a multitude of phenotypes.  In 
essence, the field of epigenetics investigates the cellular mechanisms that control how 
the genetic code is interpreted.  Epigenetic control is critical not only for development 
and differentiation, but also for normal cellular function.  The promise of the field of 
epigenetics is best represented by James D. Watson (2003), “You can inherit something 
beyond the DNA sequence.  That’s where the real excitement in genetics is now.” 
 The molecular mechanisms underlying epigenetic modulation include a variety of 
cellular processes such as DNA methylation, RNA-directed gene silencing, and 
chromatin remodeling.  DNA methylation is a well characterized covalent modification of 
cytosine residues of CpG dinucleotides.  When these nucleotides are clustered together, 
they are referred to as CpG islands, and their associated DNA methylation results in 
transcriptional repression [58].  DNA methylation also plays a pivotal role in X 
chromosome inactivation and mammalian gene imprinting, two well characterized 
epigenetic phenomena [59].  RNA, in particular noncoding RNA, has also been 
implicated in epigenetic mediated gene silencing [60].  By far the most characterized 
epigenetic regulation involves alternations to chromatin.  Chromatin is an intimate 
complex of DNA and proteins.  One function of chromatin is to condense a cell’s DNA so 
that it can be packaged into chromosomes.  Histone proteins, the primary constituents of 
chromatin, are key components to epigenetic regulation, as they can be both covalently 
modified and noncovalently remodeled to direct downstream cellular processes. 
 
B.  Histones and their code 
 The fundamental component of chromatin is the nucleosome, which is composed 
of an octamer of canonical (core) histone proteins (two each of histones H2A, H2B, H3, 
and H4) encircled by 147 bp of DNA.  Histone 1 (H1) binds to the linker DNA connecting 
repetitive nucleosomes forming the classic pattern resembling beads on a string.  
Histones are small, basic proteins that are highly conserved throughout eukaryotes.  
Histone proteins consist of both a globular center core domain and a flexible tail domain.  
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The tails of histones extend from the surface of the nucleosome and associate with the 
DNA.  Aside from the canonical histones, variants exist that possess key compositional 
differences.  The presence of these histone variants adds an additional layer to the 
epigenetic regulation of chromatin as switching or replacing a core histone with a variant 
histone protein marks a given location for a specialized cellular function.  For instance, 
H2AX, together with its associated post-translational modifications (i.e. phosphorylation), 
is a histone variant that associates with DNA damage and is involved in recruitment of 
the necessary DNA repair machinery to the site.  Likewise, the histone variant H3.3 
marks transcriptionally active regions, whereas another histone H3 variant, CENP-A, is 
centromere-specific and involved in chromosome segregation. 
 The condensed nature of chromatin and the role of histones were recognized to 
be repressive to transcription and gene expression as early as 1950 [61].  However, 
several years later, Allfrey observed that acetylation of histones correlated with gene 
activation [62].  This observation ignited interest in understanding the connection 
between histones and gene expression.  Subsequently, other histone modifications such 
as phosphorylation and methylation were identified, but their significance remained 
unclear.  The defining moment came when Brownell and Allis (1996) made the landmark 
observation that a Tetrahymena histone acetyltransferase (HAT) was homologous to the 
yeast transcriptional activator GCN5 (general control nonderepressible-5), thereby 
providing a direct connection between histone modification and gene expression [63].  
Since this discovery, there has been an explosion of work to identify additional histone 
modifications, the residues modified, and the enzymes responsible. 
 It is now known that the N-terminal tails of histones are extensively modified, and 
to some extent even residues within the core globular domain of histones are subjected 
to modification.  The various modifications include acetylation, phosphorylation, 
methylation, ADP-ribosylation, ubiquitination, and sumoylation.  All of these 
modifications are reversible.  A plethora of enzymes capable of catalyzing the 
incorporation or removal of these modifications have been identified.  The majority of the 
chromatin-modifying enzymes are members of large multi-subunit complexes and exhibit 
remarkable specificity to target specific residues.  Interestingly, many chromatin-
modifying enzymes are also capable of targeting non-histone proteins [64,65].  
Additionally, there are enzymes capable of remodeling chromatin and changing the 
nucleosomal composition in a non-covalent manner.  These enzymes use the energy 
from ATP hydrolysis to alter the higher-order structure of nucleosomes, as well as 
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exchange canonical histones for variants.  This multitude of alterations creates a 
dynamic chromatin environment for the regulation of gene expression. 
 The modifications of histones have both cis- and trans-effects.  Cis-effects 
constitute changes in the physical properties of the histone such as structural modulation 
or alteration of electrostatic charge.  For instance, histone acetylation on lysines 
neutralizes the positive charges of these basic residues allowing for expansion of the 
nucleosome structure.  This grants the transcriptional machinery access to a particular 
region of DNA.  Chromatin modulation can also result in trans-effects, in which there is 
recruitment or stabilization of specific binding partners or chromatin-associated proteins.  
These proteins act as readers of the modifications and recruit additional proteins or 
complexes to perform downstream chromatin alterations.  For example, the 
bromodomain is a particular motif that recognizes acetylated lysine residues and is often 
found on HATs.  It is believed that through the recognition of acetylated histone tails, 
bromodomain-containing proteins are able to direct additional modifications and thus 
participate in acetylation-dependent chromatin remodeling [66,67].  The complex 
language established by the modifications to chromatin resulted in the histone code 
hypothesis [68].  The histone code hypothesis proposes that there are writers and 
readers of the histone modifications.  Together they constitute a cellular code that must 
be interpreted to produce specific downstream effects [68]. 
 Although all the histone modifications are important and play a distinct role in 
cellular function, the focus of this thesis will be on histone acetylation by the enzyme 
GCN5. 
 
III.  GCN5 is a HAT involved in transcriptional activation 
 
A.  Definition, classification, and summary of HATs 
 As the bridge that linked histone acetylation to transcriptional activation, GCN5 
as well as histone acetylation in general, became an extensively studied topic.  Since the 
initial discovery by Brownell and Allis (1996), a multitude of HATs have been identified, 
many of which were previously categorized as transcriptional activators [63].  HATs can 
broadly be divided into two subcategories:  type A HATs, which localize to the nucleus, 
and type B HATs, which have a cytoplasmic distribution.  The general consensus is that 
type B HATs are involved in acetylating newly synthesized free histones prior to their 
nuclear import, whereas type A HATs acetylate nucleosomal histones within chromatin 
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and are linked with transcriptional activation.  HATs are further characterized into 
families defined by sequence similarity and possession of conserved protein domains.  
Interestingly, each HAT family is very diverse in terms of the HAT domain structure and 
associated protein characteristics.  For instance, the GNAT family (GCN5-related N-
acetyltransferase) is characterized by a HAT domain of approximately 160 amino acids 
followed by a bromodomain, a motif that recognizes acetylated lysine residues [67,69].  
On the other hand, MYST family HATs (named for the members MOZ, Ybf2/Sas3, Sas2, 
and Tip60) contain HAT domains of roughly 250 residues and possess N-terminal 
chromodomains, involved in recognition of methylated lysine residues [69,70].  Several 
other HAT families exist, each with their own characteristics. 
 Enzymatically, HATs transfer an acetyl group from acetyl-coenzyme A (acetyl 
CoA) to the Ɛ-amino group of certain lysine side chains within histones [71].  This 
modification neutralizes the positive charge of lysine, which weakens the interaction 
between the histone and DNA, or between two nucleosomes, or results in a 
conformational change in the nucleosomal structure [72,73,74].  Such alterations to the 
chromatin structure allow various factors, such as the transcriptional machinery, to gain 
access to genetic loci. 
The antagonists of HATs are histone deacetylases (HDACs) that catalyze the 
removal of the acetyl group from specific lysine residues, allowing the chromatin to 
resume a restricted state.  Hypoacetylation of a given region and the activity of HDACs 
are considered repressive to transcription.  The reciprocal activities of HATs and HDACs 
govern the steady-state histone acetylation balance within a cell and thereby regulate 
gene expression. 
 Very few HAT inhibitors exist.  Some compounds, such as curcumin, garcinol, 
and anacardic acid are derived from naturally occurring products and show HAT 
inhibitory properties [75]; however, there are limitations to each.  Curcumin has anti-
oxidant properties and therefore might interfere with other cellular pathways, making it 
non-specific [75,76].  Garcinol has low potency, resulting in high cellular toxicity, 
including apoptosis [75,77].  Anacardic acid has low cell permeability, limiting its in vivo 
usage [75,78].  Other synthetically derived HAT inhibitors such as the bisubstrate 
inhibitors, histone peptide connected to CoA, are likewise unable to permeate cells 
[79,80].  In general, the currently available HAT inhibitors have limited in vivo utility due 
to lack of specificity, low potency, and decreased cell permeability [80].  The discovery or 
synthesis of additional HAT inhibitors would greatly facilitate the study of HATs and their 
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epigenetic roles in biological and medical processes.  Several HDAC inhibitors are being 
examined in clinical trials for various human diseases, including various types of cancers 
[81]. 
 
B.  GCN5 is a conserved HAT 
 GCN5 is a well conserved HAT with homologues in a multitude of diverse 
organisms from yeast to plants (Arabidopsis) to humans.  As a member of the GNAT 
family, GCN5 shares similarities with other members including Elp3 (elongation protein 
3), Hat1, and Hpa2 (histone and other protein acetyltransferase 2).  The GCN5 
homologues share common sequence motifs in their HAT domains, C-terminal 
bromodomains, and Ada2 interaction domains, a necessary co-activator (Figure 3, 
Chapter 1, section IV-C) [69].  Interestingly, vertebrates such as humans and mice 
possess a second GCN5 homologue termed PCAF (p300/CBP-associated factor) [82].  
PCAF not only functions as a HAT but has intrinsic E3 ubiquitinase activity [83]. 
 In vitro studies in S. cerevisiae have revealed that recombinant GCN5 strongly 
acetylates free histone H3 lysine 14 (K14), and to a lesser extent free histone H4 (K8 
and K16) [84].  However, when GCN5 is incorporated into one of its multi-subunit 
complexes, its substrate specificity expands for histone H3 and includes histone H2B 
[85].  The acetylation of histone H3 K36, in yeast, has also been shown to occur in a 
GCN5-dependent manner [86].  Additionally, GCN5 acetylates free histone H3 K56 in 
vitro [87,88]. 
 Mechanistically, GCN5 catalyzes the acetylation of histones by forming a ternary 
complex between the enzyme, histone, and acetyl-CoA.  GCN5 deprotonates the 
histone substrate thereby, allowing the Ɛ-amino group of the lysine to directly attack the 
bound acetyl-CoA.  In S. cerevisiae, the glutamic acid residue 173 is essential for 
catalytic function and serves as a general base for deprotonation [89].  This residue is 
conserved throughout the GCN5 homologues. 
 
C.  GCN5 functions within multi-subunit complexes 
 In order for transcription to occur, a series of well coordinated events must take 
place.  First gene-specific transcription factors bind to upstream activating sequences 
(UAS) in promoters and recruit additional transcriptional activation complexes and 
cofactors.  These complexes include chromatin modifying enzymes that create an open 
chromatin confirmation, allowing general transcription factors to access the genetic loci.  
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These events lead to the recruitment and formation of the pre-initiation complex (PIC) 
and hence, the commencement of RNA polymerase II mediated transcription.  As a 
HAT, GCN5 is the enzymatic component of several multi-subunit complexes that are 
integral for the activation and initiation of transcription.  To date, the S. cerevisiae SAGA 
(Spt-Ada-GCN5 acetyltransferase) complex has been the most widely studied and best 
characterized GCN5 complex. 
 The S. cerevisiae SAGA complex is a 2 MDa complex that is composed of 
several distinct functional modules.  Within SAGA, GCN5 is the enzymatic component of 
the acetyltransferase unit, along with the Ada (alteration/deficiency in activation) proteins 
[90].  Ada2, the co-activator of GCN5, along with Ada3, regulate the acetylation activities 
within SAGA [91,92].  Other members of SAGA include Spt proteins (suppressor of Ty) 
and TAFs (TBP-associated factors).  Together, Spt3 and Spt8 form the TBP (TATA-
binding protein) interaction unit with Spt3 being crucial for the recruitment of TBP and 
PIC formation [93].  The complex member Tra1, an ataxia telangiectasia mutated (ATM)-
related protein, interacts with specific transcription factors such as GCN4 (general 
control nonderepressible 4) to recruit the entire complex to a given genetic locus [94,95].  
Most of the other members of SAGA are integral for the architectural structure of the 
complex or have less defined functions.  Recently, it was determined that SAGA 
contains a second enzymatic component, Ubp8, a deubiquitinase (Dub).  Ubp8 is the 
enzyme responsible for the deubiquitination of H2B K123 within the context of its SAGA 
modular unit components Sus1, Sgf11, and Sgf73 [96,97,98].  Table VII (Chapter 3, 
section II-A) lists all 21 members of the S. cerevisiae SAGA complex. 
 The SAGA complex plays an integral role in the transcription of approximately 
10% of the S. cerevisiae genome [99].  Most of the genes are stress induced, and 
include genes that regulate the response to environmental stress, starvation, DNA 
damage, and heat [99].  The SAGA complex members have also been implicated in a 
variety of other important cellular processes.  For instance, SAGA can localize not only 
to gene promoters but also to the coding regions, where acetylation by GCN5 promotes 
nucleosome eviction and facilitates transcriptional elongation [100].  Additionally, the 
subunits Sus1, Sgf11, and Sgf74 link SAGA physically to the nuclear export machinery 
and are involved in the export of transcribed mRNA [101,102].  This study indicated the 
existence of coupling between transcriptional elongation and mRNA export [103]. 
 There is a high level of homology between the S. cerevisiae SAGA complex and 
the GCN5 complexes purified from other species including Drosophila and humans.  
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Each of these species has SAGA complexes (also referred to as STAGA, Spt3-TAF9-
GCN5 acetyltransferase in humans) that are conserved in protein subunit composition 
and structure.  This similarity suggests that each complex serves a related function 
across species [104].  PCAF, the second GCN5 homologue in vertebrates, also 
functions within multi-subunit complexes that are analogous to the GCN5 complexes.  
Furthermore, metazoans possess two homologues of Ada2 (ADA2-A and ADA2-B) that 
play distinct roles in the various GCN5/PCAF complexes [104]. 
 The other distinctive GCN5 complex in S. cerevisiae is the ADA complex.  At 
approximately 700 kDa, this complex is considerably smaller than SAGA.  The yeast 
ADA complex is composed of the SAGA members GCN5, Ada2, Ada3, and Sgf29, along 
with Ahc1 and Ahc2 (ADA histone acetyltransferase complex component), which are 
necessary for structural integrity.  There are also several unidentified proteins that may 
be members the S. cerevisiae ADA complex [105,106,107].  Although not all functions of 
the S. cerevisiae ADA complex have been elucidated, the complex is able to acetylate 
H3 K14 and K18 [85]. 
Likewise, a smaller (700 kDa) GCN5-containing complex has been identified in 
both Drosophila and human cells [107,108,109].  The ATAC (ADA two a containing) 
complex was first purified in Drosophila due to its defining feature of possessing ADA2-
A, one of GCN5’s co-activator homologues [109].  Metazoans have two Ada2 
homologues, and it has subsequently been determined that metazoan SAGA complexes 
selectively incorporate ADA2-B while ADA2-A is a member of the smaller GCN5 
complex ATAC.  The ATAC complex also contains proteins homologous to SAGA’s 
Ada3 and Sgf29.  Several other proteins have been identified from both Drosophila and 
human ATAC including an additional HAT enzyme, ATAC2 (Drosophila), which has 
specificity for histone H4 [108].  The human ATAC complex can contain either GCN5 or 
PCAF although the homologue of ATAC2 (CSRP2BP) does not appear to have in vitro 
H4 HAT activity, despite having a conserved GNAT domain [107].  The ATAC complex is 
involved in transcriptional activation but has additional functions including stimulation of 
nucleosome sliding (Drosophila), as well as a potential involvement in stress signaling 
pathways and even transcriptional repression (humans) [107,108]. 
In summary, GCN5 is a member of two distinctive complexes that are conserved 
throughout many species.  Aside for the SAGA and ADA/ATAC complexes, there are 
several minor variations to each that further expand the GCN5 (or PCAF) complexes.  
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All the GCN5 complexes have been attributed to transcriptional activation; however, 
additional functions are being defined for each. 
 
D.  The role of GCN5 in cellular physiology 
 In S. cerevisiae, GCN5 is not essential and acts as a specific co-activator of only 
approximately 4% of genes, mostly genes involved in stress response pathways 
[110,111].  Although other HATs appear to compensate for the loss of GCN5 in S. 
cerevisiae, it has been determined that GCN5 has additional roles.  For instance, it was 
determined that GCN5 functions as a global chromatin remodeling enzyme in S. 
cerevisiae, by setting a basal state of genome-wide acetylation upon which specific 
targeted acetylation is superimposed [112].  Additionally, more specific roles have been 
assigned to GCN5.  The SAGA complex appears to be instrumental in coordinating 
transcription with RNA splicing because GCN5 activity was also shown to be required for 
recruitment of particular components of the splicing machinery [113].  GCN5 also plays a 
role in S. cerevisiae nucleotide excision repair, demonstrated by increased H3 K9 and 
K14 acetylation in response to ultraviolet (UV) irradiation [114].  This acetylation can 
result in increased transcription of certain nucleotide excision repair proteins and also 
appears to function in a transcription-independent manner [114,115].  Consequently, the 
loss of GCN5 results in deficient nucleotide excision repair [114]. 
 In Drosophila, GCN5 is essential; deletion mutants fail to complete 
metamorphosis, dying at the end of the larval period [116].  Likewise, GCN5 is also 
essential for vertebrates, as GCN5-null mice die during embryogenesis due to a failure 
to form the dorsal mesoderm causing death by day 10.5 post coitum [117].  Interestingly, 
mice with HAT-dead or catalytically inactive GCN5 survive until day 16.5 post coitum 
and show defects in neural tube closure and exencephaly [118].  These data show the 
necessity of GCN5 activity for proper development.  In contrast, PCAF-null mice develop 
normally, with no observable phenotype.  However, increased levels of GCN5 
expression were noted in specific tissues that normally expressed PCAF, suggesting a 
compensatory function [117,119]. 
 Studies in chicken DT40 cells show that PCAF deletion does not affect cell 
growth, whereas cells lacking GCN5 have a delay in growth rate.  Additionally, in the 
cells with deletion of GCN5, both PCAF and HDAC4 displayed increased expression, 
suggesting compensatory mechanisms exist [120].  These studies also revealed that 
GCN5 plays a role in the transcription of certain G1/S phase transition-related genes as 
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well as apoptotic genes [120].  Studies in human and mouse cells indicate that GCN5 is 
also integral for telomere maintenance through regulation of components of the shelterin 
complex [121].  GCN5 and PCAF can also acetylate cellular proteins other than histones 
[122,123,124,125].  Collectively, these data indicate that GCN5 is an important mediator 
of transcriptional activation and plays a pivotal role in several other cellular processes. 
 
E.  Nuclear import of HATs 
 In order for proteins such as type A HATs to perform their role in transcriptional 
activation, they must enter the nucleus of the cell.  The nuclear membrane forms a 
barrier that prevents the passive diffusion of macromolecules into the nuclear 
compartment.  To traffic necessary nuclear proteins to their site of action, specific 
chaperones exist that facilitate nuclear import.  These chaperones not only recognize 
their cargo via specific signals but navigate through the nuclear pore complex for 
delivery.  In the classical nuclear localization model, the chaperones are termed 
karyopherins or importins and use the energy provided by Ran, a small Ras family 
GTPase, to direct nuclear traffic [126,127,128].  Ran exists as either a GTP- or GDP-
bound nucleotide state, with compartmentalized regulatory proteins controlling the 
switch.  Ran guanine nucleotide exchange factor (RanGEF) is the nuclear regulatory 
factor, while Ran GTPase-activating protein (RanGAP) is cytoplasmic.  This separation 
provides an asymmetric distribution of the nucleotide states of Ran and allows for 
selective binding by karyopherins, thus facilitating nuclear trafficking [129,130,131]. 
 The classical nuclear import pathway begins with the karyopherin importin-α 
recognizing and binding to a cargo protein via a signal (nuclear localization signal, NLS).  
Importin-β then binds importin-α forming a ternary complex that is translocated through 
the nuclear membrane via importin-β’s interactions with the nuclear pore complex.  Once 
inside the nucleus, the binding of RanGTP to importin-β results in the dissociation of the 
complex and release of the cargo.  Both importins are recycled back to the cytoplasm 
bound to RanGTP.  In the cytoplasm, RanGTP is hydrolysed by RanGAP, resulting in 
release of the importins and formation of RanGDP.  RanGDP is then shuttled back to the 
nucleus by a specialized transporter where it is converted to RanGTP by RanGEF 
[130,131,132].  Variations to this model exist and are represented by a variety of 
importins capable of performing the same role as importin-α.  Alternatively, cargo can be 
bound directly to importin-β [133,134,135,136]. 
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 The first step in this process, the recognition of a cargo protein by an importin 
through a signal, is crucial in the transportation of proteins into the nucleus.  These 
signals found on the cargo proteins are specific targeting sequences termed NLSs.  The 
classical NLS is a short cluster of basic amino acids and is exemplified by the NLS of the 
SV40 large T antigen, PKKKRRV [137].  This type of NLS is termed monopartite 
because the entire signal exists in a single cluster of amino acids.  Bipartite NLSs 
contain two clusters of basic residues separated by 10 – 12 amino acids.  The NLS of 
nucleoplasmin, KRPAATKKAGQAKKKK, is a classical bipartite sequence [138].  Since 
the discovery of NLSs, a plethora have been discovered, some of which conform to the 
classical pattern while others are divergent, forming multiple classes and patterns 
[130,139,140]. 
 The NLSs of HATs have been studied in order to understand the regulation of 
these important cellular modulators.  PCAF contains an NLS at its C-terminus between 
amino acids 428 – 442 [141].  Five lysine residues within the NLS are autoacetylated.  
The acetylation of these lysines is crucial for nuclear localization as mutations to 
arginines or over-expression of HDAC3 (capable of deacetylating these residues) results 
in cytoplasmic accumulation [142].  The acetylation of HATs has also been shown to 
play an important role in regulating enzymatic function [143].  The only GCN5 NLS 
characterized to date is a GCN5 homologue from Toxoplasma that possesses a classic 
monopartite basic-rich cluster at its N-terminus and is capable to interacting with 
importin-α [144]. 
 
IV.  Gene expression and epigenetic modulation in Toxoplasma 
 
A.  Regulation of gene expression 
Toxoplasma is a haploid organism in both the tachyzoite and bradyzoite stages, 
and has a genome of approximately 63 Mb distributed among 14 chromosomes [145].  
Sequencing and annotation of the Toxoplasma genome is available for strains from each 
type (I, II, and III), along with other genomic-wide data such as ESTs (expressed 
sequence tags), expression and proteomics data.  This information is housed at 
Toxoplasma database (ToxoDB, http://ToxoDB.org) and is a valuable research tool [11]. 
The complexity of the life cycle of Toxoplasma as well as the ability to adapt to 
numerous host environments necessitates precise coordination and regulation of gene 
expression.  Gene expression analysis has revealed that changes to the transcriptome 
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of the parasite are critical for survival and differentiation.  The progression of gene 
expression through the cell cycle of Toxoplasma has been examined using microarrays.  
The parasites have a strict program of gene expression, with subsets of genes 
expressed at given points during the cell cycle [146].  Additionally, serial analysis of 
gene expression (SAGE) studies have revealed that Toxoplasma uses a just-in-time 
progression, where genes are expressed only as needed throughout the cell cycle [147].  
Studies analyzing the transition from tachyzoites to bradyzoites using cDNA microarrays 
reveal a hierarchical gene expression program may direct the differentiation process 
[148].  Taken together, these studies indicate Toxoplasma utilizes a tightly controlled 
process, reliant on transcriptional regulation, to control gene expression.  Although 
Toxoplasma possesses the basal transcriptional machinery, initial searches revealed a 
dearth of identifiable specific transcription factors found in other eukaryotes [149,150].  
Interestingly, Toxoplasma was found to possess a large repertoire of chromatin 
remodeling enzymes, possibly implying an increased reliance on epigenetic 
modifications to regulate its gene expression [151,152,153].  Additionally, histone 
acetylation and methylation, as analyzed by chromatin immunoprecipitation (ChIP), are 
associated with modulation of gene expression pertinent to stage-specific gene 
expression in Toxoplasma [154,155,156]. 
Recently, in silico evidence suggested that apicomplexan parasites possess a 
lineage-specific expansion of proteins containing motifs similar to AP2 (Apetala2)-
integrase DNA-binding domains [157].  AP2 proteins are transcription factors important 
for developmental transitions and the stress response in plants [158].  This information 
implies that apicomplexan parasites might utilize plant-like transcription factors as 
opposed to those that are prevalent in metazoans.  Using protein binding microarrays 
(PBMs), De Silva et al. (2008) demonstrated that Plasmodium AP2-domains were able 
to bind specific DNA motifs, and these motifs were subsequently found upstream of 
coordinately regulated genes [159].  A study demonstrating that a specific Plasmodium 
AP2 protein (PF11_0442, AP2-O) activates ookinete stage-specific genes through 
binding of a specific DNA motif provided functional validation that AP2 proteins function 
as transcription factors within apicomplexans [160].  Additionally, select apicomplexan 
AP2 proteins were found to be associated with Toxoplasma HDAC3 and Plasmodium 
GCN5, thereby linking the AP2 proteins to epigenetic gene regulation [154,161].  These 
discoveries have opened new avenues for gene regulation research in Apicomplexa 
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parasites, with at least 60 AP2-domain proteins identified in Toxoplasma, compared to 
27 in Plasmodium, and 17 in Cryptosporidium [157]. 
 
B.  The histones of Toxoplasma and their modifying enzymes 
 As described for other eukaryotes, Toxoplasma possesses conserved 
homologues of the canonical histones H2A, H3, and H4, as well as, centromeric H3 
(termed TgH2A1, TgH3, TgH4, and TgCenH3, respectively).  H2B is also conserved, but 
the parasite contains two nearly identical proteins (TgH2Ba and TgH2Bb) with significant 
homology to canonical H2B [162].  Additionally, there is another lineage of H2B in 
Toxoplasma consisting of the variant histone TgH2Bv1.  TgH2Bv1 is highly expressed 
and not differentially regulated; therefore, it is expected to be the main functioning H2B.  
Although TgH2Ba and TgH2Bb are very similar, only one, TgH2Ba, has been found to 
be expressed in tachyzoites and bradyzoites.  TgH2Bb could not be amplified from 
cDNA or detected during histone purification.  TgH2Ba may be differentially regulated 
since its expression was shown to be higher in tachyzoites compared to bradyzoites, 
indicating TgH2Ba may have a specialized role [162].  Toxoplasma also has variants of 
H2A (TgH2A1, TgH2AX, TgH2AZ) [163].  Due to its dimerization with TgH2Bv1 and 
association with acetylated histones at active genes, TgH2AZ acts as the main H2A 
variant.  On the other hand, the variants TgH2AX and TgH2A1 appear to have specific 
roles in response to stress [163].  Two variants of H3 have been identified, TgH3 and 
TgH3.3, which function in chromatin structure and gene regulation, respectively [164].  
Only four amino acids differ between the two H3 variant histones, but this slight change 
in sequence may result in distinct structural and functional differences [164].  To date, no 
variants of H4 have been identified.  Toxoplasma lacks a histone H1 homologue.  Due to 
the divergent nature of this protein among species and the evidence that another 
protozoa, Tetrahymena, grows normally when H1 is deficient, it is likely that Toxoplasma 
may not require H1 to function [165].  Alternatively, Toxoplasma may have a variant that 
is too divergent to detect. 
All of Toxoplasma’s histones contain the prototypical N-terminal tails and other 
well characterized conserved residues that can be extensively modified for regulation of 
chromatin architecture [151,152].  Histone marks on TgH3 and TgH4 have been studied 
using chromatin immunoprecipitation (ChIP) and ChIP coupled to microarray (ChIP-to-
chip) techniques [155].  Acetylation of H3K9 and H4 as well as trimethylation of H3K4, 
are specific concurrent histone marks that have been identified at promoters of actively 
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expressed genes [155].  Modifications of transcription repression have also been 
identified in Toxoplasma and include trimethylation of H3K9 and H4K20 [166]. 
Toxoplasma possesses a vast trove of proteins capable of modifying chromatin.  
This category includes enzymes able to write the code (acetyltransferases, methylases, 
kinases, etc.), erase the code (deacetylases, demethylases, phosphatases, etc.) and 
those able to re-organize the histones (ATP-dependent remodelers) [151,152,153].  To 
date, only a select handful of these enzymes have been studied. 
The first chromatin modifying enzyme to be cloned and characterized in 
Toxoplasma was a homologue of GCN5 [167,168].  Importantly, several years later, a 
second GCN5 homologue in Toxoplasma (distinguished from the original TgGCN5-A as 
TgGCN5-B) was identified, which was remarkable given the fact that there was no 
precedence for any invertebrates to possess two GCN5 homologues [169].  Additionally, 
two more HATs were characterized that belong to the MYST family [170].  Enzymes 
including HDACs, arginine methyltransferases, SET-domain lysine methyltransferases, 
and a SWI/SNF family ATP-dependent chromatin remodeler have all been described 
[154,166,171,172].  Each of these enzymes plays a distinct role in Toxoplasma’s 
biology, and several have been shown to regulate gene expression pertinent to 
bradyzoite differentiation [151,152,153]. 
HATs and HDACs in Toxoplasma function within their prototypical roles of 
transcriptional activation and repression as demonstrated by the presence of TgGCN5-A 
at active promoters and TgHDAC3 at inactive promoters [154].  An additional role of the 
HAT TgMYST-B was discovered that links this enzyme to the DNA damage response 
through the regulation of ATM kinase [173].  Likewise, the SET-domain lysine 
methyltransferase KMTox (TgSET13) contributes to the oxidative stress response in 
Toxoplasma and is linked with regulation of genes involved in antioxidant defense [171].  
Another SET-domain protein, TgSET8, is involved in transcriptional repression and 
heterochromatin assembly [166].  TgSET8 may also be involved in bradyzoite 
formation/persistence because high levels of monomethylation of H4K20, a mark written 
by this enzyme, were found in bradyzoites [166].  The ATP-dependent chromatin 
remodeler, TgSRCAP, is another epigenetic modulator implicated in differentiation 
because its mRNA levels increase during in vitro conversion to bradyzoites [154,172].  
Additionally, pharmacological inhibition of either HDAC3 or the arginine 
methyltransferase TgCARM1 was found to induce bradyzoite differentiation [154,174].  
Other HDAC inhibitors, such as apicidin and SAHA (suberoylanilide hydroxaminc acid), 
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have anti-Toxoplasma activity [175,176,177].  Although this summary is just a sampling, 
these examples demonstrate the importance of epigenetic and chromatin modulations in 
Toxoplasma and are summarized in Figure 2. 
 
 
Figure 2:  Diverse roles of epigenetics in Toxoplasma biology.  Schematic diagram 
shows two host cells (hN = host cell nucleus) harboring a parasite vacuole containing 
either proliferative tachyzoites (acute infection, left) or a cyst containing slow-growing 
bradyzoites (chronic infection, right).  The inserts depict a single Toxoplasma parasite in 
either the tachyzoite stage (left) or the bradyzoite stage (right) and list the known 
epigenetic characteristics associated with each life-cycle stage.  In tachyzoites, 
TgGCN5-B, TgMYST-A and -B, and TgCARM1 are histone modifying enzymes that may 
be required for propagation, based on the inability to disrupt the genetic loci.  KMTox 
and TgMYST-B have been linked to the response of Toxoplasma to reactive oxygen 
species (O2-) and DNA damage, respectively.  Additionally, the histone variant TgH2AX 
is phosphorylated in response to DNA damage in tachyzoites.  TgSET8 has been 
implicated in Toxoplasma cell cycle regulation, as has the phosphorylation of histone H3 
on Serine-10, which is delivered by an uncharacterized kinase. TgH2Ba appears to be a 
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variant histone exclusive to tachyzoites.  TgGCN5-A and TgSRCAP have been 
implicated in the differentiation of tachyzoites into bradyzoites. The inhibition of 
TgCARM1 or TgHDAC3 by AMI-1 or FR235222, respectively, has been shown to induce 
cyst formation.  The expression of the histone variant TgH2AX increases during 
bradyzoite differentiation.  Presently, TgSET8 is the only chromatin remodeler identified 
to be associated in bradyzoite biology.  Art in Figure 2 was done by Christopher Brown 
(2010) at the IUSM Office of Visual Media.  Originally published in Dixon et al. (2010) 
[153]. 
 
C.  Two GCN5 homologues in Toxoplasma 
 Two unique GCN5 homologues have been cloned and characterized from 
Toxoplasma [167,168,169].  Although no precedence exists for this occurrence in 
invertebrates, we have recently discovered that Neospora, another apicomplexan 
parasite and the nearest relative of Toxoplasma, also contains two GCN5 homologues.  
In contrast, Plasmodium only possesses a single GCN5 homologue [178].  The 
presence of two GCN5s in Toxoplasma suggests that these HAT homologues might 
have pivotal roles within the parasites. 
 TgGCN5-A (chromosome 3) encodes a protein of 1169 amino acids, while 
TgGCN5-B (chromosome 14) is a 1032 amino acid protein [168,169].  TgGCN5-A and –
B protein sequences share 54% identity and 66% similarity and are nearly identical in 
their HAT catalytic domains and possess very similar bromodomains.  The ADA2-
binding regions are less conserved [169].  The N-terminal extensions (794 amino acids 
of TgGCN5-A and 625 amino acids of TgGCN5-B) exhibit the greatest divergence 
between the two.  These N-terminal regions are unique in that they lack identifiable 
protein motifs and do not have homology to known protein sequences in other species.  
Interestingly, the N-terminal extensions of TgGCN5-A and –B bear no significant 
similarity to one another [169].  Most GCN5 homologues from lower eukaryotes have 
very short N-termini, so it is unusual that several apicomplexan parasites (Toxoplasma, 
Neospora, and Plasmodium) have GCN5 homologues with elongated N-terminal 
extensions (Figure 3). 
 The HAT domain of both TgGCN5s show strong similarity to yeast GCN5, 
suggesting that the Toxoplasma GCN5s might have a similar acetylation profile to other 
GCN5 homologues.  Using purified recombinant full-length FLAG-tagged TgGCN5-A 
and –B from Toxoplasma, the enzymatic activities and substrate profiles of each HAT 
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were examined using in vitro HAT assays [154,169].  TgGCN5-B appeared to be the 
prototypical GCN5 due to its ability to acetylate K9, K14, and K18 of histone H3.  
However, TgGCN5-A had a narrow substrate specificity limited to acetylation of K18 on 
histone H3 [154,169].  To date, TgGCN5-A is the only GCN5 homologue with such 
limited substrate specificity. 
 Like their differences in in vitro substrate specificity, the Toxoplasma GCN5 
homologues also have a differential interaction with the GCN5 co-activator ADA2.  
Interestingly, Toxoplasma possesses two distinct ADA2 homologues (termed TgADA2-A 
and TgADA2-B), in contrast to the single ADA2 homologue of Plasmodium [169,179].  
Using directed yeast two-hybrid tests, it was determined that TgGCN5-A can only 
interact with TgADA2-B, while TgGCN5-B can interact with both TgADA2s [169].  These 
data are in agreement with the fact that the ADA2 binding domains of the Toxoplasma 
GCN5 homologues have notable differences and are less conserved than the catalytic 
domains and bromodomains [169]. 
 Toxoplasma is able to survive without TgGCN5-A.  Sullivan et al. (2006) 
constructed a knock-out TgGCN5-A (ΔGCN5-A) parasite strain [169].  Although 
parasites lacking TgGCN5-A have no obvious phenotype when cultured under normal 
growth conditions, they do not recover from certain stresses as robustly as parental wild-
type parasites, and ΔGCN5-A parasites fail to express stress-induced bradyzoite-marker 
genes.  Additionally, microarray data from this strain suggest that TgGCN5-A might be 
important for stress-induced bradyzoite differentiation [Sullivan and Nagulaswaran et al., 
unpublished].  In contrast, attempts to knock-out TgGCN5-B through an analogous 
approach have failed, suggesting that this GCN5 homologue may be essential for 
tachyzoite growth and development.  Both anacardic acid and curcumin inhibit 
Plasmodium GCN5 in vitro, and both agents decrease proliferation of Plasmodium in 
culture [180,181]. 
 The roles of the elongated N-terminal extensions in the apicomplexan GCN5 
homologues remain to be elucidated.  TgGCN5-A possesses a unique NLS (RKRVKR) 
within its N-terminus [144].  Although the N-terminus of TgGCN5-B is required for 
localization to the parasite nucleus, the NLS of TgGCN5-A is not conserved in TgGCN5-
B [169].  Therefore, TgGCN5-B must use a novel signal to facilitate nuclear localization.  
Using a high-throughput yeast two-hybrid screen, LaCount et al. (2005) discovered that 
the N-terminus of Plasmodium GCN5 associates with a variety of other proteins [161].  
The Plasmodium GCN5 associating proteins include other potential chromatin-modifying 
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proteins, as well as, some potential transcription factors.  In this study, Plasmodium 
GCN5 associated with two AP2 domain proteins along with other proteins containing 
putative DNA-binding motifs (Myb DNA binding domain and AT-hook DNA binding 
domain).  Interestingly, GCN5 was found to be the most highly connected protein in 
Plasmodium [161].  These studies suggest that the N-termini of the Apicomplexa GCN5 
homologues are critical for the functions of these proteins. 
 
 
Figure 3:  Comparison of apicomplexan GCN5s to other eukaryotic GCN5 
homologues.  Schematic diagrams compare Toxoplasma GCN5s with homologues 
from other species.  Both Toxoplasma GCN5s share homology in the catalytic (green), 
ADA2 (red), and bromo- (yellow) domains.  However, each possesses a unique N-
terminal extension that does not share homology to protein sequences in other species.  
Other apicomplexans such as Neospora and Plasmodium also possess GCN5 
homologues with elongated N-termini.  Drosophila and human GCN5 homologues 
contain N-terminal extensions that have a high degree of similarity to the N-terminal 
region of PCAF.  This PCAF homology domain is absent from the GCN5 homologues 
found in plants, fungi, and protozoa examined to date.  Other invertebrates and protozoa 
have GCN5 homologues with short N-termini.  Orange regions represent the C-termini of 
each homologue. 
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V.  Hypothesis and aims 
 
 The preliminary studies characterizing the Toxoplasma GCN5 homologues 
suggest that these two HATs may have separate functions within the parasite.  If this 
hypothesis is correct, the Toxoplasma GCN5 HATs would mimic the roles of GCN5s in 
higher eukaryotes such as mouse or human.  Due to the differential interaction with 
ADA2 co-activator proteins and lack of homology between the two N-terminal extensions 
of each Toxoplasma GCN5 homologue, it is possible that the TgGCN5s form distinct 
complexes within the parasite.  Interestingly, bioinformatic searches of the ToxoDB 
reveal a dearth of identifiable SAGA complex homologues.  Therefore, the components 
of the Toxoplasma GCN5 complexes are likely to be novel or highly divergent.  
TgGCN5-A possess a unique NLS (RKRVKR) within its N-terminus that is not conserved 
in TgGCN5-B demonstrating that TgGCN5-B utilizes a different signal to enter the 
parasite nucleus.  The fact that parasites are able to tolerate the deletion of TgGCN5-A, 
while TgGCN5-B appears essential, also suggests a distinct role for each homologue 
within the parasite.   The initial characterization of the ΔGCN5-A parasite strain, 
suggests that TgGCN5-A is necessary for Toxoplasma differentiation and stress 
response, whereas TgGCN5-B is critical for parasite growth and survival.  Collectively, 
this information led me to the thesis hypothesis that TgGCN5-B is an essential HAT 
that resides within a unique, multi-subunit complex in the parasite nucleus.  This 
hypothesis was examined by performing the following specific aims: 1) Determine the 
nuclear localization signal of TgGCN5-B, 2) Identify the proteins associating with 
TgGCN5-B, and 3) Evaluate the impact of TgGCN5-B on parasite physiology. 
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Chapter 2:  Materials and Methods 
 
I.  Tissue culture and parasite techniques 
 
A.  Host cell and parasite culture  
 Toxoplasma is a ubiquitous pathogen capable of infecting a multitude of host 
cells, including most mammalian cells frequently used in tissue culture research.  For all 
studies presented in this work, human foreskin fibroblasts (HFF; ATCC #SCRC-1041) 
were used because they are large and flat, enabling an ease in monitoring parasite 
growth through microscopy.  HFF cells also have strong contact inhibition allowing for 
confluent monolayers to be prepared and stored prior to passage of parasites.  
Additionally, since HFF cells have no or minimal growth after reaching confluency, they 
are resistant to metabolic inhibitors, allowing for drug selection of parasites [182].  The 
disadvantage of HFF cells is that they are a primary cell line, so they will senesce at 
higher passage numbers.  Recently, another cell line has been developed, HTERT-HFF 
(human telomerase reverse transcriptase; ATCC #CRL-4001), which retain the 
characteristics of HFFs but are immortal [183].  For routine passage of parasites and 
generating parasite lysates, HTERT cells were used as they produced higher parasite 
yields as compared to HFF cells (personal observation).  For all assays, HFF cells were 
utilized as these are the established cell line in the field. 
  Standard tissue-culture techniques were followed, and all work was performed 
under sterile conditions within a laminar flow hood.  For maintenance of HFF and 
HTERT cells both lines were grown in Dulbecco’s Modified Eagle’s Medium (DMEM, 
Gibco #19625-126) containing 10% heat inactivated fetal bovin serum (FBS, Gibco 
#16000).  To split cells, a confluent monolayer from a large flask (T75 or T150) was 
washed once in sterile phosphate buffer saline (PBS, Gibco #10010-049) to remove 
residual media.  Next, the monolayer was disrupted using 0.25% Trypsin-EDTA (Gibco 
#25200) digestion for approximately 30 seconds at 37oC, followed by manual agitation.  
The trypsin was deactivated by resuspension of cells in host cell media.  Cells were then 
seeded into the appropriate number of flasks or plates depending on downstream 
applications.  All host cells were grown at 37oC in a humidified incubator containing 5% 
CO2.  Cells typically reached confluency in 4 – 10 days depending on cell type, 
inoculation conditions, and passage number.  HFF cells grew slower than HTERT cells 
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(personal observation).  HFF cells were maintained in culture to approximately passage 
15, whereas HTERT could be kept through passage 30. 
 For all the work presented in this thesis, RH strain (type I lineage) derived 
Toxoplasma tachyzoites were used.  Parasites were maintained via serial passage onto 
confluent host cell monolayers in Toxoplasma media, DMEM supplemented with 1% 
heat-inactivated FBS.  A lower amount of serum must be used with parasite culture in 
order to minimize the exposure of parasites to antibodies or complement [182].  Upon 
host cell lysis, parasite lines were serially passed onto another confluent monolayer of 
host cells.  Typically, parasites double inside the host cells every 7.5 hours.  After lysis, 
parasites must be passed onto the next monolayer fairly quickly because the parasites 
have a limited extracellular half-life of approximately 10 hours [182].  Parasite lysis 
occurred every 2 – 4 days depending on inoculation.  Parasites were grown at 37oC in a 
humidified incubator containing 5% CO2
 Contamination of tissue culture is a serious complication that can destroy cell or 
parasitic lines or alter experimental results.  Therefore, cautions were taken to ensure 
sterile tissue culture techniques were carried out.  This included filtration of reagents 
through 0.2 µM filters and use of sterile equipment.  Antimicrobials are typically included 
in tissue culture media as a preventative to ward off potential contaminants.  However, 
continual use of antimicrobials could inadvertently select for resistant contaminants and 
thereby complicate treatment options if contamination arises.  Therefore, antimicrobials 
were not routinely used in either host cell or Toxoplasma media.  When contamination 
was suspected or arose in another area of the lab, gentamicin (5 µg/ml, Gibco #15710-
072) was included in the media until the issue was resolved.  If parasites or host cells 
had overt contamination, they were immediately destroyed and new stocks initiated.   
.  Both parasite and host cell growth was 
monitored using an inverted microscope with phase-contrast optics.  All tissue culture 
and parasitic waste was decontaminated with either bleach or 70% alcohol and 
autoclaved prior to disposal. 
An inconspicuous contaminate of tissue culture is Mycoplasma.  Mycoplasma is 
a free-living bacterium that lacks a cell wall and is extremely small, making it 
undetectable using basic microscopy.  It is estimated that 15 – 80% of long-term tissue 
culture cell lines are contaminated by this nuisance [184].  Mycoplasma contamination 
has been documented in cultures of Plasmodium, and its presence can result in false or 
blemished data interruption [185].  Therefore, both host cells and parasite cultures were 
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routinely tested for the presence of Mycoplasma using the MycoAlert Mycoplasma 
Detection kit (Lonza #LT07-318) per the manufacturer’s protocol. 
Mycoplasma was never detected in my culture samples; however, there are a 
few treatment options if it were to arise.  First, contaminated parasites can be passed 
through mice and then re-isolated and put back into tissue culture.  For this technique, 
the mouse’s immune system will eradicate the Mycoplasma infection, and the parasites 
can be re-isolated from the peritoneal fluid.  Toxoplasma cultures contaminated with 
Mycoplasma can also be treated with Mycoplasma Removal Agent (MRA, MP 
Biomedicals #093050044), an inhibitor of bacterial gyrase, per the manufacturer’s 
guidelines [183,185]. 
 
B.  Freezing and thawing of host cells and parasites 
 In order to preserve stocks of both low passage host cells and all parasite lines, 
cryopreservation in liquid nitrogen was used for long-term storage.  In both cases, 
DMSO (dimethyl sulfoxide) was used as a cryoprotectant in a freeze mix that included 
25% DMSO and 20% FBS in DMEM.  To freeze host cells, a large flask (T150 or T75) 
was trypsinized, as described above, to dislodge the cells from the monolayer.  Cells 
were next resuspended in host cell media and centrifuged at 400 x g for 10 minutes at 
4oC to pellet the cells.  Following centrifugation, the supernatant was discarded and the 
cellular pellet was resuspended in an equal volume of cold host cell media and freeze 
mix (2.0 ml each for T150 and 1.0 ml each for T75).  The cellular mixture was 
immediately aliquoted into cryovials (Simport #T311-1), 0.5 ml each, and placed at -
80oC.  Following at least an overnight incubation at -80oC, the cryovials  were transferred 
to liquid nitrogen for long-term storage.  In a similar fashion, parasites that had lysed 
approximately 80% of the host cell monolayer from a T25 flask were scraped and 
centrifuged at 400 x g for 10 minutes at 4oC.  For freezing Toxoplasma, it is best to 
harvest the parasites prior to complete host cell lysis, because the host cells provide an 
added protection during the freeze/thaw process.  Following centrifugation, the 
supernatant was discarded, and the parasite pellet was resuspended in 0.5 ml each of 
cold Toxoplasma media and freeze mix.  The mixture was then aliquoted (0.5 ml each) 
between two cryovials (Simport #T311-1), which were placed at -80oC overnight prior to 
extended storage in liquid nitrogen.  To thaw both host cells and parasites, cryovials 
were quickly removed from liquid nitrogen and thawed in a 37oC water bath.  Host cells 
were inoculated into a T75 flask containing 30 ml host cell media, whereas parasites 
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were inoculated into a T25 flask with a confluent host cell monolayer containing 
Toxoplasma media.  Following inoculation, flasks were incubated as described earlier for 
standard culture.  Following overnight incubation, the media of the flask was replaced to 
remove any residual DMSO, which could reduce viability of both host cells and 
parasites. 
 
C.  Parasite transfection 
Toxoplasma is highly amenable to genetic manipulation, and a variety of tools 
have been developed to assist in both forward and reverse genetics in the haploid 
tachyzoites.  Toxoplasma has a high frequency of non-homologous random integration 
of vectors, allowing for stable expression of transgenes within the parasites.  
Additionally, mutant strains of Toxoplasma have been engineered to assist in genetic 
manipulation.  For instance, the RHΔKu80 strain has been engineered for high efficiency 
in homologous recombination through disruption of the gene Ku80, which is an integral 
component of the nonhomologous end-joining (NHEJ) pathway.  This strain is ideal for 
disruption of genomic loci and also allows genes to be endogenously tagged [186,187]. 
In this thesis, two methods were used to genetically manipulate the parasites:  
expression of transgenes or the tagging of an endogeneous locus.  In general, to 
express transgenes, the parasite strain RHΔHX was utilized [188].  RHΔHX parasites 
lack the gene HXGPRT (hypoxanthine-xanthine-guanine phosphoribosyltransferase; HX) 
which is involved in purine synthesis (Figure 4).  Therefore, the parasites are resistant to 
6-thioxanthine (6TX) since they are unable to scavenge xanthine.  To produce purines, 
RHΔHX parasites are reliant on de novo synthesis through the enzyme IMPDH (inosine 
monophosphate dehydrogenase), which is inhibited by mycophenolic acid (MPA).  When 
used for transfection purposes, RHΔHX parasites are given back the gene HXGPRT via 
the transfection vector.  Addition of MPA will inhibit IMPDH and select for parasites that 
incorporated the transfected DNA, which included HXGPRT.  Xanthine (XAN) is also 
given as a supplement, since it is the cofactor scavenged by the parasites [188].  
Although this is the most common selection scheme used, other selection agents exist.  
Parasites can be given the gene chloramphenicol acetyltransferase (CAT) allowing for 
resistance to chloramphenicol (CAM) [189].  Additionally, a mutant version of the 
enzyme DHFR-TS (dihydrofolate reductase-thymidylate synthetase) can be used to 
confer resistance to pyrimethamine (PYR) [190].  Table I summarizes the above 
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selection schemes and lists the concentrations of each selection agent included in the 
parasite media. 
 
Figure 4:  Summary of guanine biosynthesis in Toxoplasma and the manipulation 
of the pathway for selection purposes.  The enzyme HXGPRT (hypoxanthine-
xanthine-guanine phosphoribosyltransferase) is not essential for Toxoplasma as 
parasites lacking this enzyme are able to synthesize guanine nucleotides through AMP 
deaminase and IMPDH (inosine monophosphate dehydrogenase).  Inhibition of IMPDH 
by addition of MPA (mycophenolic acid) results in the parasites being dependent on 
HXGPRT and xanthine for the production of guanine nucleotides.  Therefore, the 
addition of MPA to RHΔHX parasites results in death, unless the parasites incorporated 
HXGPRT through transfection.  Inversely, RHΔHX parasites are resistant to 6TX (6-
thioxanthine), due to the lack of HXGPRT.  This scheme allows for both positive 
selection with MPA and negative selection through 6TX.  The table summarizes these 
points for both wild-type (RH) and RHΔHX parasites with + or – indicating the presence 
or absence of a given gene respectively [188].  R signifies resistance and S represents 
sensitivity. 
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Table I:  Selection agents for Toxoplasma 
Selection Agent Concentration Dilutant/Vehicle Additional Information 
Mycophenolic acid 
(MPA) 
25 µg/ml 100% ethanol For RHΔHX parasites 
when HXGPRT gene is 
utilized for selection 
Must include Xan as a 
supplement 
Xanthine (XAN) 50 µg/ml fresh 0.5M KOH Used in combination 
with MPA 
6-thioxanthine (6TX) 320 µg/ml fresh 0.5M KOH For RHΔHX parasites 
prior to transfection to 
verify strain 
Chloramphenicol (CAM) 20 µM 100% ethanol CAT gene utilized for 
selection 
Pyrimethamine (PYR) 1 µM 70% ethanol DHFR* gene utilized for 
selection 
Shield-1 (Shld) 250 nM - 1 µM 100% ethanol Used to stabilize any 
protein tagged with the 
DD 
* indicates a mutant form of the enzyme DHFR that is resistant to pyrimethamine [190]. 
DD, destabilization domain. 
 
To endogenously tag a genomic locus, the parasite strain RHΔKu80 was 
utilitzed.  As mentioned earlier, this strain has been engineered to have a high efficiency 
in homologous recombination as compared to normal Toxoplasma strains [186,187].  
RHΔKu80 parasites were a gift from the lab of Dr. Vern Carruthers (University of 
Michigan). 
For simplicity, this section will generally describe the method of parasite 
transfection to introduce foreign DNA.  All vectors designed for parasite transfection 
have a Bluescript pKS plasmid backbone (Strategene) that contains an ampicillin 
resistance gene for selection in E. coli bacteria (used for construction and propagation).  
Other essential elements of the parasite expression vectors include a selectable marker 
for parasite expression and 5’ and 3’ flanking UTR (untranslated region) sequences for 
expression of the gene of interest. Table II lists all parasite vectors used and includes 
their properties and purpose. 
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Table II:  Toxoplasma transfection vectors 
Plasmid name Strain / Selection 5’UTR / 3’UTR Description 
ptubXFLAG Must be in RHΔHXGPRT 
parasites 
::HX 
Gives back HXGPRT 
gene conferring resistance 
to MPA 
Tubulin / DHFR For over-expression of gene 
of interest (X).  Contains a 
C-terminal FLAG epitope 
sequence 
NotI to linearize 
ptubXFLAG For any parasite strain ::CAT 
Confers resistance to 
chloramphenicol through 
CAT 
Tubulin / DHFR For over-expression of gene 
of interest (X).  Contains a 
C-terminal FLAG epitope 
sequence 
NotI to linearize 
pLIC.3xHA::DHFR For use in RHΔKu80 
parasites 
Confers resistance to PYR 
by providing the parasites 
with a resistant form of 
DHFR* 
N/A Contains the sequence 
necessary for LIC.  Used to 
endogenously tag a genomic 
locus with 3X HA epitope at 
the C-terminus 
Insert must contain unique 
RE site for linearization 
pLIC.2xHA-DD::DHFR For use in RHΔKu80 
parasites 
Confers resistance to PYR 
by providing the parasites 
with a resistant form of 
DHFR* 
N/A Contains the sequence 
necessary for LIC.  Used to 
endogenously tag a genomic 
locus with 2X HA epitope 
followed by the DD at the C-
terminus 
Insert must contain unique 
RE site for linearization 
All Toxoplasma transfection vectors contain a Bluescript pKS+
* The Toxoplasma minigene DHFR (dihydrofolate reductase) contains two point 
mutations, Ser(36)  Arg and Thr(83)  Asn, that confer resistance to pyrimethamine 
[190].  RE, restriction enzyme; LIC, ligation independent cloning; DD, destabilization 
domain; UTR, untranslated region; HX, hypoxanthine-xanthine-guanine 
phosphoribosyltransferase; CAT, chloramphenicol acetyltransferase; PRY, 
pyrimethamine. 
 backbone (Stratagene) 
conferring ampicillin resistance for selection in bacteria. 
 
Prior to transfection, vector DNA was linearized via restriction digestion overnight 
to facilitate recombination.  Following digestion, DNA was sterilized by ethanol 
precipitation in which 2.5X cold 100% ethanol and 0.1X 3M NaOAc, pH 5.2 was added 
to the digested vector (X = volume of digestion), followed by mixing and incubation at  
-20oC for at least 30 minutes.  The DNA was then pelleted by centrifugation at 16,000 x 
g at 4oC for 10 minutes, washed once in 70% ethanol, and then centrifuged again under 
the same conditions.  The 70% ethanol wash was discarded while in the laminar flow 
hood to ensure DNA sterility.  The DNA pellet was allowed to dry for approximately 2 
hours to remove residual ethanol.  The DNA was then used either immediately for 
parasite transfection or stored at -20oC until needed. 
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For transfection, parasites from a freshly lysed T25 flask were purified through a 
sterile 3 µM polycarbonate 25 mm filter (Whatman #110612) and harvested via 
centrifugation at 400 x g for 10 minutes at room temperature.  The supernatant was 
removed, and the parasite pellet was resuspended in 10 ml of cytomix, an 
electroporation buffer designed to mimic the parasites’ intracellular environment.  
Cytomix contains 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4/KH2PO4 (pH 7.6), 25 
mM HEPES (pH 7.6), 2 mM EDTA, 5 mM MgCl2 [191].  Cytomix was made and 
sterilized prior to transfection and stored at 4oC.  Parasites were counted using a 
hemocytometer (Appendix A).  Meanwhile, supplemented cytomix was prepared fresh by 
adding 15 mg ATP and 18 mg glutathione to 12.5 ml cytomix (final concentration of 2 
mM ATP and 5 mM glutathione), following by sterilization with a 0.22 µM filter (Fisher 
#09-7194A).  The DNA pellet was resuspended in 100 µl of supplemented cytomix and 
allowed to sit at room temperature until needed.  Following counting, the parasites were 
centrifuged again under the same conditions, and the pellet was resuspended to 2.0 x 
107
 
 parasites per 0.3 ml in supplemented cytomix.  Next, 0.3 ml of parasites was mixed 
with the DNA for a final volume of 0.4 ml that was placed in a sterile 2 mM gap 
electroporation cuvette (Fisher #BTX620).  Parasites were electroporated in a BTX ECM 
630 with a single 1.5 kV pulse with a resistance setting of 25 ohms and a capacitor 
setting of 25 µF.  Following electroporation, the parasites were left undisturbed for 15 
minutes at room temperature, then inoculated into 2 – 4 T25 flasks of confluent 
monolayers containing Toxoplasma media, and incubated as described earlier.  
Parasites were put on drug selection 24 hours after transfection or following the first 
lysis.  The concentration of each selection agent used is listed in Table I. 
D.  Cloning by limiting dilution 
 If a clonal, homogenous parasite population was required following transfection, 
the parasites were seeded into 96-well plates containing confluent host cell monolayers 
at a concentration of approximately a single parasite per well.  This allowed for a single 
parasite to generate a clonal population that could be used for down-stream 
applications.  Prior to cloning, transfected parasites were passed under drug selection at 
least twice.  Freshly lysed parasites from a T25 flask were harvested by scraping and 
purified through a 3 µM polycarbonate 25 mm filter (Whatman #110612).  The 
concentration of parasites was determined by counting 4 times using a hemocytometer 
(Appendix A).  Next, the parasites were diluted 1:1000 (10 µl into 10 ml Toxoplasma 
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media), and based on the parasite count, and factoring in the 1:1000 dilution, the 
parasites were further diluted into 20 ml Toxoplasma media with drug to obtain 
approximately 1 parasite per well (usually 10 – 30 µl of 1:1000 dilution was added to 20 
ml Toxoplasma media).  Subsequently, the latter dilution was distributed into a 96-well 
plate containing confluent HFF cells.  The plates were incubated as described earlier 
and not disturbed for 7 days.  Typically, two 96-well plates were set-up for each flask of 
transfected parasites.  After incubation, the plates were inspected for single parasite 
plaques, representing a clonal population.  If multiple plaques were seen in a well, the 
well was discarded.  Once wells containing single plaques were identified, they were 
allowed to grow until approximately 50% of the well was lysed (about 14 days).  At this 
point, the well was scraped with a pipet tip, and parasites were inoculated into a 12-well 
plate for expansion.  Typically 10 – 20 clones were selected between all the 96-well 
plates (3 – 6 per plate).  Each clone was expanded and evaluated (via 
immunofluorescence assay or genomic PCR) for desired phenotype (i.e. expression of 
transgene). 
 
E.  Harvesting parasites and generating lysates 
 Typically, parasites were harvested from T150 flasks of hTERT-HFF host cells 
because approximately 109 to 1010 parasites could be obtained from a single flask, about 
10-fold greater than from a T150 of parasites in HFF host cells (personal observation).  
To inoculate a T150 flask for harvesting, 4 – 5 ml lysed parasites were inoculated into 
the flask and allowed to incubate for approximately 36 – 40 hours as previously 
described.  When the parasites began to lyse the host cell monolayer, the flask was 
scraped, and the parasites were purified from host cell debris by filtration through a 3 µM 
polycarbonate 47 mm filter (Whatman #111112) into a conical tube.  The parasites were 
pelleted by centrifugation at 400 x g for 10 minutes at 4oC.  The media was aspirated 
away from the parasite pellet, which was subsequently washed in PBS and centrifuged 
again under the same conditions.  Next, the PBS was aspirated and the parasite pellet 
was resuspended in 1 ml PBS, transferred to an eppendorf tube, and centrifuged for 10 
minutes at 1.0 x g at 4oC.  After centrifugation, this final PBS wash was aspirated away 
and the parasite pellet was stored at -80o
 Alternatively, some experiments required harvesting of intracellular parasites, in 
order to preserve parasitic processes such as protein complex formation.  For these 
C until needed.  The freezing and thawing of 
parasite pellets assisted in the lysing process. 
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experiments, a slightly modified harvest was utilized.  When parasite vacuoles were 
large (greater than 100 parasites) and engorged, the flask was scraped and the 
parasites were purified from host cell debris by filtration through a 3 µM polycarbonate 
filter into a conical tube.  The parasites were pelleted by centrifugation at 400 x g for 10 
minutes at 4oC.  The media was aspirated away from the parasite pellet, which was 
subsequently washed in PBS and centrifuged again under the same conditions.  Next, 
the PBS was aspirated and the parasite pellet was resuspended in 1 ml 1% 
paraformaldehyde (PFA), diluted in PBS, and allowed to incubate at room temperature 
for 8 minutes.  The addition of 1% PFA served to cross-link any protein-protein 
interactions.  Next, 125 mM glycine was added (100 µl from 1.25 M stock glycine 
solution) to quench the PFA reaction.  The mixture was incubated at room temperature 
for an additional 5 minutes, followed by centrifugation at 1.0 x g at room temperature to 
pellet the parasites.  The parasite pellet was then washed two times in PBS with similar 
centrifugations at 4oC prior to being stored at -80o
 The preserved parasite pellets were used to generate lysates that could be used 
for immunoprecipitation or analyzed via SDS-PAGE and western blotting.  The parasite 
pellet was first thawed on ice for approximately 10 minutes.  Next, the pellet was 
resuspended in 500 µl Lysis Buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% Nonidet 
P40) supplemented with mammalian protease inhibitor cocktail (10 µl per 1 ml Lysis 
Buffer; Sigma-Aldrich #P8340).  The mixture was then incubated at 4
C. 
oC with rocking for 
15 minutes.  Next, the lysate was sonicated 3 times for 15 seconds at 30% power with a 
30 second recovery on ice between each round using an Ultrasonic processor sonicator.  
Sonication was used to lyse the parasites and to shear the genomic DNA.  Next, all 
insoluble material was separated from soluble lysate by centrifugation at 16,000 x g for 
10 minutes at 4o
 
C.  The soluble lysate was removed from the insoluble pellet into a new, 
pre-chilled tube and quantified for protein concentration using Bio-Rads’ DC protein 
assay kit (#500-0111), per the manufacturer’s instructions.  To determine protein 
concentration, a standard curve was established using a range of known concentrations 
of albumin (albumin standard, Thermo Scientific #23210) diluted in the Lysis Buffer. 
F.  Generating parasite nuclear-enriched lysates 
 To prepare nuclear-enriched lysates, parasites were harvested from a T150 as 
described previously (Chapter 2, Section I-E).  The parasite pellet was resuspended in 2 
ml cytoplasmic lysis buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 2 mM MgCl2, 1 mM 
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DTT) supplemented with 20 µl mammalian protease inhibitor cocktail (Sigma #P8340).  
The mixture was incubated on ice for 15 minutes followed by the addition of NP-40 to a 
final concentration of 0.6%.  The mixture was vortexed vigorously 3 times for 15 seconds 
with a 30 second recovery on ice after each round.  Next, the mixture was centrifuged at 
2,800 x g for 10 minutes at 4oC.  The supernatant representing the cytoplasmic fraction 
was removed.  Next, the pellet (nuclear fraction) was resuspended in 2 ml nuclear lysis 
buffer (50 mM HEPES, pH 7.9, 50 mM KCl, 300 mM NaCl, 1 mM DTT, 10% glycerol) 
supplemented with 20 µl mammalian protease inhibitor cocktail (Sigma #P8340).  The 
mixture was incubated at 4oC with rocking for 20 minutes followed by sonication (3 times 
for 15 seconds at 30% power with 30 second recovery on ice after each round).  
Following sonication, the mixture was centrifuged for 10 minutes at 2,800 x g at 4o
 
C.  
The supernatant was the nuclear-enriched fraction.  The nuclear-enriched fraction was 
dialyzed into an appropriate solution for downstream applications.  For use in affinity 
chromatography, the nuclear fraction was dialyzed in MBP wash buffer (50 mM Tris (pH 
7.5), 150 mM NaCl, 10% glycerol). 
II. Molecular biology techniques 
 
A.  General PCR protocol 
 All PCRs were assembled in a designated area using PCR-only specific supplies 
and equipment to avoid contaminating DNA.  All reactions were assembled on ice.  
Primers were ordered from either Invitrogen or IDT (Integrated DNA Technologies) and 
resuspended in ddH2O to a concentration of 100 µM.  Table III lists all the primers used, 
as well as a description for each.  PCRs were performed with Phusion™ High-fidelity 
DNA polymerase (NEB #F530S), a proof-reading enzyme that produces blunt-ended 
products, per the manufacturer’s guidelines.  A 50 µl reaction was assembled containing 
10 µl 5X GC Buffer (preferred due to the GC-rich nature of the Toxoplasma genome), 
1.5 µl DMSO, 1 µl 10 mM dNTPs, 10 µM both forward and reverse primers, 10 – 20 ng 
template DNA (added after all the above reagents) and 0.5 µl Phusion™ DNA 
polymerase (always added last).  The reaction was mixed gently by tapping followed by 
a brief centrifugation.  After assembly, the reaction was placed in a thermocycler 
(Eppendorf Mastercycler) with a pre-heated lid temperature of 104o
  
C. 
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The general thermocycler protocol is as follows: 
1. 98o
2. 98
C for 30 seconds 
o
3. T
C for 10 seconds 
m
To calculate the T
 for 30 seconds 
m
Once the T
, the following formula was use based on the nucleotide 
sequence of the primers: [2*(A + T)] + [4*(G + C)] 
m for each primer was determined, the lowest Tm minus 5o
4. 72
C was 
used 
o
5. Repeat steps 2 – 4 for a total of 30 cycles 
C for 30 seconds per kilobase of amplicon 
6. 72o
7. 4
C for 10 minutes 
o
Upon completion of the thermocycler program, the PCR reaction products were 
analyzed via agarose gel electrophoresis using a 0.8% agarose gel containing 1 µg/ml 
ethidium bromide.  For agarose gel electrophoresis, the running buffer was 1X TBE 
diluted from a 10X TBE stock (89 mM Tris-base, pH 8.0, 89 mM Boric acid, 20 mM 
EDTA, pH 8.0).  The gel was run at approximately 117V for about 30 minutes.  To 
visualize the PCR products, the gel was viewed under low UV light (365 nm), and the 
desired band was excised using a clean razor blade.  The gel slice containing the 
appropriate DNA was purified using a gel extraction kit (Invitrogen #K2100-12) per the 
manufacturer’s protocol.  The purified PCR product had one of two fates.  It was either 1) 
cut directly with restriction enzymes and ligated into a destination vector or 2) cloned into 
pCR®4Blunt-TOPO® (Invitrogen #K2875-J10) following the manufacturer’s instructions.  
In general, if the amplicon was to clone a new fragment from genomic or cDNA, then the 
PCR was sub-cloned into pCR®4Blunt-TOPO® so the product could be confirmed by 
sequencing at ACGT, Inc. (Wheeling, IL).  Primers used to sequence the amplicon in 
pCR®4Blunt-TOPO® were M13 forward and M13 reverse.  Alternatively, if the PCR 
product was amplified from plasmid DNA, then usually it was directly ligated into its 
destination vector. 
C indefinitely 
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Table III:  Description of primers for PCR 
# Description Orientation Primer Sequence (5’  3’) 
1 NdeI-FLAG-
GCN5-Bstart 
Sense CATATGAAAATG(F)GCGCCTTCAGAGTGTCCCAGC 
2 GCN5-Bend-
AvrII-stop 
Anti-sense CCTAGGCTAGAAAAATGTCGGATGCTTCGCGCCCACAAGCC
CCTCGTCTCC 
3 NdeI-HA-myc-
GCN5-B-start 
Sense CATATGAAAATG(H)(M)GCGCCTTCAGAGTGTCCCAGCGAC 
4 GCN5-Bend-
AvrII (no stop) 
Anti-sense CCTAGGGAAAAATGTCGGATGCTTCGCGCC 
5 NdeI-FLAG-
Δ310-GCN5-B 
Sense CATATGAAAATG(F)AGGCCCGCGGAGAACAAGAAGCGCGGC
AGAGACGCCTGCGAGGGC 
6 NdeI-FLAG-
Δ313-GCN5-B 
Sense CATATGAAAATG(F)GAGAACAAGAAGCGCGGCAGAGACGCC
TGCGAGGGCCCTCAGGCG 
7 NdeI-FLAG-
Δ310-R311A-
GCN5-B 
Sense CATATGAAAATG(F)GCGCCCGCGGAGAACAAGAAGCGCGGC
AGAGACGCCTGCGAGGGC 
8 NdeI-FLAG-
Δ310-P312A-
GCN5-B 
Sense CATATGAAAATG(F)AGGGCGGCGGAGAACAAGAAGCGCGGC
AGAGACGCCTGCGAGGGC 
9 NdeI-FLAG-
Δ310-
RP311/312AA-
GCN5-B 
Sense CATATGAAAATG(F)GCGGCGGCGGAGAACAAGAAGCGCGGC
AGAGACGCCTGCGAGGGC 
10 Inverse PCR to 
create ΔNLS 
Sense GCTAGCGACGCCTGCGAGGGCCCTCAGGCG 
11 Inverse PCR to 
create ΔNLS 
Anti-sense GCTAGCCGCCTGGGCGAGCGGCGGTGC 
12 BglII-β-gal-
start 
Sense AGATCTAAAATGGCGGTCGTTTTACAACGTCGTGACTGGGAA 
13 β-gal-end-AvrII 
(no stop) 
Anti-sense CCTAGGTTTTTGACACCAGACCAACTGGTAATG 
14 β-gal-end-
NLS-AvrII (no 
stop) 
Anti-sense CCTAGGTCTGCCGCGCTTCTTGTTCTCCGCGGGCCTTTTTTG
ACACCAGACCAACTGGTAATG 
15 β-gal-end-
NLS-HA-AvrII 
Anti-sense CCTAGGCTACGCGTAGTCCGGGACGTCGTACGGGTATCTGC
CGCGCTTCTTGTTCTCCGCGGGCCTTTTTTGACACCAGACCA
ACTGGTAATG 
16 BglII-NLS-β-
gal-start 
Sense AGATCTAAAATGGCGAGGCCCGCGGAGAACAAGAAGCGCGG
CAGAGTCGTTTTACAACGTCGTGACTGGGAA 
17 NdeI-HA-Imp-
α-start 
Sense CATATGAAAATG(H)ATGGAGCGCAAGTTGGCCGATCGTCGAT
CG 
18 Imp-α-end-
stop-AvrII 
Anti-sense CCTAGGCTACTGGCCGAAGTTGAAGCCTCCCTGAGGCGGCG
CTGC 
19 BamHI-GCN5-
Bstart (MBP 
fustion) 
Sense GGATCCGCGCCTTCAGAGTGTCCCAGCGAC 
20 GCN5-Bend-
stop-HindIII 
Anti-sense AAGCTTTCACTAGAAAAATGTCGGATGCTTCGC 
21 LIC-AThook-
056400 fwd 
Sense TACTTCCAATCCAATTTAATGCTTCACCACCCACGGTGAACG
CTTTGATCTGC 
22 LIC-AThook-
056400 rev 
Anti-sense TCCTCCACTTCCAATTTTAGCACCGCGAGCAGGCACCACGAA
ACCGTCCACTGGACC 
23 LIC-AP2-3816 
fwd 
Sense TACTTCCAATCCAATTTAATGCGAACTCTGCTGTCACCGTGTC
GGGAGATACG 
24 LIC-AP2-3816 
rev 
Anti-sense TCCTCCACTTCCAATTTTAGCGGCAGTGGCGGGTTCTCCCAC
CTCAAGACATGATGAGAGC 
25 LIC-AP2-3948 
fwd 
Sense TACTTCCAATCCAATTTAATGCAGAGTACGGCCGAATGCTTCA
AAAGTGG 
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26 LIC-AP2-3948 
rev 
Anti-sense TCCTCCACTTCCAATTTTAGCAAAGTCTTCGTCAACAACGAAC
TTGCGAGTGC 
27 SDM GCN5-B 
E703G fwd 
Sense CAGCAGAAATTCGCCGGCATCGCTTTCCTCGCG 
28 SDM GCN5-B 
E703G rev 
Anti-sense CGCGAGGAAAGCGATGCCGGCGAATTTCTGCTG 
29 NdeI-DD Sense CATATGAAAATGGCGGGAGTGCAGGTGGAAACCATCTCC 
30 DD-Nsi-AvrII Anti-sense CCTAGGATCGATATGCATTTCCGGTTTTAGAAGCTCCACATC
GAAGACGAGAGTGGC 
31 Nsi-HA-GCN5-
Bstart 
Sense ATGCAT(H)GCGCCTTCAGAGTGTCCCAGCGACGCG 
32 LIC-GCN5-B 
fwd 
Sense TACTTCCAATCCAATTTAATGCCGTTCCTCAAACCTGTGAGTC
G 
33 LIC-GCN5-B 
rev 
Anti-sense TCCTCCACTTCCAATTTTAGCGAAAAATGTCGGATGCTTCGC
GCCCACAAGC 
34 B1 assay fwd Sense GGAGGACTGGCAACCTGGTGTCG 
35 B1 assay rev  Anti-sense TTGTTTCACCCGGACCGTTTAGCAG 
36 pLIC vectors 
sequencing 
Sense ACCTCACTCATTAGGCACCCCAGG 
37 ptubXFLAG Sense ::HX 
sequencing 
TCAGGACGCTTGCGCTCATCGC 
38 pMAL-c2X 
sequencing 
Sense AACCTCGGGATCGAGGGAAGG 
39 GCN5-B 1928 
sequencing  
Sense AGATGCCCAGAGAGTACATTGTCCGTCTCG 
40 GCN5-B 656 
sequencing  
Sense CAACGCGAGCATTGGAGACATTGC 
41 GCN5-B 2828 
sequencing 
Sense ACACGACTGCGCAGATGTTTGCGGACG 
42 GCN5-B 2852 
sequencing 
Sense ACGAAGTTCAGTTGATGTTCAAGAA 
43 DD 
sequencing 
Anti-sense TGGGTGCCCAGTGGCACCAT 
44 AP2-3816 
sequencing 
Sense AGGTTCGCGAGGCCTTAATGC 
45 AP2-3948 
sequencing 
Sense ACCTGCTGCTCCTCAAGTGCAGG 
(F) = FLAG epitope sequence GACTACAAGGACGACGACGACAAG 
(H) = HA epitope sequence TACCCGTACGACGTCCCGGACTACGCG 
(M) = c-myc epitope sequence GAGCAGAAGCTCATCTCTGAGGAGGACCTC 
LIC for sense primer TACTTCCAATCCAATTTAATGC 
LIC for anti-sense primer TCCTCCACTTCCAATTTTAGC 
Shading = nucleotides mutated for site-directed mutagenesis 
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B.  Ligation, bacterial transformation, and plasmid preparation 
 To ligate inserts into destination vectors, two approaches were used.  The first 
involved cloning the insert into pCR®4Blunt-TOPO® followed by sequence verification.  
The insert was then removed from pCR®4Blunt-TOPO® through restriction enzyme 
digestion.  The products of the digestion were resolved via agarose gel electrophoresis 
as previously described.  The desired band was excised and purified using a gel 
extraction kit (Invitrogen #K2100-12).  The purified DNA was then ready for ligation.  
Alternatively, a PCR could be digested with restriction enzymes directly after gel 
purification.  Following this digestion, the enzymes and buffers could be removed from 
the DNA by either agarose gel electrophoresis or phenol/chloroform extraction followed 
by ethanol precipitation.  The DNA was then ready to ligate into its destination vector.  
The destination vector was also digested with restriction enzymes and purified in the 
same manner.  All restriction enzymes and appropriate buffers were from NEB (New 
England Biolabs).  Restriction digestion reactions were performed at recommended 
temperatures, usually 37o
  To extract DNA via phenol/chloroform treatment, an equal volume of 
phenol:chloroform:isoamyl alcohol (25:24:1, USB #75831) was added, mixed, and 
centrifuged at 16,000 x g for 3 minutes.  The top, aqueous layer contains the DNA and 
was carefully removed to a new tube.  Next, an equal volume of pure chloroform was 
added, mixed, and centrifuged at 16,000 x g for 2 minutes.  Again, the top layer 
(containing the DNA) was removed to a new tube and mixed with 2.5X 100% cold 
ethanol, 0.1X 3M NaOAc, pH 5.2, and 0.01X glycerol, where X is the volume of starting 
material (from phenol/chloroform extraction).  The solution was mixed and incubated at -
20
C for at least one hour. 
oC for at least 30 minutes to precipitate the DNA.   Following incubation, the mixture 
was centrifuged at 16,000 x g for 10 minutes at 4o
 To ligate the purified insert into the purified vector, a quick ligation protocol 
employing T4 DNA ligase was utilized (NEB #M2200S).  First, both the vector and insert 
DNA were quantified with a NanoDrop® spectrophotometer (ND-1000).  For the ligation 
reaction, approximately 10 ng vector was combined with 50 ng insert in a 10 µl volume 
completed with ddH
C to pellet the DNA.  The DNA pellet 
was washed once in 70% ethanol and centrifuged again at 16,000 x g for 5 minutes.   
This wash was removed and the pellet was allowed to dry before resuspension in 10 mM 
Tris, pH 8.0. 
2O.  To this mixture, 10 µl of 2X reaction buffer was added along 
with 1 µl of T4 DNA ligase.  The reaction was mixed and allowed to incubate at room 
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temperature for 10 minutes.  Following incubation, the ligated vector was transformed 
into E. coli. 
 Bacterial transformation into E. coli was performed following cloning into 
pCR®4Blunt-TOPO® or after ligation of an insert into its destination vector.  Basically 
2.5 µl of reaction mixture was gently added to 50 µl One Shot® TOP10 chemically 
competent E. coli (Invitrogen #C4040-03).  The cells were gently mixed by tapping and 
incubated on ice for 20 minutes.  Following the incubation, the cells were heat shocked 
at 42oC for 30 seconds, followed by 2 minutes recovery on ice.  Next, 250 µl S.O.C. 
media (Invitrogen #15544034) was added to the cells, followed by a one hour incubation 
at 37oC with shaking at 250 rpms.  Next, the transformed E. coli bacteria were plated on 
LB agar plates containing appropriate antibiotic selection.  Plates were incubated at 
37o
 To test for bacteria containing the desired plasmid DNA, between 4 – 8 bacterial 
colonies were selected from each plate and inoculated into 2 ml liquid LB with 
appropriate antibiotic selection.  The cultures were allowed to grow between 8 and 16 
hours at 37
C overnight.  All pCR®4Blunt-TOPO® reactions required kanamycin selection (50 
µg/ml) while the destination vectors used ampicillin selection (50 µg/ml).  Table IV lists 
all vectors constructed and the primers used to amplify each insert. 
o
-80
C with shaking at 250 rpms.  After sufficient culture growth, 1.5 ml of each 
culture was used to isolate the plasmid DNA with 5 Prime’s FastPlasmid Mini Kit 
(#2300000) per the guidelines of the manufacturer.  Following purification, the plasmid 
DNA was screened via restriction digestion, followed by agarose gel electrophoresis.  
Any plasmid displaying the predicted bands following restriction digestion was sent for 
sequence verification at ACGT, Inc. (Wheeling, IL).  The primers used to sequence all 
destination vectors are listed in Table III.  A glycerol stock from the original bacterial 
culture was also made for all positives plasmids.  To make the glycerol stock, 250 µl 
bacterial culture was added to a sterile eppendorf tube and a large drop of sterile 
glycerol was added (approximately 25 µl or 10%).  The glycerol stock was stored at  
o
 For a large scale preparation of plasmids, a starter culture of 2 ml was inoculated 
from the glycerol stock and grown at 37
C and was used to inoculate additional cultures for propagation of the plasmid. 
oC with shaking at 250 rpms for 8 hours.  Next, 
100 µl of the starter culture was used to inoculate a 50 ml culture that was subsequently 
incubated overnight at 37oC.  This large culture was used for plasmid isolation with 
GenElute™HP Plasmid Maxiprep Kit (Simga-Aldrich #NA0310) per the manufacturer’s 
guidelines.  Upon completion, the elutant was centrifuged at 16,000 x g for 7 minutes to 
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remove residual resin from the purified plasmid DNA.  After centrifugation, the 
supernatant was ethanol precipitated as previously described, and the DNA was 
resuspend in 0.5 ml 10 mM Tris, pH 8.0.  The DNA was then quantified with a 
NanoDrop® spectrophotometer (ND-1000) and saved at -20o
  
C until needed for 
downstream applications. 
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Table IV:  Plasmids 
# Plasmid Name Parental vector Insert Primers 
1 TOPO®-GCN5-B pCR®4Blunt-TOPO® FL GCN5-B 1 & 2 
2 FLAG ptubXGCN5-B FLAG FL GCN5-B  ::HX 1 & 2 
3 HA-mycGCN5-B ptubXFLAG FLAG FL GCN5-B  ::HX 3 & 4 
4 FLAG ptubXΔ310GCN5-B FLAG Δ310GCN5-B  ::HX 5 & 2 
5 FLAG ptubXΔ313GCN5-B FLAG Δ313GCN5-B ::HX 6 & 2 
6 TOPO®-GCN5-BΔNLS pCR®4Blunt-TOPO® † GCN5-BΔNLS 10 & 11 
7 FLAG ptubXGCN5-BΔNLS FLAG GCN5-BΔNLS ::HX 1 & 2 * 
8 FLAG ptubXΔ310-R311A-GCN5-B FLAG Δ310-R311A-GCN5-B  ::HX 7 & 2 
9 FLAG ptubXΔ310-P312A-GCN5-B FLAG Δ310-P312A-GCN5-B ::HX 8 & 2 
10 FLAG ptubXΔ310-RP-AA-GCN5-B FLAG Δ310-RP-AA-GCN5-B ::HX 9 & 2 
11 β-gal ptubXFLAG FLAG FL β-gal ::HX 12 & 13 
12 β-gal-NLS ptubXFLAG FLAG FL β-gal + NLS ::HX 12 &14 
13 β-gal-NLS ptubXHA FLAG FL β-gal + NLS ::HX 12 & 15 
14 NLS-β-gal ptubXFLAG FLAG NLS + FL β-gal ::HX 16 & 13 
15 HA ptubXImp-α FLAG FL Imp-α ::HX 17 & 18 
16 AT-hook-056400 pLIC.3xHA::DHFR HA last 1,130 bp w/o TGA 21 & 22 
17 MBP-GCN5-B pMAL-c2X (NEB) FL GCN5-B 19 & 20 
18 AP2-3816 pLIC.3xHA::DHFR HA last 1,530 bp w/o TGA 23 & 24 
19 AP2-3948 pLIC.2xHA-DD::DHFR HA-DD last 1,014 bp w/o TAA 25 & 26 
20 TOPO®-DD-linker pCR®4Blunt-TOPO® ♦ DD 29 & 30 
21 TOPO®-DD-HA pCR®4Blunt-TOPO® GCN5-B DD & FL GCN5-B 31 & 2 
22 TOPO®-DD-HAGCN5-B DN pCR®4Blunt-TOPO® ± DD & FL GCN5-B; SDM 
for DN 
27 & 28 
23 DD-HA ptubXGCN5-B-WT FLAG DD & FL GCN5-B ::CAT 29 & 2 
24 DD-HA ptubXGCN5-B-DN FLAG DD & FL GCN5-B DN ::CAT 29 & 2 
FL = full-length; bp = base pairs; w/o = without; TGA, TAA = stop codons; DD = 
destabilization domain; WT = wild-type; SDM = site-directed mutagenesis; DN = 
dominant-negative allele 
† Refer to Chapter 2, Section II-D for details on construction of this plasmid. 
*To generate the insert for the construct ptub:FLAGGCN5-BΔNLS::HX, the plasmid 
TOPO®-GCN5-BΔNLS was used as the template DNA along with primers 1 & 2 to 
amplify GCN5-B lacking only the 10 residue NLS (aa 311-320). 
♦ The linker is an NsiI restriction site followed by 6 random nucleotides and an AvrII 
restriction site.  This allows a gene to be cloned downstream and in-frame with the DD 
using the NsiI and AvrII restriction sites. 
±Site-directed mutagenesis was performed on plasmid #21 (TOPO®-DD-HA
Note:  Plasmids #21 and #22 were used as template to amplify inserts for construction of 
plasmids #23 and #24, respectively. 
GCN5-B) 
with primers 27 & 28 to mutate the glutamic acid at position 703 to glycine (E703G), thus 
creating the dominant-negative allele. 
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C.  Ligation independent cloning 
 Ligation independent cloning (LIC) was an alternative method used to ligate 
inserts into certain destination vectors [192].  This method of cloning was utilized to 
construct all parasite transfection vectors used for endogenously tagging genes in 
Toxoplasma.  These vectors all contain LIC in their name (Table II) and were a gift from 
Dr. Michael White (University of South Florida).  LIC eliminates the need for traditional 
restriction enzyme digestion followed by ligation.  Instead, the LIC method involved 
generating insert PCR products that incorporate conjoining sequences at the termini.  
After treatment with T4 DNA polymerase in the presence of a single deoxyribonucleotide 
triphosphate, overhangs were generated that were complementary to overhangs 
produced after vector treatment.  The complementary overhangs allowed for sufficient 
annealing prior to transformation into bacteria.  After transformation, repair enzymes 
within the bacteria completed the ligation of the plasmid [192].  This process is highly 
efficient and allowed a single insert to be shuttled between several vectors without the 
need to switch restriction enzyme sites. 
 For LIC, the method developed and modified by Huynh et al. (2009) was utilized 
[187].  PCR inserts were generated as previously described using Phusion™ High-
fidelity DNA polymerase (NEB #F530S) with sense and anti-sense primers listed in 
Table III.  The LIC complementary conjoining sequences are underlined for each primer 
sequence.  The DNA template was Toxoplasma genomic DNA (gDNA) prepared as 
described in the next section (Chapter 2, Section II-D) and diluted in ddH2O.  To 
endogenously tag a gene, approximately 1 – 2 kB genomic fragment immediately 
upstream of the stop codon (but not including the stop codon) was amplified.  This 
fragment must contain a unique restriction site at least 350 bp from either end, in order 
to linearize the vector prior to parasite transfection.  Following amplification of the 
desired fragment by PCR, the insert was gel purified as previously described and 
quantified with a NanoDrop® spectrophotometer (ND-1000).  Next, 0.2 pmol insert was 
treated with T4 DNA polymerase (Invitrogen #18005017) in the following 20 µl reaction:  
4 µl 5X buffer, 1 µl 100 mM DTT, 0.8 µl 100 mM dCTP (Invitrogen #10217016), 0.5 µl T4 
DNA polymerase, 8.7 µl ddH2
  
O, 5 µl insert.  The reaction was mixed on ice and then 
placed in a thermocycler (Eppendorf Mastercycler) for the following program: 
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1. 22o
2. 75
C for 30 minutes 
o
3. 4
C for 20 minutes 
o
The insert was either used immediately or stored at -20
C indefinitely 
o
 To prepare the vector, approximately 5 µg vector DNA was digested with PacI 
overnight at 37
C until needed. 
oC.  After digestion, the vector DNA was subjected to phenol:chloroform 
extraction, followed by ethanol precipitation as described previously.  Next, the linearized 
vector was treated with T4 DNA polymerase (Invitrogen #18005017) in the following 60 
µl reaction:  12 µl 5X buffer, 3 µl 100 mM DTT, 2.4 µl 100 mM dGTP (Invitrogen 
#10218014), 1.5 µl T4 DNA polymerase, 35.1 µl ddH2
-20
O, 6 µl vector (200 – 300 ng/µl).  
The reaction was mixed on ice and then placed in a thermocycler.  The same program 
described above for the insert was used for the vector DNA as well.  At the completion of 
the thermocycler program, the vector DNA was either used immediately or stored at 
o
 To anneal the T4-treated vector and insert DNA, 1 µl treated vector was 
combined with 2 µl treated inserted.  The mixture was incubated at room temperature for 
10 minutes followed by the addition of 1 µl 25 mM EDTA with an additional incubation of 
5 minutes at room temperature.  Next, 1 µl of the annealing reaction was transformed 
into 50 µl One Shot® TOP10 chemically competent E. coli (Invitrogen #C4040-03) as 
previously described.  The remainder of the LIC construct preparation is the same as the 
plasmid preparations described earlier (Chapter 2, Section II-B). 
C until needed. 
 
D.  Inverse PCR 
 Inverse PCR was the method used to delete the NLS (30 nucleotides) from 
TgGCN5-B cDNA.  The inverse PCR is shown in Figure 5.  Template DNA was 
pCR®4Blunt-TOPO® containing full-length TgGCN5-B cDNA.  Primers #10 and #11 
were used to amplify the entire plasmid excluding the 30 nucleotides containing the NLS.  
The PCR reaction utilized Phusion™ High-fidelity DNA polymerase (NEB #F530S) and 
was set-up as previously described, except an extended elongation time of 4 minutes 
was used to ensure the entire plasmid was amplified.  Each primer incorporated a NheI 
site at the termini.  Therefore, following PCR amplification, the purified DNA was 
digested with NheI overnight at 37oC.  The digested vector was next subjected to a rapid 
ligation reaction with T4 DNA ligase (NEB #M2200S) as described earlier.  The 
remainder of the plasmid preparation was as previously described (Chapter 2, 
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Section II-B).  The 30 nucleotides encoding the NLS of TgGCN5-B were replaced with a 
NheI restriction site (6 nucleotides that encode for the amino acids Ala and Ser). 
 
 
Figure 5:  Inverse PCR to remove the nucleotides encoding the NLS of TgGCN5-B.  
Primers #10 (sense) #11 (anti-sense) were used to amplify the entire plasmid 
pCR®4Blunt-TOPO® containing full-length TgGCN5-B cDNA excluding the 30 
nucleotides encoding the NLS.  The plasmid was re-ligated after digestion with NheI, a 
restriction site incorporated into each primer.  This procedure replaced the NLS 
nucleotides of TgGCN5-B with a NheI site. 
 
E.  Genomic PCR from parasites 
The method described below utilized parasite DNA as a template for genomic 
PCR.  This protocol was used to amplify genomic fragments for vector construction or to 
screen parasite clones for the incorporation of genetic information into the genome.  In 
general, only a small amount (approximately 1 x 105-6) of parasites were needed to have 
enough material for PCR.  For this protocol, 1 ml of lysed parasites was transferred to a 
sterile eppendorf tube.  The parasites were pelleted by centrifugation at 3.3 x g for 5 
minutes at room temperature.  The media was aspirated away from the parasite pellet, 
and these pellets were either frozen until needed at -80o
To process parasite pellets for genomic PCR, the pellets were thawed on ice (if 
frozen) and then resuspended in 49 µl Genomic PCR Lysis Buffer (50 mM KCl, 10 mM 
Tris pH 8.3, 2.5 mM MgCl
C or processed directly for 
genomic PCR. 
2).  Next, 0.5 µl each of 1% SDS and ProteinaseK (20 mg/ml) 
was added to each lysate.  All lysates were mixed and incubated at 55oC overnight in a 
hybridization oven.  The following day, the lysates were heated at 95oC for 10 minutes to 
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deactivate the ProteinaseK.  The lysates were now ready to be used as templates in the 
PCR reactions. 
 General PCR procedures were used to amplify inserts from parasite gDNA and 
were performed as previously described (Chapter 2, Section II-A).  All parasite genomic 
PCRs for screening purposes were performed with Taq DNA polymerase (Invitrogen 
#10342-053).  The following formula is a master mix for four reactions.  If there were 
more reactions, this recipe could be appropriately manipulated.  Master Mix for Taq 
parasite genomic PCR included 79.5 µl H2O, 10.0 µl 10X Taq PCR buffer, 1.0 µl each 
primer (100 µM), 1.0 µl dNTPs (10 mM), 3.0 µl MgCl2, and 0.5 µl Taq DNA polymerase.  
All reactions were assembled on ice.  A 25 µl volume total PCR reaction was obtain by 
adding 24 µl master mix with 1 µl of treated lysate.  PCRs were then placed in a 
thermocycler (Eppendorf Mastercycler) with the lid temperature pre-incubated to 104o
1. 95
C.  
The following thermocycler protocol was performed: 
o
2. 95
C for 2 minutes 
o
3. T
C for 1 minute 
m for 2 minutes (See Tm
4. 72
 calculation in Chapter 2, Section II-A) 
o
5. Repeat steps 2 – 4 for a total of 35 cycles 
C for 2 minutes 
6. 72o
7. 4
C for 10 minutes 
o
After conclusion of the thermocycler protocol, all reactions were analyzed via 
agarose gel electrophoresis as previously described.  To view the PCR products, the gel 
was visualized under UV light. 
C hold 
 
F.  Site-directed mutagenesis 
 Site-directed mutagenesis was utilized to mutate a single amino acid (3 
nucleotides) in the HAT domain of TgGCN5-B that is critical for enzymatic activity.  The 
mutation of the glutamic acid at residue 703 to glycine (E703G) results in a catalytically 
inactive enzyme or HAT-dead TgGCN5-B [89].  To perform the mutagenesis of this 
residue, Stratagene’s QuikChange II XL Site-Directed Mutagenesis kit (#200521) was 
utilized and the manufacturer’s recommendations were followed.  The first step was to 
use PCR to synthesize the mutated strand.  The template DNA was pCR®4Blunt-
TOPO® containing full-length TgGCN5-B cDNA (plasmid #21).  The reaction included 10 
ng of template DNA, 1 µl 1:10 dilution of primers #27 and #28, 5 µl 10X reaction buffer, 
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1 µl dNTP mix, 3 µl QuikSolution, 1 µl PfuUltra DNA polymerase, and ddH2O to 
complete the volume to 50 µl.  The reaction was mixed on ice and then placed in a 
thermocycler (Eppendorf Mastercycler; lid preheated to 104o
1. 95
C) for the following program: 
o
2. 95
C for 1 minute 
o
3. 60
C for 50 seconds 
o
4. 68
C for 50 seconds 
o
5. Repeat steps 2 – 4 for 18 cycles 
C for 8 minutes 
6. 68o
7. 4
C for 7 minutes 
o
Following completion of the PCR thermocycler program, 1 µl DpnI was added to 
the PCR mixture, and the reaction was placed at 37
C indefinitely 
o
 
C overnight.  DpnI is an 
endonuclease that specifically cuts methylated and hemimethylated DNA.  The purpose 
of this step is to digest the parental DNA template leaving only the newly synthesized 
mutated DNA.  After DpnI digestion, 2 µl of the digested PCR reaction was transformed 
into 50 µl One Shot® TOP10 chemically competent E. coli (Invitrogen #C4040-03) as 
previously described.  The remainder of the site-directed mutageneis preparation is the 
same for the plasmid preparations described earlier.  To confirm the mutated residues, 
plasmids were sequenced by ACGT, Inc. (Wheeling, IL). 
III.  Biochemical techniques 
 
A.  Immunofluorescence assay 
 Immunofluorescence assays (IFA) were used to monitor parasite expression of 
epitope-tagged transgenic proteins using commercial antibodies as well as native 
proteins with custom-made antibodies.  Parasites (50 – 100 µl from lysed T25 flask or 
approximately 1 x 104-5) were inoculated into a 12-well plate with coverslips containing 
confluent HFF cell monolayers.  The parasites were incubated at previously described 
conditions (Chapter 2, Section I-A) for 18 – 24 hours.  Following incubation, the parasite 
media was removed and the coverslips were washed 3 times in PBS to remove any 
extracellular parasites or debris.  Next, the cells were fixed and permeabilized using 
100% cold methanol for 10 minutes at -20oC, followed by 3 washes in PBS.  After the 
PBS washes, the coverslips were blocked in 3% bovine serum albumin (BSA, Sigma-
Aldrich #A3059) diluted in PBS for 2 hours at room temperature or overnight at 4oC.  
52 
Following blocking, the primary antibody was diluted in 3% BSA in PBS and incubated 
for 1 – 2 hours at room temperature, followed by 3 washes in PBS.  Table V provides 
descriptions, including the dilutions, of primary and secondary antibodies used for IFA.  
The secondary antibody, which is conjugated to a fluorescent dye, was diluted in 3% 
BSA in PBS and incubated on the coverslips for 1 hour at room temperature in the dark.  
For the remainder of the IFA protocol everything was done in the dark to prevent photo-
bleaching.  The coverslips were washed 3 times in PBS followed by application of 4’,6-
diamidino-2-phenylindole (DAPI; Invitrogen #D3571) diluted to 0.2 µM in PBS for 5 
minutes at room temperature.  After 3 final washes in PBS, coverslips were mounted 
onto a glass slide using 8 µl mounting reagent containing 50% glycerol with Mowiol 4-88 
(Calbiochem #81381) and DABCO (Sigma #10981) to reduce photobleaching.  Slides 
were allowed to dry prior to being viewed with a Leica DMLB scope with a 100X HCX 
Plan Apo oil immersion objective.  All images were captured with a monochrome SPOT-
RTSE (model 12) camera and Spot Diagnostic software (version 7.0) and pseudocolored 
using Adobe Photoshop 7.0. 
 The majority of the IFAs presented in this manuscript were fixed and 
permeabilized with cold 100% methanol at -20o
  
C for 10 minutes.  However, this method 
of fixation/permeabilization can distort the parasite morphology.  For the purpose of 
visualization of nuclear versus cytoplasmic protein distribution, a slight distortion of 
parasite morphology does not alter the results, which is why methanol fixation was still 
used.  Alternatively, another method for fixation and permeabilization exists that 
preserves the parasite morphology.  This method uses paraformaldehyde (PFA) to fix 
the parasites and Trition-X to permeablize.  When analyzing parasites for cell-cycle and 
division, this alternative was utilized.  In general, after washing infected coverslips in 
PBS, cells were fixed in 3% PFA diluted in PBS for 15 minutes at room temperature.  
After 3 washes in PBS, the cells were quenched by adding 1 ml 0.1M glycine in PBS for 
5 minutes at room temperature.  Cells were again washed in PBS 3 times, followed by 
permeabilization with 0.2% Triton X-100 diluted in 3% BSA in PBS for 10 minutes at 
room temperature.  After 3 washes in PBS, the cells were blocked in 3% BSA and the 
remainder of the IFA is as described above. 
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Table V:  Antibodies used in IFA and Western blotting 
Antibody Description Source Dilution 
Primary Antibodies   
Anti-HA (clone 3F10) 
rat, monoclonal 
Roche #11867423001 
#11815016001 (affinity resin) 
WB or IFA: 
1:1000 – 2000 
Anti-FLAG® M2 
mouse, monoclonal 
Sigma #F1804 IFA:  1:2000 
Anti-FLAG® 
rabbit, polyclonal 
Sigma #F7425 
#A4596 (M1 affinity gel) 
WB:  1:1000 
Anti-c-myc (clone 9E10) 
mouse, monoclonal 
Roche #11667149001 WB:  1:1000 
Anti-acetyl histone H3 
rabbit, polyclonal 
Upstate #06-755 WB:  1:1000 
Anti-histone H3 
rabbit, polyclonal 
Upstate #06-755 WB:  1:1000 
Anti-acetyl lysine 
rabbit, polyclonal 
Stressgen #KAP-TF120 WB:  1:500* 
Anti-Sag1 Toxoplasma 
mouse, monoclonal 
Meridian Life Science, Inc. #C86319M IFA:  1:4000 
Anti-TgGCN5-B (peptide) 
rabbit, polyclonal from terminal bleed 
(not affinity purified) 
QBC, custom antibody 
designed to last 30 amino acids 
WB or IFA:  1:1000 
Anti-TgIMC1 Toxoplasma 
mouse, gift from Dr. Michael White 
(University of South Florida) 
Custom antibody IFA:  1:2000 
Anti-TgPCNA Toxoplasma 
rabbit polyclonal, gift from Dr. Michael 
White (University of South Florida) 
Custom antibody IFA:  1:5000 
Anti-MBP 
mouse, monoclonal 
NEB #E80325 WB:  1:5000 
Secondary Antibodies   
ECL rat IgG, HRP-linked 
(from goat) 
GE Healthcare # NA935 WB:  1:5000 
ECL mouse IgG, HRP-linked 
(from goat) 
GE Healthcare #NA931 WB:  1:5000 
ECL rabbit IgG HRP-linked 
(from goat) 
GE Healthcare # NA934 WB:  1:5000 
Alexa Fluor® 488 anti-rat, IgG 
(from goat) 
Molecular Probes # A-11006 IFA:  1:2000 
Alexa Fluor® 488 anti-mouse, IgG 
(from goat) 
Molecular Probes # A-11017 IFA:  1:2000 
Alexa Fluor® 488 anti-rabbit, IgG 
(from goat) 
Molecular Probes # A-11070 IFA:  1:2000 
Alexa Fluor® 594 anti-mouse, IgG 
(from goat) 
Molecular Probes # A-11072 IFA:  1:2000 
WB, Western blot; HA, hemagglutinin; MBP, maltose binding protein; ECL, enhanced 
luminol-based chemiluminescent; HRP, horseradish peroxidase 
The dilutant for WBs was either 5% non-fat dry milk or 3% BSA in TBST.  Most 
antibodies were diluted in milk although occasionally BSA was required (denoted by *).  
The dilutant for all IFAs was 3% BSA in PBS. 
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B.  Immunoprecipitations 
 Immunoprecipitations were typically performed using parasite lysates to isolate 
epitope-tagged proteins.  Parasite lysates were generated and quantified as described in 
Chapter 2, Section I-E.  Typically 300 – 500 µg of lysate was used for each 
immunoprecipitation reaction.  The majority of proteins were expressed with an HA 
epitope tag, although a few had a FLAG tag.  A resin that contains antibody coupled to 
beads exists for both tags (Roche anti-HA affinity matrix #11815016001 and Sigma 
Aldrich Anti-FLAG® M1 Agarose Affinity Gel #A4596).  Prior to being added to lysates, 
the resin was washed 3 times in Lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% 
Nonidet P40) and then approximately 50 µl of slurry (resin/Lysis buffer mixture) was 
added to each lysate.  The mixtures were incubated overnight at 4oC with rocking to 
immunoprecipitate the epitope-tagged protein.  The next day, the resins were washed 3 
– 5 times in Lysis buffer for 10 minutes each.  At this point, the resin/immunoprecipitated 
material was ready for down-stream applications such as HAT assays or analysis via 
SDS-PAGE and western blotting.  To prepare the resin/immunoprecipitated material for 
SDS-PAGE, the resin was resuspended in 50 – 100 µl of 1X SDS load dye.  The master 
mix for the 1X SDS load dye includes 300 µl ddH2O, 100 µl 4X NuPAGE Loading Dye 
(Invitrogen #NP0007), 20 µl beta-mercaptoethanol (β-Me; Sigma #M7154) and was 
made fresh each time.  Next, the samples were heated at 95o
 If a resin (antibody coupled to beads) did not exist for a given antibody to be 
used in an immunoprecipitation reaction, then usually 5 – 10 µl of antibody (depending 
on concentration, if available) was added directly to lysate (see Table V).  This was 
incubated overnight at 4
C for 10 minutes.  The 
combination of the SDS load dye and the heating disassociates the immunoprecipitated 
material from the resin.  The samples were then ready for analysis via SDS-PAGE. 
oC with rocking.  The next day, 50 µl agarose beads coupled to 
either Protein A (Roche #11719408001) or Protein G (Roche #11719416001) were 
added to each immunocipitation reaction and allowed to incubate for an additional hour 
at 4oC with rocking.  The beads were washed 3 times in Lysis buffer prior to being 
added.  Protein A has the ability to bind rabbit antibodies, whereas Protein G binds best 
to mouse antibodies.  The addition of the beads coupled to either Protein A or G allows 
for the antibody/immunoprecipitated protein complex to be captured and purified from 
the rest of the lysate.  The remainder of the immunoprecipitation protocol is the same as 
described above. 
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Another modification to immunocprecipitation reactions involves the stringency of 
the Lysis buffer and/or wash buffer.  The concentration of NP-40 in the Lysis/wash buffer 
can be lowered to 0.05% or switched to another detergent such as Triton-X, which is 
less stringent. 
 
C.  SDS-PAGE and Western blotting 
 Prior to analyzing protein samples via gel electrophoresis, all samples were 
mixed with 4X NuPAGE Loading Dye (Invitrogen #NP0007) and 5% beta-
mercaptoethanol (β-Me; Sigma #M7154).  Typically, 30 µl of sample was mixed with 10 
µl 4X loading dye and 2 µl β-Me.  Samples were then heated to greater than 70o
 To silver-stain, the gel was fixed twice for 15 minutes in a solution of 30% ethanol 
and 10% acetic acid.  The fixing reagent was removed, and the gel was next incubated 
for 30 minutes in Reducer, a thiosulfate buffer containing 10 mM sodium acetate, 30% 
ethanol, and 1 mg/ml sodium thiosulfate (pH 6.0 with acetic acid).  The Reducer was 
made without the addition of sodium thiosulfate and stored at 4
C for 10 
minutes prior to being resolved on 4 – 12% NuPAGE Bis-Tris SDS gels (Invitrogen 
#NP0335BOX).  Each gel included 10 µl of SeeBlue® Plus2 Protein Standard 
(Invitrogen #LC5925) to estimate molecular weight.  The running buffers for 
electrophoresis contained either MES (2-Morpholinoethanesulfonic acid) or MOPS (3-(N-
Morpholino) propanesulfonic acid).  Each chemical has a different pKa accounting for a 
variance in running time and separation range of proteins.  MES runs faster than MOPS, 
although MOPS provided better resolution of higher molecular weight proteins [193].  
Therefore, MOPS was the preferred buffer.  All buffers for SDS-PAGE and Western 
blotting were diluted from 20X stocks:  20X MOPS Buffer (50 mM MOPS, 50 mM Tris-
base, 0.1% SDS, 1 mM EDTA, pH 7.7) or 20X MES Buffer (50 mM MES, 50 mM Tris-
base, 0.1% SDS, 1 mM EDTA, pH 7.3).  Following electrophoresis, gels could be 
processed for Western blotting (see below) or stained with Simply Blue™ Safe Stain 
(Invitrogen #LC6060) or silver-stained to visualize the proteins. 
oC until needed.  Prior to 
use, the Reducer was warmed to room temperature, and sodium thiosulfate was added.  
Following the incubation in the Reducer, the gel was washed 3 times in ddH2O.  Next, 
50 mg silver nitrate was diluted in 50 ml ddH2O.  To this solution, 12.5 µl of 37% 
formaldehyde was also added.  The gel was incubated in the silver nitrate solution for 30 
minutes.  After this incubation, the gel was rinsed briefly in ddH2O, prior to the addition 
of the Developer solution (2.5 % Na2CO3 + 25 µl of 37% formaldehyde per 50 ml).  After 
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approximately 2 minutes of incubation in Developer, the protein bands of the gel would 
appear.  At this point, the reaction was quenched by the addition of 1% acetic acid.  The 
gel was allowed to incubate an additional 5 – 10 minutes prior to visualization and 
recording. 
 For Western blotting, proteins from the gel were transferred to a nitrocellulose 
membrane (Invitrogen #LC2001) with a 1X dilution of Transfer Buffer from a 20X stock 
solution (25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA, pH 7.2).  To ensure proper 
transfer, the membrane was stained with Ponceau S (Sigma-Aldrich #P7170-1L) to 
visualize proteins.  Next, the membrane blot was blocked in either 5% non-fat dry milk or 
3% BSA diluted in TBST (20mM Tris, pH 7.4, 150mM NaCl, 0.1% v/v Tween-20).  
Blocking was either overnight at 4o
 
C or for at least 2 hours at room temperature.  The 
preferred blocking reagent was non-fat dry milk, although some antibodies required BSA 
(where indicated, see Table V).  BSA was a more sensitive blocking reagent, although 
more background occurred with its use.  Immediately following blocking the primary 
antibody was applied, diluted in either 5% milk or 3% BSA in TBST.  The primary 
antibody was incubated on the blot for at least one hour at room temperature, followed 
by 3 washes in TBST.  Next, the secondary antibody diluted in either 5% milk or 3% BSA 
in TBST was applied to the blot and allowed to incubate for at least one hour at room 
temperature followed by 3 washes in TBST.  Refer to Table V for antibody specifics 
including dilutions.  All secondary antibodies were coupled to horseradish peroxidase 
(HRP).  To visualize the Western, the blot was treated in the dark with Amersham’s 
ECL™ detection reagent (#RPN2209) for one minute.  Excess reagent was removed 
and the blot was wrapped in cellophane and placed in a metal film tray.  In a 
photography dark room, the blot was exposed to High Senstive Blue photographic film 
(RPS imaging #33-0810) for various times (30 seconds to 5 minutes).  The film was 
processed through an automated developer. 
D.  HAT assays 
 In vitro HAT assays were used to evaluate the enzymatic activity of TgGCN5-B.  
For all work presented in this thesis, a non-radioactive method was utilized.  Typically, 
HAT assays were performed “on-bead,” meaning with enzymes purified from 
immunoprecipitation reactions that were still attached to the resin.  Prior to starting the 
assay, a 5X HAT buffer was prepared and included 250 mM Tris HCl, pH 8.0, 25% 
glyercol, 0.5 mM EDTA, 250 mM KCl, 5 mM DTT, 5 mM PMSF, and 50 mM sodium 
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butyrate.  This buffer was aliquoted, stored at -80oC, thawed, and diluted when needed.  
For on-bead HAT assays, the IP resin was first washed once in 1X HAT buffer prior to 
being resuspended in 28 µl 1X HAT buffer.  To this mixture, 1 µl recombinant histone H3 
(1 µg/µl, Upstate #14-411) and 1 µl acetyl CoA (1 mM, Sigma-Aldrich #A2056) was 
added.  The mixture was then incubated at 37oC for one hour with manual mixing every 
10 minutes.  After the completion of the incubation, 10 µl 4X NuPAGE Loading Dye 
(Invitrogen #NP0007) and 2 µl β-Me were added.  The reactions were heated for 10 
minutes at greater than 70o
 Alternatively, a similar reaction could be assembled using recombinant enzyme.  
In this case, purified enzyme was combined with 6 µl 5X HAT buffer, 1 µl recombinant 
histone H3, 1 µl acetyl CoA, and completed to a total volume of 30 µl with ddH
C and resolved using SDS-PAGE gel electrophoresis, 
followed by processing for Western blotting as previously described (Chapter 2, Section 
III-C).  Anti-acetyl histone H3 antibody (Table V) was used for detection. 
2
 
O.  The 
remainder of the procedure is the same as described above. 
E.  Bacterial Inductions 
 Bacterial inductions were utilized to generate proteins, such as the MBP-
TgGCN5-B fusion protein used in affinity chromatography.  This method also can be 
applied to the production of both GST- and His-tagged proteins.  The methods described 
below represent a general protocol for bacterial inductions.  For each individual protein 
that was purified, slight modifications might be needed to obtain optimal results. 
 After completion of vector construction for any plasmid destined for bacterial 
induction, the plasmid must be transformed into bacteria capable of inducing proteins.  
The preferred bacterial strain (and the one used for all MBP fusion constructs) was One 
Shot® BL21 Star™ (DE3) chemically competent E. coli (Invitrogen #C601003).  The 
plasmid(s) were transformed into this bacterial strain as previously described.  From the 
transformation plate, a single colony was picked and inoculated into a 2 ml LB culture 
(containing appropriate antibiotic) for growth at 37oC overnight.  Part of this culture was 
used to make a glycerol stock (as previously described; Chapter 2, Section II-B) while 
the rest was used for a pilot induction.  The pilot induction followed the same protocol as 
will be outlined for a large scale induction, except the induced culture was 10 ml instead 
of 100 ml.  Pilot inductions were performed to ensure the bacteria were able to produce 
the protein of interest, test the conditions, and ensure the protein was soluble. 
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 For the large scale induction, a 5 ml starter culture was inoculated from the 
glycerol stock and allowed to grow overnight at 37oC.  The next day, 1 ml of the starter 
culture was used to inoculate a 100 ml culture.  The 100 ml culture was grown at 37oC 
until an OD600 of approximately 0.6 was reached.  Next, the 100 ml culture was moved to 
a shaking incubator (250 rpms) at 15oC (in cold room) and allowed to acclimate to the 
new temperature for approximately 30 minutes.  After acclimation, 0.5 mM IPTG 
(isopropyl β-D-1-thiogalactopyranoside) was added to the culture, which continued to 
incubate overnight at 15oC.  Before the additional of IPTG, a 1 ml sample was removed 
from the culture that would serve as an uninduced control when testing the induction.  
The next day, another 1 ml sample was removed (induced sample), while the rest of the 
culture was pelleted by centrifugation (2,800 x g for 30 minutes).  The media was 
decanted away from the bacterial pellets, which were subsequently stored at -20o
 The 1 ml samples were used to test the induction and ensure protein was 
produced.  The bacteria from each sample were pelleted by centrifugation (16,000 x g 
for 2 minutes) followed by removal of the media away from the bacterial pellet.  Next, the 
bacterial pellets were resuspended in 100 µl PBS and lysed by sonication (3 times for 15 
seconds at 30% power following by 30 second recovery on ice after each round using an 
Ultrasonic processor sonicator).  The insoluble protein was separated by centrifugation 
at 16,000 x g for 10 minutes at 4
C until 
needed. 
o
 
C.  The soluble fraction was removed to a new, pre-
chilled tube on ice, while the insoluble pellet was resuspended in 100 µl 1X SDS load 
dye and sonicated again under the same conditions.  At this point, both the soluble and 
insoluble fractions were ready to be analyzed via SDS-PAGE followed by staining with 
Simply Blue™ Safe Stain (Invitrogen #LC6060) to visualize the proteins.  A Western blot 
could also be performed if necessary.  If the induction was successful, then the larger 
bacterial pellets would be processed for harvesting and purifying the induced protein.  
The next section will outline this protocol for MBP-tagged proteins.  Similar methods 
exist for other protein tags. 
F.  Purification of MBP fusion proteins 
 To purify MBP-fused proteins expressed in bacteria, the bacterial pellets were 
thawed on ice for approximately 20 minutes, followed by resuspension in 5 ml MBP 
column buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA).  Protease inhibitors were 
added to each bacterial suspension and included 1 uM PMSF and 50 µl of Sigma’s 
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protease inhibitor cocktail (#P8849).  Next, the bacterial solution was sonicated 3 times 
for 30 seconds at 45% power with a 30 second recovery on ice after each round using 
an Ultrasonic processor sonicator.  Following sonication, the solution was centrifuged at 
2,800 x g for 20 minutes to separate the soluble and insoluble fractions.  The soluble 
supernatant was removed from the insoluble pellet.  A 100 µl sample from the soluble 
portion was saved for analysis (termed crude extract).  To prepare for purification, the 
remaining soluble fraction was diluted with an equal volume column buffer. 
 To purify the MBP-fusion proteins, a column containing 1 ml amylose resin (NEB 
#E80215) was assembled with glass wool in a 10 ml syringe.  The column was washed 
3 times with 3 ml column buffer.  Next, the diluted soluble fraction was passed over the 
column.  The flow through from this step was saved for analysis.  The column was next 
washed 4 times in 3 ml column buffer.  The washes were also saved for analysis.  To 
elute the bound protein from the column, an elution buffer consisting of column buffer 
supplemented with 10 mM maltose was utilized.  The elution buffer was added to the 
column in 1 ml aliquots with each fraction collected individually.  After completion of the 
purification, all samples including crude extract, flow through, washes, and elutions were 
analyzed via SDS-PAGE followed by staining with Simply Blue™ Safe Stain (Invitrogen 
#LC6060) to visualize the proteins.  If the purification was successful, the desired elution 
fractions were combined and dialyzed in coupling buffer (0.1 M phosphate buffer, pH 
7.0). 
 
G.  Affinity chromatography 
 The first step in affinity chromatography was to couple the desired protein to the 
Affi-Gel 15 resin (Bio-Rad #153-6051).  To determine TgGCN5-B associating proteins, 
two Affi-Gel resins were prepared, one containing MBP alone and the other with MBP-
GCN5-B.  To prepare each resin, 1 ml of Affi-gel was utilized.  Prior to coupling the Affi-
Gel was washed once in 30 ml ice cold ddH2O followed by a wash in 10 ml of cold 
coupling buffer (0.1 M phosphate buffer, pH 7.0).  Next, the dialyzed protein (prepared 
as described in previous section) was added to the Affi-Gel resin and allowed to 
incubate overnight with rocking at 4oC.  The next day, the unbound portion was removed 
and the Affi-Gel resin was washed in 10 ml 10 mM Tris, pH 7.5.  This was followed by a 
single wash each in 10 ml 100 mM glycine, pH 3.0 and 10 ml 10 mM Tris, pH 8.8.  The 
final 2 washes were in 10 ml 10 mM Tris, pH 7.5.  The coupled Affi-Gel resin was stored 
in 5 ml 10 mM Tris, pH 7.5 containing 0.01% azide at 4oC until needed. 
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 For affinity chromatography, the storage solution was removed from the coupled 
Affi-Gel resins by centrifugation at 2,800 x g for 1 minute.  The MBP resin was then 
washed 3 times in 5 ml MBP wash buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10% 
glycerol).  Next, the dialyzed nuclear-enriched parasite lysate (Chapter 2, Section I-F) 
was added to the MBP resin and allowed to incubate at 4oC for 4 hours with rocking.  
This step was to pre-clear the nuclear-enriched lysate of any protein that would bind 
non-specifically to MBP.  After incubation, the pre-cleared nuclear-enriched lysate was 
separated from the MBP-Affi-Gel resin by centrifugation and added to the MBP-GCN5-B-
Affi-gel resin.  The MBP-GCN5-B-Affi-Gel resin was washed 3 times in 5 ml MBP wash 
buffer prior to the addition of the pre-cleared nuclear-enriched lysate.  The pre-cleared 
nuclear-enriched lysate was incubated with the MBP-GCN5-B-Affi-gel resin overnight at 
4o
 To elute the proteins that bound each individual resin (MBP bound, and MBP-
GCN5-B bound), 2 ml 100 mM glycine pH 3.0 was added to each resin, followed by 
incubation for 5 minutes at 4
C with rocking.  After incubation with the nuclear-enriched lysate, each column was 
washed 3X in 5 ml MBP wash buffer prior to elution of the bound proteins. 
o
 After eluting the bound proteins, each Affi-gel resin was washed once in 10 ml 10 
mM Tris, pH 8.8 and 10 mM Tris, pH 7.5.  The resin was stored in 5 ml 10 mM Tris, pH 
7.5 containing 0.01% azide and stored at 4
C.  The eluted protein fraction was separated from the resin 
by centrifugation and removed to a new tube containing 1.0 M Tris, pH 8.0, (10% of the 
eluted volume).  The eluted portion was saved for analysis and downstream 
applications. 
o
 Samples of both the eluted proteins from the MBP and MBP-GCN5-B resins 
were analyzed via SDS-PAGE followed by silver staining to visualize the proteins.  The 
eluted fractions were also analyzed via mass spectrometry (in collaboration with Dr. W. 
Andy Tao, Purdue University) for identification (Appendix B).  Protein identified in the 
MBP-GCN5-B sample but not the MBP sample was a potential TgGCN5-B interacting 
protein. 
C.  The resins could be used multiple times. 
 
IV.  Toxoplasma growth assays 
 
 Several assays were utilized to monitor the replication rate and survival of 
Toxoplasma under various conditions.  When evaluating the growth of different mutants 
of Toxoplasma, multiple types of growth assays were used to validate the results. 
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A.  Plaque assay 
 Toxoplasma plaque assays were performed in 12-well culture plates containing 
confluent monolayers of HFF cells.  Prior to infection with the parasites, the host cell 
media in each well was replaced with Toxoplasma media.  Freshly lysed parasites from 
each strain/mutant to be examined were counted 4 times using a hemocytometer 
(Appendix A).  Based on the counts, the parasites were diluted in Toxoplasma media to 
a concentration of 1.0 x 105 parasites per 1 ml.  From these dilutions, 5 µl 
(corresponding to 500 parasites) was inoculated into each well in duplicate or triplicate.  
The parasites were incubated for 2 hours at previously described conditions (Chapter 2, 
Section I-A) to allow for invasion.  Following incubation, the media and any parasites that 
did not invade were removed and replaced with Toxoplasma media containing treatment 
or vehicle control.  Plates were incubated as previously described (Chapter 2, Section I-
A) for 5 – 6 days.  During the incubation period, it was important to not disturb the plates, 
as movement could distribute the parasites and cause the formation of secondary 
plaques.  After 6 days, plates were examined using light microscopy to ensure that 
control parasites had formed visible plaques.  Next, the media was removed, wells were 
washed once in PBS, and each well was fixed with 100% cold methanol at -20o
 
C for 10 
minutes.  Following fixation and removal of the methanol, the plates were allowed to dry 
overnight at room temperature under ambient conditions.  After drying, the host cell 
monolayer became opaque and the parasite plaques could be visualized as cleared, 
transparent areas among the nontranslucent background.  Plaques could be counted 
and scored at this time, although if a difficulty in visualization occurred, the wells could 
be stained with crystal violet to enhance the contrast between the cleared parasite 
plaques and the host cell monolayer.  Each individual well was counted for number of 
plaques three independent times, blind to treatment and strains.  The data was recorded 
in Microsoft Office Excel, where subsequent statistical analysis was performed.  To 
determine significant values, the student’s t-test was utilized with p values < 0.01 being 
significant. 
B.  B1 gene detection assay to monitor Toxoplasma growth 
 To prepare for the B1 gene detection growth assay [194,195], freshly lysed 
parasites from each strain/mutant to be examined were counted 4 times using a 
hemocytometer (Appendix A).  Parasites were diluted in Toxoplasma media to a 
concentration of 1.0 x 105 parasites per 1 ml.  From these dilutions, 10 µl per well 
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(corresponding to 1000 parasites) was inoculated into an entire row (6 wells) of a 24-well 
culture plate containing confluent HFF monolayers.  Prior to parasite inoculation, the 
host cell media was replaced with Toxoplasma media.  The parasites were incubated for 
2 hours at previously described conditions (Chapter 2, Section I-A) to allow for invasion.  
Following incubation, the media and any parasites that did not invade was removed and 
replaced with Toxoplasma media containing treatment or vehicle control.  Plates were 
incubated as previously described (Chapter 2, Section I-A).  Every 24 hours a well 
(containing host cells and parasites) for each strain and treatment was harvested.  The 
B1 gene is specific for Toxoplasma, so the presence of host cells will not affect the 
assay. 
 To harvest and subsequently purify the genomic DNA, Qiagen’s DNeasy Blood 
and Tissue kit (#69506) was used.  The lysis solution for harvesting the cells/parasites 
included 200 µl PBS, 200 µl AL buffer, and 20 µl Proteinase K (the latter two items were 
provided in the kit) per well.  After addition of lysis solution, each well was scraped with 
the end of a pipet tip to obtain all material, and the contents were stored in an eppendorf 
tube.  Following harvesting, each well was viewed under a light microscope to ensure all 
material was obtained.  Samples were stored at -20o
 Upon completion of the assay, the genomic DNA was purified from each sample 
using Qiagen’s DNeasy Blood and Tissue kit (#69506) per the manufacturer’s protocol.  
Included in the genomic DNA purification was a parasite pellet containing a known 
quantity of parasites, which served as a standard for quantification.  Following DNA 
purification, samples were heated at 95
C until completion of the assay.  
Harvests were performed through day 5 when control parasite strains typically began to 
lyse the host cell monolayer. 
o
 Quantitative real-time PCR was utilized to amplify the Toxoplasma B1 gene from 
each sample [194].  A 25 µl reaction was assembled in triplicate for each sample.  The 
reaction included 1 µl 1:10 dilution of sample DNA, 12.5 µl SYBR green mix (Applied 
Biosystems #4309155), 1.0 µl of each primer (#34 and #35, diluted to 12.5 µM), and 9.5 
µl ddH
C for 5 minutes to heat inactivate residual 
Proteinase K. 
2O.  In addition to each sample, triplicate reactions were assembled for 1 µl of 
DNA from 4 standards of known parasite quantities (102, 103, 104, 105).  The quantitative 
PCR was performed using the StepOnePlus™ Real-Time PCR System (Applied 
Biosystems) with data analysis provided by the system’s software.  To determine 
significant values, the student’s t-test was utilized with p values < 0.01 being significant. 
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C.  Doubling assay 
 To directly assess the difference between various Toxoplasma strains and 
treatments with respect to parasite replication rates, a doubling assay was performed.  
This assay monitors the number of parasite doublings as a function of time and thereby 
provides a means to monitor parasite growth at an individual level [182].  The doubling 
assay was performed in T25 flasks containing confluent monolayers of HFF host cells.  
Prior to infection with the parasites, the host cell media in each flask was replaced with 
Toxoplasma media.  Freshly lysed parasites from each strain/mutant to be examined 
were counted 4 times using a hemocytometer (Appendix A).  Parasites were diluted in 
Toxoplasma media to a concentration of 1.0 x 105 parasites per 1 ml.  Then, 1 ml 
containing 1.0 x 105
  
 parasites was inoculated into each T25 flask for each strain and 
each treatment.  The parasites were incubated for 2 hours at previously described 
conditions (Chapter 2, Section I-A) to allow for invasion.  Following incubation, the 
media, along with parasites that did not invade was removed from each flask and 
replaced with Toxoplasma media containing treatment or vehicle control.  The flasks 
were incubated as previously described (Chapter 2, Section I-A).  Every 12 hours, flasks 
were removed and examined via light microscopy.  The number of individual parasites 
within 50 randomly selected vacuoles was counted for each time point.  The assay was 
continued with counting every 12 hours until parasite vacuoles began to lyse.  The 
doubling assay counts were performed blind to both strain and treatment.  Data was 
recorded in Microsoft Office Excel.  Since the parasite vacuoles were scored using a 
discontinuous numerical set, the data could not be analyzed by standard parametric 
statistics. 
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Chapter 3:  Results 
 
I.  Aim 1:  Determine how TgGCN5-B enters the parasite nucleus 
 
A.  TgGCN5-B requires its N-terminus to enter the parasite nucleus 
 Bhatti et al. (2006) initially discovered that Toxoplasma possesses two GCN5 
homologues, which at the time was thought to be unique among protozoans [169].  In 
the initial characterization of these HATs, it was determined that parasites expressing a 
FLAG-tagged truncated TgGCN5-B lacking its N-terminal extension (FLAGGCN5-BΔ528) 
excluded the protein from the parasite nucleus [169].  Scanning of the primary amino 
acid sequence of N-terminal region of TgGCN5-B revealed that this protein does not 
possess the same nuclear localization signal that is required for TgGCN5-A to enter the 
parasites nucleus (RKRVKR) [144].  However a basic-rich region, a hallmark 
characteristic of nuclear localization signals (NLSs), was identified from amino acid 316 
– 319 (KKRGR).  Bhatti et al. began to determine if this was the NLS of TgGCN5-B by 
designing various FLAG-tagged truncation mutants of TgGCN5-B, expressing these 
proteins in the parasite, and determining their cellular distribution via IFA [Sullivan and 
Bhatti et al., unpublished data].  The results are summarized in Figure 6.  TgGCN5-B 
lacking the first 320 amino acids (FLAGGCN5-BΔ320) showed cytoplasmic localization, 
whereas TgGCN5-B lacking only the first 304 amino acids (FLAGGCN5-BΔ304) was able 
to enter the parasite nucleus.  Unexpectedly, the truncation mutant that lacked the first 
315 amino acids but still included the basic-rich stretch (FLAG
  
GCN5-BΔ315) was 
excluded from the parasite nucleus.  Therefore, it was concluded that the five amino acid 
basic-rich stretch by itself was not sufficient to localize TgGCN5-B to the parasite 
nucleus but required additional upstream residues. 
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Figure 6:  Preliminary mapping of TgGCN5-B NLS.  The diagrams represent different 
truncation mutants of TgGCN5-B that were tagged N-terminally with the FLAG epitope 
and over-expressed in the parasites.  The localization of each protein was determined 
via IFA and results are listed in the right-hand column, where N = nuclear and C = 
cytoplasmic.  For each TgGCN5-B protein diagram, the blue region represents the HAT 
catalytic domain whereas the orange box signifies the bromodomain (Br).  The basic rich 
stretch (KKRGR) from amino acids (aa) 316 – 320 is depicted by a green box.  From 
these experiments it was concluded additional residues between amino acids 304 to 315 
(in box) are necessary for proper nuclear localization [Sullivan and Bhatti et al., 
unpublished data]. 
 
B.  TgGCN5-B contains a unique NLS within its N-terminus 
 To determine the full and necessary NLS of TgGCN5-B, I designed two 
additional truncation mutants to delineate which residues in the 11 amino acids 
upstream of the basic-rich stretch were required for TgGCN5-B to enter the parasite 
nucleus (Figure 7).  Similar to the previous constructs, these two truncation mutants 
were FLAG-tagged N-terminally, expressed in the parasites, and visualized via IFA to 
determine their cellular distribution.  The construct FLAGGCN5-BΔ313 (Plasmid #5), 
which begins with a glutamic acid residue at position 314 of TgGCN5-B (ENKKRGR), 
displayed a largely cytoplasmic distribution (Figure 7A). However, the construct 
FLAGGCN5-BΔ310 (Plasmid #4), which begins with the dipeptide RP at position 311 of 
TgGCN5-B (RPAENKKRGR), was able to enter the parasite nucleus (Figure 7B).  These 
data revealed that the NLS of TgGCN5-B requires the 5 residues immediately upstream 
of the basic-rich stretch.  Therefore, the complete NLS of TgGCN5-B is the 10 amino 
acids, RPAENKKRGR, from positions 311 to 320.  When these 10 amino acids were 
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excised from full-length TgGCN5-B (FLAG
Although the ectopic protein 
GCN5-BΔNLS; Plasmid #7), the mutated 
protein was predominantly cytoplasmic (Figure 7C), validating that these 10 residues are 
necessary for nuclear localization. 
FLAGGCN5-BΔ310 was largely nuclear, the staining 
pattern did not entirely correspond to the DAPI staining pattern, which represents the 
DNA.  Either a portion of FLAG
Next, I wanted to investigate the nature of the additional five amino acids 
upstream of the basic-rich stretch.  I hypothesized that this upstream sequence could 1) 
be non-specific and just served as a “landing pad” for chaperone binding, or 2) the 
arginine and the proline, both common residues to NLSs, were necessary for the proper 
localization [140,196].  To examine these hypotheses, I designed mutated versions of 
the construct 
GCN5-BΔ310 is located in the nuclear periphery or the 
nuclear membrane (areas not stained by DAPI), or something in the first 310 amino 
acids facilitates nuclear localization.  TgGCN5-B is acetylated (Figure 16 D).  It is 
possible that the acetylation of TgGCN5-B might facilitate the nuclear localization of the 
protein. 
FLAGGCN5-BΔ310 in which I mutated select residues to alanines.  As done 
previously, I expressed these mutated proteins in the parasites and determined the 
localization via IFA.  Mutating the arginine at position 311 or the proline at position 312 
individually to alanine in the constructs FLAGGCN5-BΔ310-R311A (Plasmid #8) and 
FLAGGCN5-BΔ310P312A (Plasmid #9), respectively, did not exclude these mutant 
proteins from the parasite nucleus (Figure 8A and B).  However, it appears as if these 
mutant proteins linger in the nuclear periphery, particularly FLAGGCN5-BΔ310-R311A.  It 
is possible that although the mutation of a single residue does not exclusively hinder 
nuclear localization, it could slow the process, resulting in the mutant proteins 
concentrating around the nuclear pore.  The double mutation of both the arginine and 
proline together in the construct FLAGGCN5-BΔ310-RP311/312AA (Plasmid #10) was 
excluded from the parasite nucleus (Figure 8C) indicating that the presence of either the 
arginine or the proline are required for nuclear localization.  Therefore, it can be 
concluded that an additional basic residue (the arginine) and/or helix breaking residue 
(the proline) in the upstream sequence preceding the basic-rich stretch are necessary 
and contribute to the nuclear localization signal of TgGCN5-B. 
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Figure 7:  Mutation constructs of TgGCN5-B elucidate the complete NLS.  All 
constructs above contain an N-terminal FLAG tag followed by various mutant versions of 
TgGCN5-B.  Each was expressed within the parasites with localization determined via 
IFA.  Below each construct name is a diagram of the protein.  The blue box of each 
protein diagram represents the HAT catalytic domain of TgGCN5-B, whereas the orange 
box depicts the bromodomain.  Panel A demonstrates the cytoplasmic distribution of 
TgGCN5-B after removal of the first 313 amino acids (Δ313).  Nuclear localization is 
restored when only the first 310 residues are removed from TgGCN5-B (Δ310, Panel B).  
Internal deletion of just the 10 residue NLS (ΔNLS, Panel C) excluded TgGCN5-B from 
the nucleus.  TgN, Toxoplasma nuclei; hN, host cell nucleus; Green = Anti-FLAG; Red = 
DAPI, 4’,6-diamidino-2-phenylindole. 
68 
 
Figure 8:  Mutation constructs of TgGCN5-B reveal that specific residues in the 
upstream sequence are key to nuclear localization.  All constructs expressed above 
contain an N-terminal FLAG tag followed by various mutant versions of TgGCN5-B.  
Below each construct name is a diagram of the protein.  The blue box of each protein 
diagram represents the HAT catalytic domain of TgGCN5-B, whereas the orange box 
depicts the bromodomain.  Panels A and B demonstrate that a single point mutation of 
either the arginine (residue 311) or proline (residue 312) still allow nuclear entry.  
Nuclear localization is hindered when both the upstream arginine and proline are 
mutated to alanines (Panel C).  TgN, Toxoplasma nuclei; hN, host cell nucleus; Green = 
Anti-FLAG; Red = DAPI, 4’,6-diamidino-2-phenylindole. 
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C.  The TgGCN5-B NLS is sufficient to localize β-gal to the nucleus 
 In order to demonstrate that a putative NLS is sufficient and is the minimal 
required sequence, it must be capable of localizing a non-nuclear protein to the nucleus.  
To determine the sufficiency of the TgGCN5-B NLS, I followed a similar approach used 
by Bhatti et al. (2005) for TgGCN5-A [144].  When the E. coli protein β-galactosidase (β-
gal) was expressed in the parasites, it was distributed throughout the cytoplasm (Figure 
9A) and excluded from the parasite nucleus.  However, the addition of the TgGCN5-A 
NLS allowed partial localization of β-gal to the parasite nucleus [144].  When the NLS of 
TgGCN5-B is fused to the C-terminal end of β-gal followed by a FLAG tag (β-gal-
NLSFLAG) the protein becomes predominantly nuclear (Figure 9B).  To exclude the 
possibility of the combination of the NLS-FLAG forming a unique sequence that was 
responsible for the nuclear localization, the FLAG tag was replaced with an HA tag (β-
gal-NLSHA
 
).  The latter construct also demonstrated chiefly nuclear distribution (Figure 
9C), thereby eliminating the possibility of the tag affecting the localization.  The 
localization of both the above ectopic β-gal-NLS fusion proteins corresponded nearly 
exclusively with the DAPI staining pattern of the nuclear DNA.  Therefore, it can be 
assumed that the NLS of TgGCN5-B is sufficient and does not require any additional 
upstream residues or post-translational modifications.  Interestingly, when the NLS of 
TgGCN5-B was moved to the N-terminal portion of β-gal, the protein was no longer able 
to localize to the parasite nucleus (Figure 9D).  It is possible that in this circumstance, 
the NLS is being cleaved from the rest of the protein; therefore, it is unable to result in 
nuclear localization. 
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Figure 9:  The GCN5-B NLS is sufficient to localize E. coli β-gal to the parasite 
nucleus.  Panel A demonstrates that over-expression of bacterial β-gal in the parasites 
with a C-terminal FLAG tag results in cytoplasmic distribution.  However, when the 10 
residue NLS of TgGCN5-B is added to the C-terminus of the protein followed by a 
FLAG-tag (Panel B) or HA-tag (Panel C) the protein localizes to the parasite nucleus.  If 
the NLS is attached to the N-terminus of β-gal, it no longer is able to localize the protein 
to the parasite nucleus (Panel D), possibly due to cleavage.  The diagrams on the right 
of each panel depict each construct.  TgN, Toxoplasma nuclei; Green = Anti-FLAG or 
Anti-HA; Red = DAPI, 4’,6-diamidino-2-phenylindole. 
 
D.  The NLS of TgGCN5-B has predictive value 
Although the genome of Toxoplasma has been sequenced to 12X coverage 
(http://ToxoDB.org), many predicted proteins remain uncharacterized and have unknown 
functions [11].  Identifying potential motifs such as NLSs in an uncharacterized protein 
can contribute to determining the function of the protein.  To determine the utility of the 
TgGCN5-B NLS as a predictor for nuclear localization of other Toxoplasma proteins, I 
searched the ToxoDB (http://ToxoDB.org) for predicted proteins harboring a similar motif 
(Table VI).  TgGCN5-B was the only protein to possess the exact 10 residue NLS.  
However, when permutations were allowed for residues that were not basic or proline 
(RP . . . KKR . R, with “.” being any amino acid), then three unique proteins were 
identified. This dataset included two uncharacterized hypothetical proteins and another 
protein possessing a PHD-finger domain, commonly found in chromatin remodeling 
enzymes.  By far, the largest dataset was obtained when just the basic cluster (KKR . R) 
was searched, resulting in over 800 proteins being identified.  Many of the proteins in 
this dataset are hypothetical proteins, and only a select few were listed in Table VI.  
Indeed, some of the proteins identified in our search are likely nuclear proteins (i.e. DNA 
polymerases or DNA repair proteins) or possess domains that might interact with DNA 
(AT-hook domains or zinc finger motifs).  This bioinformatic survey demonstrates that 
the TgGCN5-B NLS might be helpful in predicting additional nuclear proteins within 
Toxoplasma. 
Additionally, a similar search could be expanded to include other Apicomplexa 
parasites, such as Neospora, since many proteins in other phylum members remain 
uncharacterized.  Neospora, Toxoplasma’s closest apicomplexan cousin, is currently the 
only other protozoan known to possess two GCN5 homologues.  With these two 
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parasites being so closely related, I sought to determine if the NLSs between the GCN5 
homologues were conserved.  Interestingly, the GCN5-B homologues in both parasites 
contain 82% identity, and the N-terminal extensions of both are well conserved including 
the NLS regions.  Neospora’s GCN5-B contains an identical basic-rich cluster (KKRGR) 
that is likely to function as part of its NLS.  The upstream sequence flanking Neospora’s 
basic-cluster (RPVPES) is similar to Toxoplasma’s additional upstream activating 
residues (RPAEN).  Conversely, the GCN5-A homologue of Neospora appears to have 
either a divergent or novel NLS as only 3 of the 6 resides from Toxoplasma’s TgGCN5-A 
NLS are identical (Neospora:  SKRLKM, Toxoplasma:  RKRVKR.  Identical residues are 
underlined.) 
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Table VI:  Predictive value of the TgGCN5-B NLS 
Accession Numbers Search Results Predicted homology/motifs GO Terms 
RPAENKKRGR    
TGGT1_046420  RPAENKKRGR TgGCN5-B acetyltransferase 
RP . . . KKR . R    
TGGT1_071200 RPSDAKKRER PHD-finger domain containing protein zinc ion binding 
TGGT1_113380 RPKKGKKRKKR conserved hypothetical protein none 
TGME49_091900 RPEGRKKRLR conserved hypothetical protein nuclear 
RP . . KKR . R    
None    
RP . KKR . R    
TGGT1_071910 RPKKKRSR GIY-YIG catalytic domain protein nuclease activity 
TGGT1_056400 RPKKKRRR AT-hook motif containing protein DNA binding 
TGME49_085520 RPQKKRSR prip interacting protein, pimt putative methyltransferase 
RPKKR . R    
TGGT1_068070 RPKKRSR conserved hypothetical protein none 
KKR . R Total of 801 Toxoplasma genes  
TGGT1_117800  KKRGR DNA polymerase theta nucleic acid binding 
TGGT1_082080 KKRGR & KKRQR SET domain containing protein (TgSET1) nuclear 
TGGT1_034540 KKRQR DNA polymerase lambda DNA replication 
TGGT1_116960 KKRRR PHD-finger domain containing protein zinc ion binding 
TGGT1_010370 KKRQR zinc finger (C2H2 type) protein none 
TGGT1_121530  KKRGR DNA polymerase epsilon nuclear 
TGGT1_032500 KKRQR DNA mismatch repair protein Mismatch repair 
The predictive value of the TgGCN5-B NLS was determined by screening the ToxoDB 
(http://ToxoDB.org, release 6.0) using the protein motif pattern tool.  The shaded rows 
represent the amino acid patterns used in each search with each “.” corresponding to 
any amino acid.  For all search results, only the TGGT1 accession number is listed.  In 
the case that there was not a TGGT1 homologue, the TGME49 accession number is 
listed.  The last search, which included only the basic cluster (KKR.R), yielded 801 
genes, many of which were hypothetical proteins.  Listed in the table for this search are 
only a select few of the top hits, the ones most likely to be nuclear proteins based on 
their homology assignment.  GO terms represents the gene ontology 
(www.geneontology.org; version 1.803) predictions associated with each gene.  These 
predictions include either the predicted cellular compartment (nuclear) or a predicted 
cellular function. 
 
E.  Protein with a predicted analogous NLS localizes to the nucleus 
 To test the predictive value of the TgGCN5-B NLS, I decided to examine the 
localization of the AT-hook domain containing protein TGGT1_056400 (will subsequently 
be referred to as AT-hook 056400).  This protein was identified in the bioinformatic 
search (Table VI) and contains an analogous predicted NLS at its C-terminal end 
represented by a proline interrupting a basic cluster of amino acids, RPKKRRR (aa 
2,515 to 2,522).  AT-hook domains are small DNA binding motifs with a preference for 
A/T rich DNA regions.  These motifs are often found in proteins associated with 
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chromatin interactions or transcriptional regulation [197].  Based on their functions, AT-
hook proteins are believed to be nuclear.  In Theileria, several closely related AT-hook 
domain containing proteins are able to localize to the host cell nucleus [198,199].  
However, localization to the parasite nucleus has yet to be demonstrated for any 
Apicomplexa AT-hook motif protein.  AT-hook 056400 is predicted to be a large protein 
of 3,768 amino acids with 3 putative AT-hook domains, predicted by SMART (Simple 
Modular Architecture Research Tool, http://smart.embl-heidelberg.de/) [200,201].  These 
domains exist between amino acids 1,003 to 1,015 (E-value = 5.08e+01), 1,305 to 1,317 
(E-value = 2.50e+02) and 2,528 to 2,540 (E-value = 1.46e+00). 
To examine the localization of AT-hook 056400, I followed the methods 
established by Huynh et al. (2008) for endogenously tagging a protein using Toxoplasma 
RHΔKU80 [186,187].  Through the incorporation of a 3xHA epitope tag at the C-terminus 
of AT-hook 056400 (Plasmid #16), I was able to determine the localization of the native 
protein via IFA.  As depicted in Figure 10, AT-hook 056400 is distributed throughout the 
parasite nucleus.  Although further testing would be needed to demonstrate that this 
basic cluster is the exact NLS of AT-hook 056400, the bioinformatic search assisted in 
identifying a potential region for NLS location, and also correctly predicted a nuclear 
protein.  Incidentally, unlike Theileria, this Toxoplasma AT-hook protein localizes to the 
parasite nucleus rather than that of the host cell. 
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Figure 10:  AT-hook 054600 contains a predicted analogous NLS and localizes to 
the parasite nucleus.  The Toxoplasma protein AT-hook 056400 (TGGT1_056400) was 
tagged endogenously with a C-terminal 3xHA epitope tag.  This protein localizes to the 
parasite nucleus as determined by IFA with staining for anti-HA.  The diagram at the 
right depicts the protein and its domains.  Red boxes indicate locations of putative AT-
hook domains whereas the green box represents the predicted analogous NLS.  TgN, 
Toxoplasma nuclei; Green = Anti-HA; Red = DAPI, 4’,6-diamidino-2-phenylindole. 
 
F.  The nuclear chaperone utilized by TgGCN5-B remains to be resolved 
As discussed in the introduction section, the classical pattern of nuclear 
localization involves a ternary complex consisting of importin-β (Imp-β) binding importin-
α (Imp-α), which associates with a nuclear protein via its NLS.  This ternary complex is 
then shuttled through the nuclear pore via the interactions of Imp-β with the nuclear pore 
complex (NPC).  Using in vitro protein synthesis and 35S-labeling followed by co-
immunoprecipitation, Bhatti et al. (2005) demonstrated that TgGCN5-A is able to 
associate with TgImp-α via its NLS [144].  Following a similar approach, I set out to 
determine if TgGCN5-B also was able to interact with Imp-α via its NLS.  This approach 
failed to demonstrate a definitive interaction between TgGCN5-B and TgImp-α.  As an 
alternative approach, I co-expressed epitope tagged versions of both TgGCN5-B and 
TgImp-α within the same parasite strain to determine if I could establish an in vivo 
interaction.  Both proteins were over-expressed in the parasites under the tubulin 
promoter.  A stable, clonal parasite population (resistant to MPA) expressing N-
terminally FLAG-tagged TgGCN5-B (FLAGGCN5-B; Plasmid #2) was transfected with 
Plasmid #15 (conferring resistance to CAM) to express N-terminally HA-tagged TgImp-α 
(HAImp-α).  IFA analysis of this double expressing parasite strain demonstrates that 
HAImp-α localizes to the parasite nucleus as expected (Figure 11).  However, when co-
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immunoprecipitations were performed, an interaction between HAImp-α and FLAGGCN5-B 
was not detected despite strong over-expression of each protein (data not shown).  Co-
immunoprecipitaitions were performed with either anti-HA affinity matrix to pull down 
HAImp-α and then immunoprecipitated material was probed in Western blot analysis with 
anti-FLAG to determine if FLAG
 Recently, it has been established that several nuclear proteins bypass Imp-α and 
associate directly with Imp-β to gain access to the nucleus [133,134,135,136].  Since I 
could not detect an interaction between TgGCN5-B and TgImp-α, I tested if TgGCN5-B 
could interact with TgImp-β.  Nuclear proteins that associate directly with Imp-β do not 
bind to Imp-β in a uniform location.  Therefore, I cloned two overlapping fragments of 
Toxoplasma’s Imp-β homologue from parasite cDNA.  In total, these two fragments 
represent the entire protein and have an overlapping portion of 42 residues.  I then 
repeated the interaction studies using in vitro protein synthesis with 
GCN5-B was concurrently pulled down.  Reciprocal 
reactions were also performed, but in both cases an interaction between the two proteins 
was not established. 
35
 In conclusion, using multiple approaches, I was unable to elucidate the 
chaperone TgGCN5-B utilizes to enter the parasite nucleus.  I used in vitro protein 
synthesis with 
S-labeling followed 
by co-immunoprecipitation with each individual fragment of TgImp-β.  No interaction was 
detected between TgGCN5-B and either portion of TgImp-β (data not shown). 
35S-labeling followed by co-immunoprecipitation to test both TgImp-α and 
TgImp-β and could not establish an interaction for either within the experimental 
parameters.  One disadvantage of this approach is if post-translational modifications 
(PTMs) are need for an interaction, then in this system the PTMs would likely be absent.  
Alternatively, I also over-expressed tagged versions of both TgImp-α (HA-tagged) and 
TgGCN5-B (FLAG-tagged) within the parasites and performed co-immunoprecipitation 
experiments.  If PTMs were necessary for an interaction, then these proteins should 
have the proper modifications since they harvested from the parasite lysate.  However, 
this method did not show an interaction between TgImp-α and TgGCN5-B.  This method 
was not repeated for TgImp-β as the whole protein was not cloned, and preliminary 
studies suggest that TgGCN5-B does not interact with TgImp-β.  Toxoplasma possesses 
other nuclear chaperone homologues, including several transportins and importins 4, 5, 
and 7 [131].  Additionally, BLAST searches of the ToxoDB have identified several other 
proteins with similarity to Imp-α [131].  It is possible that TgGCN5-B utilizes another 
protein to gain access to the parasite nucleus. 
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Figure 11:  TgImp-α localizes to the parasite nucleus.  Toxoplasma’s homologue of 
Imp-α was tagged with an HA epitope at its N-terminus and over-expressed in parasites.  
IFA with staining for anti-HA was use to determine that TgImp-α localizes to parasite 
nucleus.  TgN, Toxoplasma nuclei; Green = Anti-HA; Red = DAPI, 4’,6-diamidino-2-
phenylindole. 
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II.  Aim 2:  Identify the proteins associating with TgGCN5-B 
 
A.  Bioinformatics reveal a dearth of common GCN5 complex members 
GCN5 and other chromatin remodeling enzymes operate as members of large 
multi-subunit complexes [104,202].  For GCN5, the most characterized complex is the S. 
cerevisiae SAGA complex.  The SAGA complex consists of 21 proteins and includes two 
enzymatic components, GCN5 and Ubp8, a deubiquitinase [202].  In S. cerevisiae, the 
SAGA complex regulates approximately 10% of genes but is also involved in several 
other cellular processes, including transcriptional elongation and mRNA export 
[99,100,101].  SAGA complex components are well conserved in metazoans and 
vertebrates, including Drosophila and humans [104]. 
Given the conserved nature of the SAGA complex, I attempted to determine if 
this complex is also conserved in Toxoplasma.  The ToxoDB was searched using the 
protein-protein BLAST (basic local alignment search tool; BLASTp), with the amino acid 
sequences of the S. cerevisiae SAGA homologues as the query subjects.  The results of 
this bioinformatics search are listed in Table VII.  Aside from the two known GCN5 and 
two ADA2 homologues, there is an unusual lack of other conserved SAGA members in 
Toxoplasma.  Searches with the amino acids sequences of Taf5/Taf90, Tra1, Ubp8, and 
Chd1 identified potential homologues with notable E-values, where the closer the E-
value is to zero, the more reliable the prediction.  However, these 4 proteins did not 
provide much insight into the possible GCN5 complex(s) in Toxoplasma.  For instance, 
the identified potential Ubp8 homologue could be any deubiquitinase enzyme, with the 
homology based on the catalytic domain only.  This argument can also be made for the 
Chd1 homologue.  Since yeast Chd1 is a chromodomain-containing protein, the 
analogous protein in the search may only be conserved within this region [202].  The 
potential Tra1 homologue would be an interesting protein to pursue given that in S. 
cerevisiae, Tra1 interacts with specific transcription factors to recruit the SAGA complex 
to given promoters [202].  However, the identified Toxoplasma protein resembling Tra1 
is an enormous size, over 8,000 amino acids, that can be very difficult to study.  The lack 
of other identifiable homologues suggests that if a SAGA complex does indeed exist in 
Toxoplasma, then the members are either highly divergent or novel. 
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Table VII:  SAGA complex homologues in Toxoplasma 
Protein Used in BLASTp Top Hit E-value 
GCN5 YGR252W GCN5-A  TGGT1_004130 
GCN5-B  TGGT1_046420 
2.3 e-79 
2.0 e-82 
ADA2 YDR448W ADA2-A  TGGT1_097980 
ADA2-B  TGGT1_007690 
9.9 e-47 
6.8 e-33 
ADA1 YPL254W NONE   
ADA3 YDR176W NONE   
Spt20 YOL148C NONE   
Spt3 YDR392W NONE   
Spt7 YBR081C TGGT1_004130 2.4 e-6 
Spt8 YLR055C TGME49_016880 3.2e-7 
Taf5/Taf90 YBR198C TGME49_016880 1.6 e-26 
Taf6/Taf60 YGL122C NONE   
Taf9/Taf17 YMR236W NONE   
Taf10/Taf25 YDR167W NONE   
Taf12/Taf68 YDR145W NONE   
Tra1 YHR099W TGGT1_106430 1.1 e-66 
SGF29 YCL010C NONE   
SGF11 YPL047W NONE   
SGF73 YGL066W NONE   
Sus1 YBR111W-A NONE   
Ubp8 YMR223W TGGT1_043540 2.1 e-26 
Chd1 YER164W TGGT1_011870 1.2 e-135 
Rtg2 YGL252C NONE   
The table depicts bioinformatic search results for the presence of conserved S. 
cerevisiae SAGA complex homologues in Toxoplasma.  The SAGA members are listed 
in the left-hand column followed by the systematic name assigned to each protein in the 
Saccharomyces Genome Database (SGD, www.yeastgenome.org).  The amino acid 
sequence of each protein was retrieved from the SGD and then used in a BLASTp 
search on the ToxoDB (http://ToxoDB.org, release 6.0).  The top homologous 
Toxoplasma protein identified in each search is listed via its accession number.  The 
right-hand column represents the E-value for each identified homologue. 
 
B.  TgGCN5-B is disordered in its N-terminal extension 
 An unusual aspect of each Toxoplasma GCN5 homologue is a lengthy N-
terminal extension.  Other protozoa and invertebrates, such as S. cerevisiae and 
Tetrahymena, have a single GCN5 homologue with a very short N-terminus.  On the 
other hand, GCN5 homologues from higher-order metazoans and vertebrates have long 
N-terminal extensions [104].  Therefore, Toxoplasma’s GCN5 homologues and the 
GCN5s from other Apicomplexa parasites resemble those of higher eukaryotes as 
opposed to their closer kin (Figure 3; Chapter 1, Section IV-C). 
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 Interestingly, the N-terminal extensions of Toxoplasma’s GCN5 homologues do 
not have identifiable protein motifs or domains other than the NLSs discussed in Aim 1 
[144].  These N-terminal extensions also do not share homology with other characterized 
proteins including each other [169].  Thus, the functions of the elongated N-termini in 
Toxoplasma’s GCN5s remain elusive.  To analyze the amino acid sequence of TgGCN5-
B’s N-terminus, I collaborated with Drs. Vladimir N. Uversky and A. Keith Dunker 
(Indiana University School of Medicine) to determine if this region was intrinsically 
disordered. 
 Regions of a protein that lack fixed structures are referred to as having intrinsic 
disorder.  A multitude of proteins, especially eukaryotic proteins, are unstructured or 
contain regions that lack a distinct three-dimensional configuration [203].  Intrinsically 
disordered proteins can have a variety of important biological functions including signal 
transduction, molecular recognition, and regulation [204,205,206].  A protein’s primary 
amino acid sequence can be used to predict the degree of disorder.  Disordered regions 
are characterized by low amino acid sequence complexity, which includes few bulky, 
hydrophobic amino acids and an enrichment of polar and charged amino acids.  For 
instance, regions of intrinsic disorder are likely to contain amino acids such as Ala, Arg, 
Gly, Gln, Ser, Glu, Lys, and Pro and are also depleted in Trp, Tyr, Phe, Ile, Leu, Val, 
Cys, and Asn residues [204,205,206,207].  To date, many computational predictors of 
disorder have been developed to identify regions or entire proteins characterized by 
intrinsic disorder [205].  Determining the degree of disorder in a protein can assist in 
predicting the biological relevance of a given domain, as many regions of disorder map 
to areas of protein-protein interactions or post-translational modifications.  It has 
previously been determined that the genomes of early-branching eukaryotic protozoa, 
including Toxoplasma, contain a large proportion of predicted proteins containing 
intrinsic disorder [208].  Therefore, insight into the degree of intrinsic disorder in 
TgGCN5-B might help provide clues as to the function(s) of its N-terminal extension. 
 Drs. Vladimir N. Uversky and A. Keith Dunker analyzed the primary amino acid 
sequence of TgGCN5-B using several PONDR® (Predictor of Natural Disordered 
Regions) prediction versions as well as other computational techniques [205].  Figure 12 
demonstrates that TgGCN5-B has multiple regions of intrinsic disorder in its N-terminus, 
including a region that corresponds to the sequence of the NLS.  This is an intriguing 
correlation since intrinsically disordered regions have been shown to map to regions of 
protein-protein interactions, and the NLS region of TgGCN5-B is very likely to bind to a 
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chaperone protein for nuclear import [204,205,207].  Likewise, the ADA2 binding domain 
of TgGCN5-B also corresponds to a region of intrinsic disorder.  From this observation, it 
can be hypothesized that other regions of intrinsic disorder in TgGCN5-B might predict 
regions of protein-protein interaction.  As expected, the HAT catalytic domain is not 
disordered, thereby following the prediction that regions of structure or distinct three-
dimensional characteristics lack disorder.  In summary, the analysis of TgGCN5-B’s 
amino acid sequence suggests that certain regions, particularly in the N-terminal 
extension, are intrinsically disordered, which may suggest functions such as protein-
protein interaction domains or protein modification sites. 
 
 
Figure 12:  TgGCN5-B contains several regions of intrinsic disorder within the N-
terminus.  Three computational PONDR® algorithms (VSL1, VL3, VL-XT) were utilized 
to examine the primary amino acid sequence of TgGCN5-B.  PONDR® scores above 
0.5 are considered disordered, whereas those below are ordered.  Large contiguous 
regions of disorder represent a predicted MoRF (molecular recognition feature).  The 
diagram of TgGCN5-B depicting its molecular domains indicates that certain regions of 
disorder map to both the NLS and the ADA2-binding domain, indicating that these MoRF 
regions might predict protein-protein interaction sites. 
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 Based on preliminary evidence, it is hypothesized that TgGCN5-B associates 
with unique proteins within a multi-subunit complex in Toxoplasma.  The data leading to 
this hypothesis include: 1) Very few SAGA complex members are conserved in 
Toxoplasma, indicating TgGCN5-B associating proteins are likely to be novel or highly 
divergent, and 2) TgGCN5-B has an elongated N-terminal extension lacking identifiable 
protein motifs but containing several regions of intrinsic disorder, which may be an 
indicator of protein-protein interaction regions.  To address this hypothesis, biochemical 
techniques including affinity chromatography and co-immunoprecipitations were utilized 
to identify proteins associating with TgGCN5-B. 
 
C.  Affinity chromatography to identify TgGCN5-B associating proteins 
 To determine TgGCN5-B associating proteins through affinity chromatography, 
recombinant TgGCN5-B protein was produced in bacteria.  Next, the recombinant 
protein was coupled to a column through which Toxoplasma nuclear-enriched lysate was 
passed.  Proteins able to interact with TgGCN5-B bound the column, whereas other 
proteins flowed through the column and were washed away.  Then, all interacting 
proteins were eluted from the column, analyzed by SDS-PAGE, and identified by mass 
spectrometry.  Figure 13 summarizes the affinity chromatography procedure. 
 To produce recombinant TgGCN5-B, the pMAL™ Protein Fusion & Purification 
System (NEB, #E8000S) was utilized.  With this system, full-length TgGCN5-B was 
incorporated downstream of the malE gene of E. coli in the expression vector pMAL-c2X 
(Plasmid #17).  The malE gene encodes maltose-binding protein (MBP).  When induced, 
bacteria expressed the fusion protein MBP-GCN5-B.  In parallel, empty pMAL-c2X 
vector was also used to produce MBP, for use as a control.  Panel A of Figure 14 shows 
both recombinant MBP and MBP-GCN5-B following purification from bacteria lysate over 
amylose resin.  The samples were resolved on SDS-PAGE and stained with Simply 
Blue®.  For both MBP and MBP-GCN5-B there seems to be a breakdown product 
running slightly smaller than the expected size (MBP ~ 42 kDa and MBP-GCN5-B ~ 142 
kDa).  The presence of a breakdown product was not anticipated to interfere with the 
affinity purification of associating proteins. 
 Interestingly, MBP-GCN5-B was shown to be catalytically active (Figure 14, 
Panel B), as evaluated by a non-radioactive HAT assay using 1.25 µg of recombinant 
protein.  Additionally, the HAT activity of MBP-GCN5-B was inhibited by the addition of 
20 µM anacardic acid (DMSO = vehicle control).  This was the first time that either 
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Toxoplasma GCN5 homologue was produced recombinantly with HAT activity.  
Previously, recombinant TgGCN5s tagged with either six histidine residues (His-tag) or 
GST (glutathione-S-transferase) never demonstrated in vitro HAT activity [Sullivan and 
Bhatti, unpublished data]. 
 
 
Figure 13:  Pictorial diagram representing affinity chromatography procedure.  The 
first step (1) was to produce the fusion protein MBP-GCN5-B, the maltose-binding 
protein (MBP) coupled to full-length TgGCN5-B.  Bacteria were induced to express the 
fusion protein that was subsequently purified from bacterial lysate over a column 
containing amylose resin.  The fusion protein bound the resin through the MBP domain 
and was then removed from the column by the addition of maltose.  Next (2), the purified 
MBP-GCN5-B fusion protein was coupled to Affi-gel® matrix for the assembly of an 
affinity column.  Toxoplasma nuclear-enriched lysate was first pre-cleared on an MBP 
affinity column prior to being used in the MBP-GCN5-B affinity column.  Nuclear proteins 
capable of associating with TgGCN5-B should be bound to MBP-GCN5-B, whereas non-
specific proteins would pass through the column.  After several washes, all associating 
proteins were eluted from the column and analyzed via SDS-PAGE and mass 
spectrometry.  Any protein identified from the MBP-GCN5-B column but not in the eluted 
proteins from the MBP column are potential TgGCN5-B associating proteins. 
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Figure 14:  Purified recombinant MBP-GCN5-B is catalytically active.  Panel A 
represents purified recombinant proteins of MBP (~42 kDA) and MBP-GCN5-B (~142 
kDA) resolved on SDS-PAGE and stained with Simply Blue®.  There appears to be a 
breakdown product for both MBP and MBP-GCN5-B; however, the presence of this 
product should not affect downstream applications.  Purified samples such as these 
were used when making the affinity columns.  Panel B shows purified recombinant MBP-
GCN5-B to be catalytically active.  An in vitro HAT assay was performed using S. 
cerevisiae GCN5 (yGCN5; positive control), MBP, or MBP-GCN5-B.  All HAT reactions 
were analyzed by Western blot probed with anti-AcH3 (anti-acetyl histone H3).  MBP-
GCN5-B catalytic activity was inhibited by the addition of 20 μM anacardic acid (AA) but 
was unaffected by the addition of vehicle (DMSO). 
 
 After purifying both MBP and MBP-GCN5-B, each protein was coupled 
separately to Affi-Gel® 15 resin (Bio-Rad #153-6051) to generate an affinity column for 
each.  Next, Toxoplasma nuclear-enriched lysate was prepared from RH strain 
tachyzoites.  Nuclear-enriched lysate was used to reduce cytoplasmic, contaminating 
proteins.  Since TgGCN5-B is an HAT that localizes to the parasite nucleus, it can be 
assumed that its associating proteins must also reside within the parasite nucleus.  The 
nuclear-enriched lysate was first pre-cleared on the MBP affinity column.  The purpose 
of this step was to remove proteins that bind non-specifically to MBP.  Next, the pre-
cleared nuclear-enriched lysate was added to the MBP-GCN5-B affinity column.  
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Proteins able to adhere to TgGCN5-B or those proteins associate indirectly through the 
interaction of with another interacting protein should bind to the column, whereas other 
proteins would pass through the column.  The bound proteins from each affinity column, 
MBP and MBP-GCN5-B, were eluted by acid wash, analyzed on SDS-PAGE followed by 
silver staining, and identified by mass spectrometry.  The affinity chromatography 
protocol was repeated in two independent trials.  For each trial, the procedure was done 
in duplicate, with one sample set analyzed by SDS-PAGE and the other parallel set sent 
to the laboratory of Dr. W. Andy Tao (Purdue University) for mass spectrometry analysis 
(Appendix B).  Figure 15 shows a representative SDS-PAGE gel analyzing each sample 
after affinity chromatography.  Protein bands identified in the MBP-GCN5-B eluted 
sample not found in the MBP eluted sample were considered possible TgGCN5-B 
associating proteins.  The sampled labeled “Unbound” contained proteins from the 
nuclear lysate that did not bind to either column. 
 
 
Figure 15:  Purification of proteins associating with MBP-GCN5-B using affinity 
chromatography.  Nuclear lysate from tachyzoites was pre-cleared through MBP 
affinity column prior to incubation with MBP-GCN5-B affinity column.  After washing, 
bound proteins from both columns were eluted, concentrated, and resolved on SDS-
PAGE with silver staining.  Proteins present in the MBP-GCN5-B lane that are not 
represented in the MBP lane are candidates for identification by mass spectrometry.  
The last lane shows the unbound proteins. 
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 For both replicates of the affinity chromatography experiment that were analyzed 
by mass spectrometry, a large number of candidate TgGCN5-B associating proteins 
were identified.  The data sets for the individual experiments are included in Appendix C.  
For the second replicate of the affinity chromatography, very few proteins were bound to 
MBP; therefore, data set #2 is quite large.  It is likely that there was not efficient elution 
of the MBP column for affinity chromatography #2.  If this hypothesis is true, then some 
of the potential Tg-GCN5-B associating proteins for this trial might be contaminants or 
non-specifically binding.  Additionally, some of the proteins identified are likely 
cytoplasmic, indicating that the nuclear-enriched fractions had some residual 
cytoplasmic protein contents.  Table VIII lists the proteins that were identified in both 
replicates.  The major caveat of the affinity chromatography experiment was that neither 
of the Toxoplasma ADA2 homologues was identified.  As known interacting proteins and 
co-activators of TgGCN5-B, either TgADA2-A or –B was expected to be identified in the 
affinity chromatography experiment [169].  It is also important to note that many of the 
candidate proteins are highly abundant proteins in Toxoplasma (ribosomal and 
cytoskeletal proteins) and might represent non-specific binding to the column. 
Since neither of the TgADA2 homologues was identified, I was a bit skeptical 
regarding the rest of the data obtained from the affinity chromatography.  It is possible 
that the majority of the proteins might be binding the recombinant TgGCN5-B in a non-
specific manner.  One reason for this non-specific binding could be the improper folding 
of the recombinant protein.  Although MBP-GCN5-B is catalytically active, this does not 
exclude the possibility that other portions of the protein, the N-terminal extension for 
example, might not be in the correct confirmation for properly associating with other 
proteins.  Additionally, the recombinant TgGCN5-B will likely not contain any post-
translation modifications that might be needed for protein association. 
The drawbacks aside, a few interesting proteins were identified in the affinity 
chromatography, such as another chromatin remodeling enzyme, the arginine N-
methyltransferase 33.m01376.  However, this protein was identified only in the first data 
set.  Several histone proteins were also identified in the affinity chromatography 
experiment, indicating that some of the proteins (histone proteins) may be substrates of 
TgGCN5-B.  However, since I had little confidence in the results from the affinity 
chromatography, I proceeded to identify TgGCN5-B associating proteins through 
another method, co-immunoprecipitation. 
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Table VIII:  Proteins identified in both replicates of affinity chromatography 
Entry # Protein Description Accession Number 
1 small heat shock protein, \ bradyzoite-specific protein 44.m02755 
2 caltractin (centrin), putative 50.m03356 
3 60S ribosomal protein L18a, putative 55.m05004 
4 ribosomal protein L21, putative 50.m00012 
5 hypothetical protein 41.m01274 
6 28 kDa antigen 42.m00015 
7 membrane skeletal protein IMC1, putative 44.m00031 
8 prohibitin, putative 49.m00051 
9 ATP synthase, putative 42.m00065 
10 elongation factor 1-beta, putative 42.m00069 
11 ATP synthase, putative 76.m01572 
12 40s ribosomal protein S6, putative 27.m00119 
13 60S acidic ribosomal protein P2, putative 583.m00610 
14 fibrillarin, putative 583.m00637 
15 hypothetical protein 44.m06355 
16 calmodulin, putative 541.m01151 
17 histone H2A, putative 55.m04926 
18 lysophospholipase, putative 76.m01665 
19 hypothetical protein 31.m00869 
20 hypothetical protein 583.m05696 
21 hypothetical protein 583.m11414 
22 conserved hypothetical protein 55.m00224 
23 ubiquinol-cytochrome C reductase complex 14 kDa 80.m00018 
24 eukaryotic translation initiation factor 3 delta subunit, putative 80.m02245 
25 tubulin beta chain 57.m00003 
26 malate:quinone oxidoreductase, putative 80.m00006 
27 60s ribosomal protein L31, putative 57.m01771 
28 adenylate kinase, putative 42.m00116 
29 hypothetical protein 55.m10265 
30 eukaryotic translation initiation factor 3, putative 83.m01278 
31 histone H2A 145.m00002 
32 histone H4, putative 49.m03134 
33 hypothetical protein 583.m05686 
34 hypothetical protein 83.m00011 
35 thioredoxin, putative 50.m00069 
36 u1 small nuclear ribonucleoprotein 70 kda-related protein 20.m03892 
37 membrane skeletal protein IMC1 44.m00004 
38 gbp1p protein (RNA bindiong protein), putative 55.m00241 
39 conserved hypothetical protein 583.m00682 
40 hypothetical protein 583.m00707 
41 40S ribosomal protein S26, putative 49.m03356 
42 60S acidic ribosomal protein P0 38.m00002 
43 U1 small nuclear ribonucleoprotein, putative 541.m01233 
44 ribosomal protein L5, putative 641.m00186 
45 40S ribosomal protein S24, putative 33.m01367 
46 articulin 4 41.m00021 
47 inner membrane complex protein (IMC3) 35.m01595 
48 hypothetical protein 44.m02644 
49 hypothetical protein 55.m05032 
50 protease-related 59.m03479 
51 surface protein rhoptry, putative 583.m00003 
52 conserved hypothetical protein 33.m01321 
53 myosin light chain TgMLC1-related 583.m05420 
For each protein, the description provided on the ToxoDB (http://ToxoDB.org) as well as 
the model ID accession number is listed. 
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D.  Expression of ectopic TgGCN5-B in Toxoplasma 
 To determine the TgGCN5-B associating proteins through co-
immunoprecipitation, a parasite line over-expressing a triple-tagged version of TgGCN5-
B was generated.  In this strain, TgGCN5-B was tagged with HA and c-myc epitopes at 
the N-terminus and a FLAG epitope at the C-terminus (HA-MYCGCN5-BFLAG; Plasmid #3).  
The expression of HA-MYCGCN5-BFLAG was under the regulation of the Toxoplasma 
tubulin promoter.  Figure 16 shows both IFA and Western blot data characterizing the HA-
MYCGCN5-BFLAG expressing parasites.  As expected, HA-MYCGCN5-BFLAG localizes to the 
parasite nucleus (Figure 16, Panel A).  Not only can HA-MYCGCN5-BFLAG be 
immunoprecipitated from parasite lysate (Figure 16, Panel B), but this tagged version of 
TgGCN5-B remains catalytically active, as determined by an in vitro HAT assay (Figure 
16, Panel C).  Additionally, HA-MYCGCN5-BFLAG
  
 is acetylated (Figure 16, Panel D).  
Acetylation of HATs has been reported in the literature for both PCAF and p300/CBP 
and is important for localization and regulation of each HAT, respectively [141,142,143]. 
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Figure 16:  Characterization of parasites expressing HA-MYCGCN5-BFLAG.  Parasites 
were transfected with Plasmid #3, selected, and cloned to obtain a homogenous 
population.  Panel A:  IFA using anti-HA demonstrating that HA-MYCGCN5-BFLAG localized 
to the parasite nucleus.  A diagram of the HA-MYCGCN5-BFLAG protein is next to IFA data 
(green box, NLS; blue box, catalytic domain; orange box, bromodomain).  TgN, 
Toxoplasma nuclei; hN, host cell nucleus; Green = Anti-HA; Red = DAPI, 4’,6-diamidino-
2-phenylindole.  Panel B:  Immunoblot showing HA-MYCGCN5-BFLAG could be 
immunoprecipitated (IP) from 300 µg parasite lysate with anti-HA affinity resin.  The blot 
was probed with anti-c-myc, and HA-MYCGCN5-BFLAG parasite lysate (30 µg) as well as 
lysate and IP material from parental wild-type (WT) parasites were included as controls.  
Panel C:  After an immunoprecipitation (IP) of 400 µg HA-MYCGCN5-BFLAG parasite lysate 
with anti-HA affinity resin, an on-bead HAT assay was performed.  The IP material was 
divided for two immunoblots:  one with anti-TgGCN5-B and the other with anti-AcH3 
(acetyl-histone H3).  Top immunoblot with anti-TgGCN5-B demonstrates that the IP was 
successful, whereas the bottom immunoblot with anti-AcH3 represents catalytic activity.  
Parental wild-type (WT) parasites were included as a negative control.  Panel D:  After 
an immunoprecipitation (IP) of 300 µg HA-MYCGCN5-BFLAG parasite lysate with anti-FLAG 
affinity gel, the IP material was divided for two immunoblots:  one with anti-TgGCN5-B 
and the other with anti-AcLys (acetyl-lysine).  This result demonstrates that HA-MYCGCN5-
BFLAG
  
 was acetylated.  Parental wild-type (WT) parasites were included as a negative 
control. 
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E.  Co-immunoprecipitation reveals novel TgGCN5-B associating proteins 
 We collaborated with Dr. Ali Hakimi (National Centre for Scientific Research in 
Grenoble, France) to perform the co-immunoprecipitation (co-IP) experiment to identify 
the TgGCN5-B complex.  Dr. Hakimi’s laboratory has had previous success in purifying 
the associating proteins of TgHDAC3 [154,209].  Dr. Hakimi’s laboratory has the 
capability to grow hundreds of large flasks (T150) of parasites for purification and 
processing for co-IP experiments.  The large amount of parasite material is preferable to 
obtain optimal results.  Figure 17 is a representation of the purification scheme used to 
co-IP TgGCN5-B associating proteins.  Once HA-MYCGCN5-BFLAG and its associating 
proteins were purified, fractions were resolved by SDS-PAGE with silver-staining and 
Western blot analysis.  Figure 18 depicts both a silver-stained gel and an immunoblot, 
demonstrating the success of the HA-MYCGCN5-BFLAG co-IP.  The silver-stained gel shows 
that several additional proteins of varying molecular weights were pulled down with HA-
MYCGCN5-BFLAG
  
 (Figure 18, Panel A). 
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Figure 17:  Schematic of co-IP protocol used for detecting HA-MYCGCN5-BFLAG 
associating proteins.  This schematic represents the protocol followed by Dr. Hakimi 
and colleagues for purification of HA-MYCGCN5-BFLAG
  
 and its associating proteins.  
Parasite extract was generated from 250 large flasks of intracellular parasites harvested 
18 hours post infection.  The parasite extract was fractioned by chromatography through 
both phosphocellulose (P11) and DEAE-Sephacel columns.  Next, the co-IP was 
performed using anti-FLAG affinity gel.  The bound proteins were eluted with 3X FLAG 
peptide in KCl.  The elutants were subsequently fractioned using SUPEROSE 6 gel 
filtration, precipitated with trichloroacetic acid (TCA), and resolved on SDS-PAGE.  
Protein bands were visualized by silver staining.  To identify the associating co-IP 
proteins, bands were excised and analyzed by nanocapillary liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS sequencing).  Figure adopted from 
Saksouk et al. (2005) and Bhatti (2006) [154,209]. 
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Figure 18:  Analysis from co-IP of HA-MYCGCN5-BFLAG and associating proteins.  
Following the co-IP protocol outlined in Figure 17, fractions were analyzed by SDS-
PAGE (Panel A, silver-stained gel) and Western blot (Panel B, anti-HA immunoblot).  
Several proteins with a variety of molecular weights were coimmunoprecipitated with HA-
MYCGCN5-BFLAG (Panel A).  The arrow shows the protein band likely to be HA-MYCGCN5-
BFLAG (~ 100 kDA).  Panel B is an immunoblot with anti-HA of the same four co-IP 
fractions.  This demonstrates that HA-MYCGCN5-BFLAG
 
 was present in each fraction.  
Various protein bands were excised from the silver-stained gel and identified by LC-
MS/MS sequencing.  Data is courtesy of Dr. Ali Hakimi (National Centre for Scientific 
Research in Grenoble, France).  M, molecular marker. 
 The mass spectrometry data of candidate TgGCN5-B associating proteins are 
listed in Table IX.  TgADA2-A was co-immunoprecipitated with HA-MYCGCN5-BFLAG, 
increasing the confidence in this method.  Interestingly, four proteins containing an AP2 
domain (50.m03194, 20.m03816, 80.m03948, 33.m01324) were also identified as 
potential associating proteins of HA-MYCGCN5-BFLAG.  As discussed in the introduction 
(Chapter 1, Section IV-A), AP2 domain proteins are the recently discovered lineage of 
plant-like transcription factors, conserved in Apicomplexa parasites.  These AP2 proteins 
may be transcription factors that recruit TgGCN5-B to specific promoters for regulation of 
gene expression.  Another potential transcription factor identified was the AT-hook motif-
containing protein (583.m05282).  AT-hook motifs bind to AT-rich regions of DNA and 
are often found in proteins associated with chromatin interactions or transcriptional 
regulation [197].  Two associating proteins (42.m03344 and 46.m01622) contain PHD-
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finger domains, a motif that can bind to tri-methylated lysine residues, and commonly 
found on proteins associated with chromatin modulation and gene regulation [210].  
There were was few proteins identified to be associated with TgGCN5-B that have an 
unknown function and are labeled as hypothetical.  Several other proteins, such as the 
heat shock proteins, are highly expressed Toxoplasma proteins and could be potential 
contaminating proteins.  None of the proteins identified in the HA-MYCGCN5-BFLAG
 
 co-IP 
experiment corresponded to proteins found in both replicates of the affinity 
chromatography experiments. 
Table IX:  Proteins co-immunoprecipitated with HA-MYCGCN5-BFLAG 
Entry # Protein Description Accession Number 
1 GCN5-B 49.m03346 
2 PHD-finger domain-containing protein 42.m03344 
3 hypothetical protein 49.m03263 
4 PHD-finger domain-containing protein 46.m01622 
5 AP2 domain transcription factor XII-4 (AP2XII-4) 50.m03194 
6 AT-hook motif-containing protein 583.m05282 
7 ADA2-A 35.m00936 
8 AP2 domain transcription factor VIIa-5 (AP2VIIa-5) 20.m03816 
9 AP2 domain transcription factor IX-7 (AP2IX-7) 80.m03948 
10 AP2 domain transcription factor X-8 (AP2X-8) 33.m01324 
11 hypothetical protein 72.m00394 
12 hypothetical protein 42.m03515 
13 alanyl-tRNA synthetase, putative 38.m01067 
14 DnaK family protein 42.m03533 
15 heat shock protein 90, putative 49.m00060 
16 myosin A, putative 46.m00001 
17 cell division protein 48, putative 59.m03661 
18 aconitate hydratase, putative 42.m03524 
19 elongation factor 2 20.m03912 
20 heat shock protein, putative 38.m01113 
21 heat shock protein 70, putative 59.m00003 
22 heat shock protein 70, putative 583.m00009 
23 heat shock protein 70, putative 50.m00085 
24 tryptophanyl-tRNA synthetase, putative 80.m00063 
25 eukaryotic translation initiation factor 3 subunit 6 interacting protein, 
putative 
59.m00055 
26 elongation factor 1-alpha, putative 76.m00016 
27 protein disulfide isomerase 27.m00003 
28 ATP synthase beta chain, putative 55.m00168 
29 DnaJ domain-containing protein 583.m05418 
30 hypothetical protein 80.m02161 
For each protein, the description provided on the ToxoDB (http://ToxoDB.org) as well as 
the model ID accession number is listed. 
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F.  Confirmation of TgGCN5-B associating proteins 
 The next step is to confirm through a second approach that TgGCN5-B does 
indeed interact with one or more of the proteins identified in the co-IP experiment.  From 
the data set, I was most interested in confirming an interaction with one of the AP2-
domain proteins or the AT-hook protein because these proteins likely function as gene-
specific transcription factors within Toxoplasma.  Additionally, proteins with these 
domains have been associated with Plasmodium GCN5 [161].  Unfortunately, the PHD-
finger proteins are very large (greater than 4,000 amino acids), indicating they could be 
more difficult to genetically manipulate.  As for the other proteins in the data set, there 
were no precedents for interactions with GCN5s from other species, and some appeared 
to be possible contaminants, so currently the other proteins are not being pursued. 
 To begin the confirmation process, I used the method of endogenously tagging a 
genetic locus in RHΔKu80 parasites [187].  I utilized this method because all the AP2-
domain proteins and the AT-hook protein were large proteins (greater than 2,000 amino 
acids), meaning they would be difficult to clone, tag, and ectopically-express.  The first 
protein that was successfully endogenously-tagged with a 3xHA epitope at its C-
terminus was the AT-hook motif-containing protein (583.m05282 – Plasmid #16).  This 
protein was also the same AT-hook protein identified in Aim 1 as containing an 
analogous NLS to TgGCN5-B (hereafter referred to as AT-hook 056400, its latest 
accession number).  The PHD-finger domain containing protein 46.m01622 
(TGGT1_071200) was also identified in the bioinformatics search of Aim 1 and contains 
a potential analogous NLS to TgGCN5-B.  The second protein that was endogenously-
tagged with a 3xHA epitope was the AP2-domain protein 20.m03816 (Plasmid #18).  
Hereafter, this protein will be referred to as AP2-3816.  Figure 19 depicts IFA data 
(Panels A and B) demonstrating that each of these proteins, AT-hook 054600 and AP2-
3816, are localized to the parasite nucleus.  Western blot data from each parasite strain 
is shown in Figure 19, Panel C.  As expected, AP2-3816 is approximately 260 kDa.  
Interestingly, the predominant band for AT-hook 054600 is ~80 kDa; however, the 
expected protein size is over 400 kDa.  Either this band is a breakdown product, the 
protein is truncated, or the protein is predicted incorrectly and is actually smaller than 
expected. 
Currently, reciprocal directed co-IPs are underway to determine if AP2-3816 
interacts with TgGCN5-B.  For these experiments, parasites are treated with 
paraformaldehyde prior to harvesting to cross-link proteins and preserve their 
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associations, and then AP2-3816 is immunoprecipitated from the parasite lysate with 
anti-HA affinity resin.  The IP material is then analyzed by Western blotting with both 
anti-HA (to confirm the pull-down of AP2-3816) and anti-TgGCN5-B to determine if there 
is an association.  This experiment will also be performed with AT-hook 056400.  
Additionally, another AP2-domain protein (80.m03948, hereafter referred to as AP2-
3948) was recently endogenously tagged in the parasites at the C-terminus with a 2xHA 
epitope followed by the DD (destabilization domain) [211,212].  Since all these proteins 
have low basal levels of expression, I wanted to determine if I could increase the protein 
expression level by exploiting the dynamics of the DD and its ligand Shield-1 (Aim 3).  
This parasite line is currently being characterized. 
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Figure 19:  Two TgGCN5-B associating proteins localize to the parasite nucleus.  
AT-hook 056400 and AP2-3816 proteins were each tagged endogenously with a C-
terminal 3xHA epitope in separate RHΔKu80 parasites.  Both proteins are localized to 
the parasite nucleus (Panels A and B) as determined by IFA with anti-HA.  The diagrams 
to the right of the IFA pictures are schematic representations of the proteins.  For AT-
hook 056400, red boxes indicate the AT-hook domains, and the green box identifies the 
location of the putative NLS (Aim 1).  In the diagram of AP2-3816, the purple box 
signifies the AP2 domain.  TgN, Toxoplasma nuclei; Green = Anti-HA; Red = DAPI, 4’,6-
diamidino-2-phenylindole.  Panel C is an anti-HA immunoblot of 50 µg whole parasite 
lysate from the strains possessing endogenously tagged AT-hook 056400 or AP2-3816.  
The predominant band for AT-hook 056400 is considerably smaller than the expected 
size of ~400 kDa, whereas AP2-3816 is at the expected size of ~260 kDa. 
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III.  Aim 3:  Determine the role of TgGCN5-B in Toxoplasma physiology 
 
A.  Preliminary evidence suggests that TgGCN5-B is essential 
 Toxoplasma tachyzoites are haploid in the asexual stage.  Therefore, to generate 
a knockout (KO) only a single allelic replacement is needed.  Sullivan et al. (2006) have 
generated a type I parasite strain that lacks TgGCN5-A (ΔGCN5-A) by replacing the 
genomic locus with a selectable marker through homologous recombination [169].  This 
strain does not demonstrate any observable difference from wild-type under normal 
culture conditions, indicating that TgGCN5-A is not an essential gene.  However, in 
media at alkaline pH (8.1) the ΔGCN5-A parasites show deficiencies in responding to 
stress [Sullivan and Naguleswaran, unpublished data].  After generating the ΔGCN5-A 
parasite strain, Sullivan and other members of the lab, including myself, attempted to 
generate a KO of TgGCN5-B using the same method of allelic replacement through 
homologous recombination, but a KO of TgGCN5-B was never obtained.  Since 
Toxoplasma is haploid, disruption of an essential gene will result in non-viable parasites.  
Therefore, since we were never able to generate a TgGCN5-B KO, we hypothesized that 
this GCN5 homologue might be crucial to Toxoplasma and likely essential.  If TgGCN5-B 
is essential, it could be exploited as a new therapeutic target, although studying an 
essential gene can be byzantine. 
 Meissner et al. (2002) developed a conditional KO system for Toxoplasma [213], 
based on the E. coli tetracycline-repressor system that allows for gene regulation at the 
transcriptional level [183].  Meissner et al. (2002) modified this system for Toxoplasma 
by performing a genetic screen using random insertion to identify a transcriptional 
activating domain for establishment of a tetracycline transactivator-based inducible 
system [213].  The efficiency of this system has been demonstrated for several genes 
[213,214,215,216,217,218].  I attempted to use this conditional KO system for 
TgGCN5-B. 
The first step to producing a conditional KO involved generating a parasite line 
expressing an exogenous copy of TgGCN5-B under the tet-regulatable promoter.  Once 
this line was established, the endogenous locus of TgGCN5-B must then be disrupted 
through the insertion of a selectable marker via homologous recombination.  After 
completion of both steps, the addition of anhydrotetracycline (ATc) will reduce the level 
of exogenous protein expression and in effect, knock out the gene.  I was able to 
generate a clonal parasite line expressing a regulatable exogenous copy of TgGCN5-B.  
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Unfortunately, after several attempts, I was never able to disrupt the endogenous locus 
of TgGCN5-B.  While troubleshooting this system, another approach became available 
for the study of essential genes. 
 
B.  Generation of a regulatable dominant-negative TgGCN5-B 
 Herm-Gotz et al. (2007) adapted a conditional protein expression system from 
mammalian cells for use in Toxoplasma [219].  This system allows for modulation of the 
stability of a target protein through coupling with the destabilization domain (DD).  The 
DD is a 12 kDa mutant version of the human rapamycin binding protein FKBP12 
[211,212].  When the DD is expressed as a tag on the target protein, this causes rapid 
degradation of the target protein, likely through the proteosome.  However, the target 
protein can be rapidly stabilized, protected from proteosomal degradation, through the 
addition of the small membrane-permeable (750 Da) ligand of the DD, Shield-1.  This 
system is reversible and allows the stabilized protein to be tuned to the correct level by 
varying the concentration of Shield-1.  Therefore, the control is at the protein level rather 
than at the promoter level, as was the case for the previous system.  This system has 
subsequently been marketed by Clontech Laboratories, Inc. as the ProteoTuner™ 
Systems.  The regulation of exogenous protein expression through the DD has been 
demonstrated for both Toxoplasma and Plasmodium [219,220].  In particular, the use of 
the DD to control the expression of dominant-negative alleles was presented as an 
alternative approach to study essential genes [219].  I took advantage of this approach 
to study the effects of TgGCN5-B on parasite viability. 
 A catalytically inactive TgGCN5-B mutant was linked to the DD and expressed 
within RHΔHX parasites to generate a regulatable dominant-negative TgGCN5-B 
parasite strain.  The mutant TgGCN5-B protein was only expressed in the parasites in 
the presence of the ligand Shield-1 (Shld), as illustrated in Figure 20.  When expressed, 
the mutant TgGCN5-B would compete with the native protein for protein complex 
formation and substrates, thus hindering the native protein from functioning properly.  As 
a control, a wild-type version of TgGCN5-B (no mutation) was also expressed under 
regulation of the DD in a separate RHΔHX parasite line. 
 To generate the catalytically inactive TgGCN5-B, site-directed mutagenesis was 
used to mutate the glutamic acid residue 703 to glycine (E703G).  This residue is 
essential for the catalytic mechanism of GCN5 homologues [89].  Additionally, a similar 
conserved glutamic acid residue is key to the catalytic function of MYST HAT 
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homologues.  Smith et al. (2005) demonstrated that mutation of the homologous 
TgMYST-A glutamic acid residue 279 to glycine (E279G) hindered catalytic activity of 
this HAT [170].  Once the mutant cDNA of TgGCN5-B was generated, it was linked to 
the DD at the N-terminus along with an HA epitope tag (Figure 20).  Likewise, a wild-
type (non-mutant) TgGCN5-B was constructed in the same manner to serve as a 
control.  Each DD-linked TgGCN5 was inserted into a parasite expression vector for 
expression under the tubulin promoter (Plasmids #23 and #24). 
 
 
Figure 20:  Illustration of conditional protein expression through the 
destabilization domain.  Pictorial representations of Toxoplasma tachyzoites 
transfected with various forms of GCN5-B fused at the N-terminus with the 
destabilization domain (DD, in red).  Without the stabilizing ligand Shield-1 (top), ectopic 
GCN5-B is degraded, whereas in the presence of Shield-1 (bottom) ectopic GCN5-B is 
stabilized.  The diagrams represent the various GCN5-B constructs, which include the N-
terminal DD domain (red) and HA epitope tag.  For each GCN5-B protein diagram, the 
green region signifies the NLS, the blue region represents the HAT catalytic domain, and 
the orange box signifies the bromodomain.  In the top diagram, the star (   ) symbolizes 
the mutation of glutamic acid residue 703 to glycine (E703G), representing the 
dominant-negative allele (DN).  The bottom diagram represents the wild-type enzyme 
(wt).  Figure adopted from Striepen et al. (2007) [221]. 
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 Both GCN5-B DN (Plasmid #24) and GCN5-B wt (Plasmid #23) were transfected 
into RHΔHX parasites so that a clonal line of each could be isolated.  After transfection, 
each parasitic population was under drug selection (20 µM CAM) and subsequently 
cloned to obtain a homogenous parasite population for each.  The selection and cloning 
of the parasites was not done in the presence of Shld.  Once clones for each population 
were obtained, they were screened for expression and regulation of ectopic GCN5-B 
protein (DN or wt) using IFA after the addition of Shld (1 µM) for 4 hours.  Figure 21 is an 
IFA from the clonal parasite strains for ectopic GCN5-B (DN or wt) used for all 
subsequent studies.  Shld (1 µM) rapidly stabilized each protein with expression present 
2 hours after the addition of the ligand.  There was no noticeable difference in protein 
expression (as viewed via IFA) between 2 and 4 hours following Shld application (data 
not shown).  A single application of 1 µM Shld would stabilize the protein for at least 3 
days (data not shown).  Samples lacking Shld still included the equivalent amount of 
vehicle (100% ethanol).  In the vehicle treated samples, a slight amount of ectopic 
GCN5-B protein could be detected for each parasite strain (Figure 21).  The presence of 
this protein likely represented protein being targeted for degradation or partially 
degraded.  As expected, both ectopic GCN5-B proteins localized to the parasite nucleus 
(Figure 21).  Interestingly, parasites expressing GCN5-B DN also appeared to have 
protein in the nuclear periphery or in the cytoplasm surrounding the nucleus.  This was 
not seen for parasites expressing GCN5-B wt protein, which localized exclusively with 
the nuclear DNA.  Assuming equivalent expression of each ectopic GCN5-B protein, it is 
possible that the acetylation status of TgGCN5-B might facilitate nuclear localization.  
Therefore, if the GCN5-B DN cannot be autoacetylated, then its nuclear localization 
might not be complete or might occur at a slower rate.  Figure 22 is a Western blot 
verifying the IFA data from Figure 21. 
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Figure 21:  Addition of Shield-1 stabilizes expression of ectopic GCN5-B proteins.  
IFA data reveals nuclear localization of ectopic TgGCN5-B proteins from clonal parasite 
populations that were engineered to express either a dominant-negative allele of 
TgGCN5-B with the point mutation E703G (GCN5-B DN; Panel B) or a wild-type allele 
(GCN5-B wt; Panel D).  The expression of each protein was dependent on regulation via 
the destabilization domain (DD, red box).  Shield-1 (1 µM) or vehicle (100% ethanol) was 
added to cultures 4 hours prior to processing for IFA.  Panels A and C depict a low basal 
level of expression of ectopic proteins in vehicle-treated samples.  TgN, Toxoplasma 
nuclei; hN, host cell nucleus; Green = Anti-HA; Red = DAPI, 4’,6-diamidino-2-
phenylindole 
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Figure 22:  Addition of Shield-1 allows for expression of ectopic GCN5-B proteins.  
Shield-1 (+; 1 µM) or vehicle (-; 100% ethanol) was added to parasite cultures 4 hours 
before harvest.  The whole cell parasite lysate (350 µg) was immunoprecipitated with 
anti-HA affinity resin, followed by analysis by Western blotting with anti-HA.  Distinct 
protein bands for each ectopic GCN5-B protein are evident in Shield-1-treated samples 
(+), whereas background is undetectable in vehicle-treated (-) or parental samples. 
 
C.  Expression of dominant-negative TgGCN5-B reduces parasite viability 
 After generating parasites expressing the ectopic GCN5-B proteins (DN or wt) 
under regulation by the DD, I wanted to determine if the expression of either ectopic 
GCN5-B protein altered the growth of Toxoplasma tachyzoites.  To evaluate parasite 
growth and viability, I used three different assays.  For doubling assays, the number of 
parasites per vacuole was counted at certain time points post infection.  This assay 
provided insight into the replication rate of the parasites [182].  The B1 growth assay and 
plaque assay both provided an estimate of the number of parasites per well based on 
either quantitative real-time PCR for a parasite-specific gene or the number of plaques 
per well, respectively [182,194].  The data sets gathered from the B1 growth assays and 
the plaque assays were amendable to standard parametric statistical analysis; however, 
due to the discontinuous integer scoring of the doubling assay, the data was not 
analyzable by standard parametric statistics. 
Even though it has been reported that the addition of Shld does not alter the 
growth of Toxoplasma tachyzoites, I first repeated these studies with my parental 
(RHΔHX) parasites at 1 µM Shld [219].  I did not observe a significant difference in the 
growth of parental parasites in the presence of Shld during any of the assays (Figure 
23).  The data in Figure 23 depicts a single experiment for each assay; however, all 
assays were repeated with at least three independent replicates each with similar 
results. 
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Figure 23:  The presence of Shield-1 does not affect the growth of parental 
parasites.  Parental (RHΔHX) parasites were evaluated in three different growth assays.  
All assays demonstrated that the parasites had similar growth and viability in the 
presence of vehicle (100% ethanol) and Shield-1 (1 µM).  The data from each growth 
assay represents one experiment; however, all assays were repeated three times 
independently with similar results.  Error bars represent the standard deviation for each 
data set.  There was not a significant growth difference observed when parental 
(RHΔHX) parasites were treated with Shield-1 (1 µM) compared to vehicle control (100% 
ethanol) as assessed by student’s t-test analysis.  Pictures representing individual wells 
stained with crystal violet from the plaque assay are also included.  Plaques are visible 
as light colored areas against the dark background. 
 
 Since the presence of Shld does not affect the growth or viability of parental 
parasites, I proceeded to evaluate the parasite strains expressing the ectopic GCN5-B 
proteins (DN or wt) using the same growth assays.  There were not significant growth 
differences between GCN5-B wt and GCN5-B DN parasites for vehicle treatment (Figure 
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24).  When compared to the parental parasites, a slight slowing of growth was noted for 
some time points during some of the assays for both GCN5-B wt and GCN5-B DN 
parasites.  It is likely that this minor growth difference may be due to the presence of the 
DD and increased proteosomal activity. 
 Importantly, in the presence of Shld (1 µM) parasites expressing the GCN5-B wt 
protein do not have a significant change in viability or growth from the vehicle treated 
controls.  However, the addition of Shld (1 µM) significantly hindered the growth of 
parasites expressing the dominant-negative allele (GCN5-B DN) compared to vehicle 
controls.  The growth differences between vehicle and Shld treated GCN5-B DN 
parasites were quite dramatic.  Data from both the B1 and plaque assays indicated that 
GCN5-B DN parasites stop proliferating in the presence of Shld (Figure 24).  This is best 
illustrated by the pictures of individual wells from the plaque assay (Figure 24), which 
revealed the near absence of plaques in the GCN5-B DN Shld-treated sample. 
The doubling assay data provided insight into the mechanism for the decreased 
viability of GCN5-B DN parasites under Shld treatment.  The GCN5-B DN parasites were 
able to replicate until approximately 30 hours, albeit at a slightly slower rate.  However, 
after this time point, parasite growth ceased, with the average vacuole size containing 16 
– 32 parasites per vacuole for at least another 24 hours.  The GCN5-B DN Shld-treated 
parasites were followed for up to 72 hours, and they never progressed beyond this point 
(data not shown). 
It is important to note that for all growth assays, Shld or vehicle were not added 
until 2 hours post infection allowing parasites time to attach and invade the host cells.  
Therefore, the growth defect observed with the expression of GCN5-B DN was 
independent of adhesion and invasion.  Additionally, a dominant-negative allele under 
DD regulation was also generated for TgGCN5-A (GCN5-A DN).  As expected, these 
parasites did not have an observable growth defect in the presence of Shld (data not 
shown).  This result indicated that the reduced growth phenotype was exclusive to the 
TgGCN5-B dominant-negative allele and cannot be attributed to the DD system. 
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Figure 24:  GCN5-B DN parasites cannot proliferate in the presence of Shield-1.  
The growth of GCN5-B wt and GCN5-B DN parasites with or without Shield-1 was 
evaluated in three different assays.  All assays demonstrated that there was not a 
significant difference between GCN5-B wt and GCN5-B DN parasites in the presence of 
vehicle (100% ethanol).  There was also no growth difference between vehicle and 
Shield-1 treated (1 µM) GCN5-B wt parasites.  On the contrary, the addition of Shield-1 
significantly decreased proliferation of GCN5-B DN parasites in all three assays.  The 
data from each growth assay represents one experiment; assays were repeated three 
times independently with similar results.  Error bars represent the standard deviation for 
each data set.  * represents p values less than 0.001 as evaluated by the student’s t-
test.  Pictures representing individual wells stained with crystal violet from the plaque 
assay are also included.  Plaques are visible as light colored areas against the dark 
background. 
 
 Since the growth defect observed for GCN5-B DN parasites in the presence of 
Shld is independent of adhesion and invasion of host cells, I decided to further 
investigate the nature of this defect by monitoring common cellular markers in an IFA.  
As tachyzoite parasites progress through the cell cycle and replicate, distinct stages can 
be distinguished based on the staining patterns of PCNA (proliferating cell nuclear 
antigen), IMC1 (inner membrane complex 1), and DAPI (4’,6-diamidino-2-phenylindole) 
[222,223].  Staining with PCNA and DAPI make it possible to monitor changes in nuclear 
morphology, while staining with IMC1 delineates the perimeter of the parasites, including 
daughter cell formation with the mother parasite.  Typically parasites in G1 phase have a 
small nucleus and represent approximately 60% of an asynchronous population, 
whereas parasites in S phase have an expanded and enlarged nucleus and account for 
30% of parasites in an asynchronous population.  In S phase, the first indication of 
daughter formation is detectable.  Parasites undergoing mitosis and cytokinesis, 10% of 
parasites in an asynchronous population, have U-shaped nuclei and the developing 
daughter cells can be identified (Appendix D) [222].  Therefore, IFAs were performed 
with staining for Toxoplasma specific PCNA and IMC1 (Table V) to monitor parasite 
progression through the cell cycle and division.  For IFAs, parasites were allowed to 
attach and invade host cells for 2 hours prior to the addition of vehicle (100% ethanol) or 
Shld (1 µM).  Parasites were allowed to grow for either 2 or 3 days before being 
processed for IFA. 
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 Figure 25 shows representative IFA data from parental and GCN5-B wt parasites 
treated with Shld as well as GCN5-B DN parasites treated with vehicle.  These images 
are from the Day 3 time point and represent an asynchronous parasite population.  The 
parasites in these images were all normal, although the parasites were at different points 
in the cell cycle or division (Appendix D).  Even parasites within the same vacuole were 
not synchronized and showed different cellular morphology.  Although only a single 
image is shown, there was not a noticeable difference among any of the parasites on the 
slide.  Additionally, these images are representative of data from parental and GCN5-B 
wt vehicle-treated parasites on Day 3 and of the corresponding strains/treatments on 
Day 2. 
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Figure 25:  Normal progression through parasite cell cycle and division.  IFA 
images from parasites demonstrated normal cellular morphology after 3 days of Shield-1 
treatment (Panel A:  Parental; Panel B:  GCN5-B wt) or vehicle treatment (Panel C:  
GCN5-B DN).  PCNA and DAPI monitor nuclear morphology through the cell cycle, while 
IMC1 stains the inner membrane complex, thus revealing the development of daughter 
cells.  TgN, Toxoplasma nuclei; hN, host cell nucleus; PCNA, proliferating cell nuclear 
antigen (green); IMC1, inner membrane complex 1 (red); DAPI, 4’,6-diamidino-2-
phenylindole (blue); G1, Gap 1 cell cycle phase; S, synthesis cell cycle phase; M/C, 
mitosis and cytokinesis. 
 
 Importantly, IFA data from both Day 2 and Day 3 of the GCN5-B DN Shld treated 
parasites revealed that the parasites were unable to replicate normally.  Figure 26, Panel 
A shows that after 2 days of Shld treatment, some GCN5-B DN parasites began to 
display unusual characteristics such as elongation of nuclei, extra-nuclear PCNA 
staining, and parasites without any appreciable PCNA staining.  However, other 
parasites in this sample showed normal morphology.  After 3 days of Shld treatment, 
these defects became more pronounced, and more parasites were affected.  For 
instance, Panel B depicts parasites with defective daughter cell formation as determined 
by IMC1 staining as well as the unusual characteristics listed above.  Significantly, Panel 
C depicts a vacuole in which half the parasites lacked PCNA staining and appeared 
dead, whereas the other half had atypical morphologies and were also likely not viable.  
These data are preliminary, and the abnormal features and morphologies suggest 
defects in nuclear division and daughter cell budding in parasites expressing the 
dominant-negative allele of TgGCN5-B. 
 The deficient phenotype of the GCN5-B DN parasites was not immediate as 
some parasites appeared normal even after 2 or 3 days of Shld treatment.  This is to be 
expected with a dominant-negative mutant because it takes time for the mutant allele to 
be expressed, associate with complex members, and replace native protein.  However, 
the parasites ultimately succumbed to the effects of the dominant-negative allele and 
were not able to continue normal cellular growth.  Collectively, the growth assay and IFA 
data indicated that TgGCN5-B is critical for Toxoplasma tachyzoite survival. 
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Figure 26:  GCN5-B DN parasites display abnormal nuclear division and daughter 
cell formation when treated with Shield-1.  IFA images from GCN5-B DN parasites 
demonstrated the progression of unusual morphological characteristics (highlighted with 
arrows, circles, or squares) after treated with Shield-1.  Panel A shows a GCN5-B DN 
parasite vacuole 2 days after addition of Shield-1.  Top arrow shows exogenous PCNA 
staining outside of the parasite, whereas the bottom arrow shows parasites that lack 
prominent PCNA and DAPI staining.  The left circle highlights a parasite with unusual 
nuclear morphology, while the right circle shows a parasite that lacks detectable DAPI 
staining.  Panel B shows GCN5-B DN parasites 3 days after the addition of Shield-1.  
Boxed parasites display defective daughter cell formation, as well as nuclear 
abnormalities.  The arrow highlights a large and engorged parasite with excess PCNA 
and DNA while its sister parasite just to the right lacks both these markers.  In Panel C 
(3 days of Shield treatment), the lower half of the parasite vacuole contains atypical 
parasites lacking PCNA and having defective membrane formation, suggesting these 
parasites are dead.  Parasites in the top half of this vacuole have abnormal nuclear 
morphology and atypical daughter cell formation as highlighted by the arrow.  TgN, 
Toxoplasma nuclei; hN, host cell nucleus; PCNA, proliferating cell nuclear antigen 
(green); IMC1, inner membrane complex 1 (red); DAPI, 4’,6-diamidino-2-phenylindole 
(blue). 
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Chapter 4:  Discussion and Future Studies 
 
I.  TgGCN5-B harbors a novel NLS within its N-terminal extension 
 
A.  Summary of Aim 1 results 
 It was discovered that TgGCN5-B possesses a novel NLS, 311RPAENKKRGR320
 
, 
within its N-terminal extension.  These 10 amino acids were required for nuclear 
localization, as the deletion of just these residues excluded the protein from the parasite 
nucleus.  The NLS of TgGCN5-B was also sufficient to localize bacterial β-galactosidase 
to the parasite nucleus.  Despite several attempts, an interaction between TgImp-α or 
TgImp-β and TgGCN5-B could never be established.  Therefore, the chaperone that 
assists in the transportation of TgGCN5-B to the parasite nucleus remains undefined.  It 
was demonstrated that the NLS of TgGCN5-B has predictive value, as several proteins 
identified in a bioinformatics search of the ToxoDB contain similar but not identical basic-
rich amino acid clusters.  One protein identified in the bioinformatics search, AT-hook 
056400, was shown to the parasite nucleus. 
B.  The classification of the TgGCN5-B NLS 
 As determined by the bioinformatics search, no other known Toxoplasma protein 
contains a motif identical to the NLS of TgGCN5-B.  The GCN5-B homologue in 
Neospora, another Apicomplexa parasite, has a similar motif (352RPVPESKKRGR362), 
but it is not identical.  Database searches of other Apicomplexa parasites and related 
protozoa also failed to identify another protein harboring the exact TgGCN5-B NLS motif.  
Interestingly, searches of the NLS database (http://cubic.bioc.columbia.edu/db/NLSdb/) 
did not reveal any other NLSs with this exact sequence, thus rendering the NLS of 
TgGCN5-B unique [139]. 
 NLSs can be classified into two broad sub-categories:  monopartite and bipartite.  
Monopartite NLSs consist of a short stretch of basic amino acids, whereas bipartite 
NLSs are comprised of two basic clusters separated by 10 – 12 amino acids.  The NLS 
of TgGCN5-B can be classified as a monopartite motif because only 4 amino acids 
separate the beginning Arg residue from the core basic cluster (KKRGK). 
Kosugi et al. (2009) have further categorized NLSs into six different classes, 
including five classes of monopartite signals, based on sequence homology and binding 
specificities to importin-α [140].  Using their classification system, the TgGCN5-B NLS 
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most resembles the Class 2 NLSs exemplified by the sequence algorithm 
(P/R)XXKR(^DE)(K/R), where X is any amino acid, and (^DE) represents any residue 
except Asp or Glu [140].  The defining member of Class 2 is the well characterized c-
myc NLS, 320PAAKRVKLD328
However, the major caveat of suggesting that the TgGCN5-B NLS should be 
categorized within Class 2 is that the TgGCN5-B NLS does not appear to associate with 
Toxoplasma’s homologue of Imp-α.  All the classes of NLSs described by Kosugi et al. 
(2009) are defined by both sequence similarities and Imp-α binding specificity [140].  
Although several Toxoplasma proteins have similarities to Imp-α, the homologue 
identified by Bhatti et al. (2005) is the only protein to have a conserved importin β 
binding domain [131,144].  It is possible that additional divergent Imp-α homologues 
exist in Toxoplasma because other eukaryotes such as humans possess multiple Imp-α 
isoforms [130,131]. 
 [140,224].  Similar to the algorithm and the c-myc NLS, the 
NLS of TgGCN5-B has a basic-core cluster of both Lys and Arg residues split by a 
neutral amino acid (Gly).  Furthermore, the TgGCN5-B basic cluster is flanked by 
proceeding residues, which begin with both an Arg and a Pro. 
Kosugi et al. (2009) performed numerous mutational analyses of each NLS class 
and determined that both the flanking residues and the basic core pattern could 
influence overall NLS activity [140].  Likewise, Makkerh et al. (1996) have characterized 
the upstream PAA residues and downstream LD residues that flank the basic-cluster of 
the c-myc NLS and found both flanks contribute to nuclear import activity [196].  
Furthermore, they provided evidence supporting the importance of both neutral and 
acidic flanking residues, and their ability to rescue single inactive basic-rich clusters 
[196]. 
Likewise, the NLS of TgGCN5-B illustrates the significance of additional residues 
since its basic cluster was not able to result in nuclear localization without the addition of 
several upstream residues.  The nature of the residues is also critical as mutations of 
both the Arg and Pro, at positions 311 and 312, hindered activity of the TgGCN5-B NLS.  
This result demonstrates that an upstream Pro or additional basic residue (Arg or Lys) 
can serve to activate certain NLSs.  Interestingly, the residue immediately following the 
TgGCN5-B NLS is an Asp (D), a residue that augments the activity of the c-myc NLS 
[196].  When the TgGCN5-B NLS was attached to the C-terminus of β-gal followed by 
the FLAG epitope tag, this Asp residue was inadvertently included because the FLAG 
epitope begins with Asp.  However, the Asp was determined not to be necessary for the 
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function of the TgGCN5-B NLS, because replacement of the FLAG epitope with an HA 
epitope (begins with Tyr) did not alter the nuclear localization. 
As discussed in the introduction (Chapter 1, Section III-E), specific Lys residues 
within the NLS of PCAF are autoacetylated, and these post-translational modifications 
are critical for proper nuclear localization [141,142].  TgGCN5-B is acetylated (Figure 
16).  However, acetylation does not appear to be required for the nuclear localization of 
TgGCN5-B.  The mutant protein GCN5-BΔNLS, which lacks the 10 residue NLS, 
retained its acetylation status, indicating that residues outside the NLS of TgGCN5-B are 
acetylated (data not shown).  However, this does not conclusively exclude the possibility 
that the TgGCN5-B NLS is acetylated.  The catalytically inactive TgGCN5-B dominant-
negative protein maintained its ability to localize to the parasite nucleus; however, 
localization is not exclusively nuclear as some ectopic GCN5-B DN protein appears to 
be in the cytoplasm.  This distribution pattern is similar to the pattern observed when 
ectopic TgGCN5-BΔ310 was expressed in the parasites.  The majority of TgGCN5-
BΔ310 localized to the nucleus, but some remained in the cytoplasm.  It is possible that 
a post-translational modification, such as acetylation, could facilitate or retain the nuclear 
localization of both these TgGCN5-B proteins.  Alternatively, the presence of GCN5-B 
DN beyond the parasite nucleus could be an artifact of over-expression. 
 
C.  Utility of the TgGCN5-B NLS 
 The NLS of TgGCN5-B was shown to have predictive value as assessed by a 
bioinformatics search of the ToxoDB for predicted proteins harboring a similar amino 
acid pattern.  Various permutations of the TgGCN5-B NLS were identified in several 
predicted proteins (Table VI), some being known nuclear proteins such as DNA 
polymerases.  To further evaluate the predictive value of the TgGCN5-B NLS, an 
identified protein, AT-hook 056400, was shown to localize to the parasite nucleus.  
However, the analogous basic-rich cluster of AT-hook 056400 (2,515RPKKRRR2,522
 Since many Toxoplasma proteins remain uncharacterized and have unknown 
functions, identifying potential motifs such as NLSs in an uncharacterized protein can 
contribute to determining the function of the protein.  Likewise, the predictive value of the 
TgGCN5-B NLS can be utilized to search other Apicomplexa and related protozoa 
) 
would need to be further evaluated in order to confirm that the motif functions as an 
NLS. 
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databases for the recognition of similar motif patterns, thereby identifying other potential 
nuclear proteins. 
Intriguingly, the NLSs of both Toxoplasma GCN5s fall within regions of the 
proteins that are considered intrinsically disordered (Figure 12 and data not shown).  
Although unstructured and lacking a three-dimensional confirmation, regions of intrinsic 
disorder can be attributed to important biological functions, such as protein-protein 
interactions [204,205,207].  Combining the predictive capabilities of the TgGCN5-B NLS 
with computational predictors of disorder could further enhance the recognition of signal 
motifs within uncharacterized proteins. 
 As mentioned in the introduction, HAT inhibitors are notorious for their low 
cellular permeability.  However, conjugation of an oligo-Arg peptide to a coenzymeA 
analogue HAT inhibitor resulted in cell permeability [225].  Since NLSs are small peptide 
motifs rich in Arg and Lys residues, could they also serve a similar function and enhance 
molecular inhibitor design?  Additionally, coupling of the SV40 large T antigen NLS with 
halogenated monocyclic aromatic compounds increases the cellular uptake of the 
peptide, suggesting that manipulation of NLSs could enhance their cellular permeability 
[226].  Taken together, it is conceivable that NLS peptides might be useful tools for not 
only localizing molecules to the nucleus, but also assisting in cellular permeability and 
could be utilized in future pharmacological development. 
 Furthermore, Kosugi et al. (2008) have described a novel method of designing 
peptide inhibitors based on an activity-based profile representing the functional 
contribution of individual amino acids within a peptide sequence [227].  Using this 
method, they developed two peptide inhibitors that bind specifically to importin-α and 
disrupt classical nuclear import [227].  Likewise, peptide aptamer technology has been 
utilized to inhibit the NLS of a human cytomegalovirus protein resulting in decreased 
viral replication [228].  UL84 is an essential human cytomegalovirus replication factor, 
which harbors a nonconventional NLS of 282 amino acids.  This NLS interacts with Imp-
α in a mechanistically distinct manner.  Exploiting these unique characteristics, Kaiser et 
al. (2009) isolated several peptide aptamers (small random peptide sequences attached 
to inactive scaffolds) that inhibit the UL84 NLS and Imp-α association and have antiviral 
activity [228,229].  Peptide aptamers act similar to antibodies, binding specifically to 
target sequences, and thereby blocking the interaction of other molecules [229]. 
Targeted inhibition of protein-protein interaction with peptide aptamers is an approach 
that should be considered as means to exploit the unique properties of other NLSs. 
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D.  Future studies 
 It would be beneficial to determine the chaperone that binds the NLS of 
TgGCN5-B and facilitates its localization into the parasites nucleus.  However, 
Toxoplasma possesses several potential proteins with similarities to Imp-α, and other 
importin-family homologues; therefore, many possibilities exist and there is no obvious 
insight to suggest one protein over the others [131,144].  It would be interesting to 
determine if TgGCN5-B could interact in vitro with yeast Imp-α.  The SV40 large T 
antigen NLS is capable of interacting with Imp-α homologues from other species [130]; 
therefore, it is plausible that the NLS of TgGCN5-B could interact with another Imp-α 
from other species.  If such an interaction were to occur, it could help to determine if 
another Imp-α homologue in Toxoplasma is likely to be the TgGCN5-B nuclear 
chaperone, or if one of the other classes of chaperones (Imp-β or transportins) should be 
further investigated [131].  Additionally, if one of the inhibitors of Imp-α identified by 
Kosugi et al. (2008) were expressed in the parasites and inhibited localization of FLAG-
tagged TgGCN5-B, then this would indicate an Imp-α type chaperone [227].  To exclude 
the possibility that TgGCN5-B does not interact with TgImp-β, the entire TgImp-β should 
be cloned and utilized in co-IP studies.  If it is discovered that TgGCN5-B does indeed 
interact with a unique or novel chaperone to enter the parasite nucleus, then this 
interaction might be an ideal target for inhibition by protein aptamers. 
 To complete the characterization of the TgGCN5-B NLS, it should be determined 
if any of the lysines within the NLS are acetylated.  Although the acetylation status of 
TgGCN5-B does not appear to regulate nuclear localization, this should be confirmed.  
Mass spectrometry can be used to determine the lysine residue(s) that are acetylated on 
TgGCN5-B. 
 Another future study should determine if the analogous motif identified in AT-
hook 056400 functions as an NLS.  This can simply be assessed by adding these 
residues to β-gal and determining its localization via IFA. 
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II.  TgGCN5-B associates with novel Apicomplexa transcription factors 
 
A.  Summary of Aim 2 results 
 The N-terminal extension of TgGCN5-B is devoid of identifiable motifs, other than 
the NLS described in Aim 1.  Additionally, the protein sequence of the N-terminal 
extension of TgGCN5-B is not homologous to other characterized GCN5 homologues; 
hence, the function of this region is yet undetermined [169].  Bioinformatics reveal that 
the N-terminal extension of TgGCN5-B contains several distinct regions of intrinsic 
disorder, suggesting the extension might have a notable biological function, possibly as 
a region for protein-protein interactions [204,205,207].  Classically, GCN5 homologues 
function within large multi-subunit complexes that are conserved among species; 
however, Toxoplasma lacks many of these conserved components [104,202].  However, 
La Count et al. (2005) demonstrated that the N-terminus of Plasmodium GCN5 
associated with a variety of proteins and was at the center of the largest protein 
interaction network within Plasmodium [161].  To determine the proteins that associate 
with TgGCN5-B two biochemical techniques, affinity chromatography and co-
immunoprecipitation were utilized.  The results indicate that GCN5-B associates with 
several proteins including novel Apicomplexa transcription factors. 
 
B.  Comparison of affinity chromatography and co-IP techniques 
 The two biochemical techniques used to determine TgGCN5-B associating 
proteins yielded very different results, with no proteins being identified in all three 
experiments (2 affinity chromatography experiments and a single co-IP experiment).  
Based on several observations, I feel that the co-IP experiment and its results are more 
likely to reflect actual protein associations with TgGCN5-B compared to the affinity 
chromatography experiments. 
First, a recombinant TgGCN5-B produced in bacteria was used for the affinity 
chromatography.  Although this protein was catalytically active, it is possible that when 
produced in this manner, parts of the protein could exist in a non-native confirmation or 
be mis-folded.  If structural confirmation is important for protein interaction, then the 
conditions of the affinity chromatography may not have been ideal for native protein-
protein interactions to occur.  Likewise, any post-translational modifications of TgGCN5-
B that facilitate protein-protein interactions would likely not be present on the 
recombinant protein, and therefore not contribute to protein associations.  As 
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demonstrated in Aim 2, TgGCN5-B is acetylated; however, the implication of this mark 
has yet to be determined. 
The affinity chromatography results included a large amount of ribosomal 
proteins and other obvious cytoplasmic contaminants, whereas the data from the co-IP 
of TgGCN5-B had less cytoplasmic contaminants.  The multiple column fractionations 
incorporated into the co-IP experimental protocol facilitated the removal of these 
contaminants and reduced the likelihood of non-specific associations. 
Finally, since the affinity chromatography experiment failed to identify either 
TgADA2-A or –B as associating proteins of TgGCN5-B, I had little confidence in the data 
generated from this experiment.  It has been shown that TgGCN5-B can interact with 
both TgADA2-A and –B by yeast two-hybrid, so the absence of either from the affinity 
chromatography data is unusual [169].  The presence of TgADA2-A in the co-IP data set 
further increases the confidence in this approach. 
However, there were still some interesting proteins identified in the affinity 
chromatography experiment.  For instance, TgPRMT5 (protein arginine 
methyltransferase 5; 33.m01376) was identified in the first replicate of the affinity 
chromatography experiment.  It has been reported that TgPRMT5 modifies histone 
H3R2 [152].  Since both TgGCN5-B and TgPRMT5 modify lysines on histone H3, it is 
possible that these proteins interact in a collaborative manner to regulation gene 
expression.  Perhaps the methylation of histone H3R2 modulates the acetylation of 
histone H3 or vice versa.  Additionally, a putative 14-3-3 protein (55.m00015) was also 
identified in the first replicate of the affinity chromatography experiment.  14-3-3 proteins 
are important eukaryotic regulatory molecules capable of binding phosphoserine and 
phosphothreonine in variety of proteins, including kinases and phosphatases, and 
thereby regulate a multitude of cellular events [230,231].  Intriguingly, it has been shown 
that a 14-3-3 protein binds and prevents the nuclear localization of HDAC4, 
consequently hindering the function of HDAC4 [232].  It is possible that the putative 14-
3-3 protein 55.m00015 could bind and regulate the function of TgGCN5-B.  Additionally, 
14-3-3 proteins were shown to be acetylated, thereby modulating their binding affinities 
for other substrates [233].  Therefore, the putative 14-3-3 protein 55.m00015 might be a 
substrate of TgGCN5-B.  Unfortunately, since both of these proteins, TgPRMT5 
(33.m01376) and the 14-3-3 protein 55.m00015, were only identified in the first replicate 
of affinity chromatography and not in the second replicate, I did not select them for 
further analysis. 
121 
A simple method to refine the affinity chromatography protocol to reduce the 
number of contaminating proteins would be to excise bands from the SDS-PAGE gel 
rather than analyzing the entire sample.  The excision of prominent protein bands was 
done in the co-IP experiment.  Although each excised band is likely is contain multiple 
proteins, this technique would reduce the number of non-specific associating proteins. 
 
C.  The pursuit of Apicomplexa AP2s 
 Toxoplasma and other apicomplexans are without the conventional eukaryotic 
specific transcription factors involved into regulating gene expression.  However, it was 
discovered that Apicomplexa harbor proteins containing the AP2 DNA-binding domain 
commonly found in plant transcription factors [157].  Furthermore, studies in Plasmodium 
demonstrate that select AP2 domains, do indeed bind to specific DNA motifs, and one 
AP2 in particular (PF11_0442, AP2-O) has been attributed to the activation of stage-
specific genes [159,160].  Interestingly, after their discovery, AP2 proteins were shown 
to be associated with chromatin remodeling enzymes.  One of the proteins identified in 
the purification of the HDAC3 complex in Toxoplasma was subsequently found to an 
AP2 protein (TgCRC350, TGME49_0727100) [152,154].  In Plasmodium, proteins 
capable of associating with N-terminal extension of PfGCN5 were discerned via a high-
throughput yeast two-hybrid screen [161].  From this screen, it was later discovered that 
2 AP2 proteins associated with PfGCN5 (PF10_0075 and MAL8P1.153.) [152,161].  The 
AP2 protein PF10_0075 also bears a putative AT-hook DNA binding motif [161].  
Importantly, the high-throughput yeast two-hybrid screen revealed that many protein-
protein interaction networks exist in Plasmodium, and that PfGCN5 is at the center of the 
most highly connected network; therefore, PfGCN5 is the most interconnected protein in 
Plasmodium [161].  Six Plasmodium AP2 proteins have been mapped to interaction 
networks consisting of several other proteins involved in chromatin remodeling and 
transcription regulation [152].  Interestingly, an AP2 factor from Arabidopsis (CBF1) 
associated within a GCN5 complex, thereby providing another connection between 
GCN5 and AP2 domains [234]. 
 From this evidence, I decided to pursue the AP2 proteins that were identified in 
the co-IP experiment for further confirmation.  I also included the AT-hook motif protein 
since this domain was also found on one of the Plasmodium AP2 proteins.  The AP2 
protein 33.m01324 was only recently annotated as an AP2 protein, and it is currently 
being pursued.  I was never able to amplify gDNA from the C-terminus of AP2 
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50.m03194 (required to endogenously tag the protein), hindering the examination of this 
protein.  However, the AP2 proteins 20.m03816 and 80.m03948 as well as AT-hook 
583.m05282 (AT-hook 056400) were endogenously tagged within separate parasites 
strains and are currently being evaluated to confirm interactions with TgGCN5-B. 
 It should be noted that the Toxoplasma homologues of the PfGCN5 associating 
proteins were not identified in the co-IP experiment.  However, some of the proteins in 
these two data sets have similar protein motifs.  Apart from the AP2 and AT-hook 
domains, PFF1440w is a PfGCN5 interacting protein that contains a PHD domain and 
two TgGCN5-B associating proteins (42.m03344 and 46.m01622) also contain this 
domain [161].  It is plausible that in each organism, GCN5 forms specific complexes that 
mediate definitive cellular processes.  In order to perform these specialized roles, the 
associating proteins differ; however, functional domains, such as the AP2 or PHD 
domains, might remain conserved.  Likewise, identification of the TgGCN5-A complex is 
expected to yield a distinct set of associating proteins with conserved functional 
domains.  Since Toxoplasma possesses two GCN5 homologues, an unusual feature for 
a lower eukaryote, it is predicted that each TgGCN5 forms discrete complexes in order 
to regulate distinct and independent processes within Toxoplasma. 
 
D.  The roles of the N-terminal extensions in Apicomplexa GCN5s 
 The major differences among GCN5 homologues exist at their N-terminal 
extensions (Figure 3).  Yeast GCN5, with a short N-terminus must associate within a 
complex in order to acetylate nucleosomal histone, whereas mammalian GCN5s with 
longer N-terminal extension readily acetylate nucleosomal substrates [235].  This 
analysis suggests that the N-terminal extension facilitates the binding affinity of GCN5s 
for their substrates.  The metazoan GCN5 homologues possess a PCAF homology 
domain within their N-terminal extensions [104].  In PCAF, this region contains the 
ubiquitin E3 ligase domain, although ubiquitinase activity has not been demonstrated for 
GCN5 homologues other than PCAF [83].  The remaining functions of the N-terminal 
extensions have yet to be defined. 
 The Plasmodium high-throughput yeast two-hybrid study provided direct 
evidence that the elongated N-terminal extensions of Apicomplexa GCN5s are involved 
in protein-protein interactions [161].  Therefore, it is very likely that some of the proteins 
associating with TgGCN5-B do so via the N-terminus.  This is in agreement with the 
bioinformatics data demonstrating that TgGCN5-B N-terminus is intrinsically disordered.  
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It is also plausible that the Apicomplexa GCN5 N-terminal extensions also function as 
the mammalian extensions and enhance the activity and substrate recognition of these 
enzymes.  However, the N-termini of the Plasmodium GCN5 and that of the two 
Toxoplasma GCN5s do not share similar sequence homology [169,178].  These results 
could indicate that each homologue associates with distinct proteins to perform different 
cellular functions.  The Apicomplexa GCN5s do not contain the PCAF homology domain, 
and currently ubiquitinase activity has not been demonstrated for any of these enzymes. 
 
E.  Future studies 
 The first study, which is currently underway, is to confirm through an independent 
experiment that TgGCN5-B does indeed associate with one or more of the proteins 
identified in Aim 2.  As discussed previously, the AP2 proteins and AT-hook motif protein 
seemed to be the most logical proteins with which to begin this study.  It would also be 
interesting to determine if TgGCN5-B and these proteins regulate similar groups of 
genes.  Currently, ChIP-to-chip (chromatin immunoprecipitation coupled to microarray 
analysis) has been shown to determine the gene networks regulated by certain 
chromatin modifying enzymes [166].  Applying such a strategy to both TgGCN5-B and 
an associating AP2 protein would reveal the patterns of genes regulated by both 
proteins and could reveal commonalities between the two gene networks. 
 Another interesting experiment would be to determine if the TgGCN5-B 
associating proteins differed during stress conditions or between type I and type II 
parasite strains.  It is possible that other proteins interact with TgGCN5-B only under 
certain environmental conditions in order to regulate a different set of genes.  Likewise, 
the determination of the TgGCN5-A associating proteins will likely reveal a different set 
of associating proteins, as we hypothesize that these two HATs form distinct complexes 
within the parasites.  The elucidation of additional TgGCN5 complex members will 
further enhance how these HATs regulate Toxoplasma gene expression. 
 Although it was noted that TgGCN5-B is acetylated, the mechanistic details and 
implications of this post-translational modification have yet to be determined.  
Additionally, S. cerevisiae GCN5 is a substrate for sumoylation, and although this 
modification does not alter catalytic activity, it appears to have a regulatory role [236].  
The proteins required for sumoylation are conserved in Toxoplasma, making this post-
translation modification of TgGCN5-B a possibility [237].  Moreover, the phosphorylation 
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of human GCN5 inhibits its catalytic function [238].  It should be determined if these 
post-translational modifications also occur on TgGCN5-B. 
 Finally, if a unique and specific interaction is determined to occur between 
TgGCN5-B and one of the associating proteins, than this interaction might be ideal for 
targeting with inhibitor peptide aptamers (Chapter 4, Section I-C).  However, it should be 
determined if TgGCN5-B and its associating protein interaction is critical for propagation 
of the parasites or differentiation prior to testing aptamer inhibitors. 
 
III.  TgGCN5-B dominant-negative phenotype decreases parasite viability 
 
A.  Summary of Aim 3 results 
 Traditional attempts to KO TgGCN5-B in haploid Toxoplasma tachyzoites failed, 
suggesting this gene might be essential.  In order to study the role of TgGCN5-B within 
the parasites, a dominant-negative mutant was generated.  A catalytically inactive 
TgGCN5-B mutant protein was expressed in the parasites under the regulation of the 
DD.  When induced to express the mutant TgGCN5-B protein, parasites demonstrated a 
reduction in viability as assessed in three different growth assays.  IFA data revealed 
that parasites expressing the mutant TgGCN5-B protein had defective nuclear division 
and daughter cell formation.  A recombinant wild-type version of TgGCN5-B protein and 
a catalytically inactive TgGCN5-A mutant protein, expressed in the same manner, did 
not show an observable phenotype, indicating the growth defects are exclusive to the 
dominant-negative TgGCN5-B. 
 
B.  GCN5 regulates normal progression through the cell cycle 
 GCN5 appears to be intimately involved in cell-cycle regulation.  S. cerevisiae 
mutants that are deficient in GCN5 accumulated in the G2/M phase, whereas the lack of 
GCN5 in DT40 mammalian cells caused suppression at the G1/S phase transition 
[120,239].  The latter study not only demonstrated that GCN5 regulates the transcription 
of key cell-cycle factors, but also that GCN5 influenced the transcription of apoptosis-
related genes [120]. 
 GCN5 is critical for proper mitotic progression [240,241].  S. cerevisiae mutants 
lacking GCN5 demonstrated improper nuclear segregation as well as a delay in mitotic 
spindle elongation [240].  Additionally, this study demonstrated that GCN5 associated 
with centromeres, was able to regulate the variant centromeric nucleosomes, and is 
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important for kinetochore function [240].  Subsequently, examination of the knock-down 
of ADA2a and ADA3 in mammalian cells, which causes GCN5 to dissociate from the 
ATAC (Ada Two A Containing) complex, resulted in mitotic dysfunction manifested by 
defects in nuclear division, spindle formation, and centrosome multiplication [241].  The 
ATAC complex was shown to localize to the mitotic spindle and control cell cycle 
progression through the GCN5-mediated acetylation of cyclin A, resulting in the 
degradation of this protein.  In the absence of GCN5 acetylation, cyclin A phosphorylates 
the HDAC SIRT2 thereby decreasing its deacetylase activity and ultimately leading to 
accumulation of hyperacetylated α-tubulin [125,241].  Additionally, GCN5 was found to 
acetylate the cell-division cycle (CDC)-6, a protein essential for initiation of DNA 
replication and promoting cell-cycle progression, with this modification contributing to the 
regulation of the CDC6 [124].  Importantly, a global analysis of protein acetylation status 
revealed that a plethora of cell-cycle related genes are acetylated, further suggesting 
that HATs are key regulators of the cell cycle [233]. 
 Given the results of these studies, it is not surprising that the dominant-negative 
TgGCN5-B mutant exhibited dramatic growth reduction.  Interestingly, the defective 
nuclear division and deficient daughter cell budding morphologies seen in the GCN5-B 
dominant-negative mutant resemble the phenotype of Toxoplasma tachyzoites exposed 
to oryzalin, a microtubule-disrupting agent [242].  In the presence of 2.5 µM oryzalin, 
parasites demonstrated defective nuclear division through disruption of the spindle 
microtubules [242].  Given this similarity and the previous findings that GCN5 mutants 
have defects in mitotic spindles, it is likely that TgGCN5-B plays a distinct role in 
regulating Toxoplasma nuclear division through modulation of mitotic spindle 
microtubules.  Although Toxoplasma does not appear to have a homologue of cyclin A, 
two divergent cyclins have been identified in Toxoplasma [243].  It is possible that 
TgGCN5-B is able to acetylate and regulate one or more of these cyclins in a manner 
similar to the regulation demonstrated for cyclin A.  Toxoplasma appears to have a 
homologue of CDC6 (TGGT1_035930).  It would be interesting to determine if this 
protein is acetylated by TgGCN5-B.  Alternatively, TgGCN5-B might act as a global 
regulator of Toxoplasma cell-cycle progression.  It is possible that the dominant-negative 
TgGCN5-B mutant could mimic GCN5-null DT40 cells, which demonstrates that a broad 
range of cell-cycle genes are under the transcriptional regulation of GCN5 [120]. 
 Parasites lacking TgGCN5-A do not have a growth defect when grown in normal 
culture conditions [169].  Also, a dominant negative TgGCN5-A mutant regulated 
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through the DD did not display growth defects, indicating that the phenotype of the 
TgGCN5-B dominant-negative is specific for the GCN5-B HAT.  It is likely that the 
Toxoplasma GCN5s form distinct complexes, and I propose that the TgGCN5-B complex 
is exclusively responsible for regulating parasite nuclear division and daughter cell 
budding through modulation of mitotic spindle microtubules.  Therefore, TgGCN5-A 
cannot compensate for the loss of TgGCN5-B. 
 
C.  TgGCN5-B is a novel therapeutic candidate 
 Given the severe growth phenotype exhibited by the TgGCN5-B dominant 
negative mutants, it is likely that specific pharmacological inhibition of TgGCN5-B will 
hinder Toxoplasma tachyzoite growth and viability.  However, there are still many 
important considerations that must be taken into account when attempting to 
therapeutically target TgGCN5-B.  First, the human host cells will also possess GCN5 
homologues; therefore, it is critical that an inhibitor be specific to TgGCN5-B and has 
little or no effect on human GCN5 and PCAF.  Second, it has not been determined if 
TgGCN5-B is crucial to bradyzoite development or maintenance.  The generation of the 
dominant-negative TgGCN5-B mutant should be recapitulated in a type II strain, one 
capable of converting to bradyzoites in vitro, in order to determine the effect of the loss 
of TgGCN5-B on this form of the parasites.  Ideally, a novel anti-toxoplasmosis therapy 
should not only target tachyzoites but inhibit the development and maintenance of 
bradyzoites to clear the infection.  Finally, the current problems with HAT inhibitors such 
as low cell permeability and low specificity should be addressed. 
 If a small molecular inhibitor screen is initiated to find inhibitors of TgGCN5-B, a 
high-throughput assay must be developed in order to screen the inhibitors.  A standard 
HAT assay utilizing recombinant enzyme would be ideal for this application.  Previously, 
attempts to produce active recombinant TgGCN5-B from bacteria have failed [Sullivan 
and Bhatti, unpublished data].  However, I have shown that expression of recombinant 
TgGCN5-B fused at the N-terminus to maltose-binding protein (MBP) is active when 
produced in E. coli (Figure 14B).  Large-scale production of recombinant MBP-GCN5-B 
would be ideal to use in inhibitor screening assay. 
 As an alternative approach, the associating proteins of TgGCN5-B could be 
novel targets for inhibitor design.  The AP2-domain proteins that associate with 
TgGCN5-B represent a class of proteins unique to Apicomplexa parasites that are not 
found in humans.  An inhibitor capable of blocking the interaction of one of the AP2-
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domain proteins with TgGCN5-B would be specific to Toxoplasma, minimizing the effect 
on the human host cells. 
 
D.  Future studies 
 The first studies should further characterize the TgGCN5-B dominant-negative 
phenotype.  For instance, studies are currently underway to confirm that histone H3 
acetylation is decreased when the dominant-negative mutant TgGCN5-B protein is 
expressed.  An overall decrease in histone H3 acetylation is expected since histone H3 
is a major target of GCN5 proteins.  However, when the GCN5-containing ATAC 
complex was disrupted, it was noted that histone H4 lysine 16 (K16) was 
hyperacetylated, an effect attributed to the dysregulation of the HDAC SIRT2 [241]; 
therefore, if hypoacetylation of histone H3 is not observed, it could be due to another 
underlying mechanism.  Additionally, it has been suggested that IFA staining with an 
antibody to examine the centrosomes would likely reveal evidence of mis-segregation, 
which could lead to chromosome fragmentation and account for the abnormal nuclear 
morphologies depicted in the TgGCN5-B dominant-negative parasites.  Since the 
dominant-negative TgGCN5-B expressing parasites resemble the phenotype of 
parasites exposed to the spindle microtubule disrupting agent oryzalin, the α-tubulin 
dynamics should be examined in the dominant-negative parasites [242].  PCNA has 
been shown to be acetylated [233].  It should be determined if Toxoplasma’s PCNA is 
also acetylated, and if there is a change in this modification with the expression of 
dominant-negative TgGCN5-B protein. 
 As suggested previously, the TgGCN5-B dominant-negative approach should be 
repeated in a type II strain of the parasite to determine the role of TgGCN5-B in 
bradyzoite development and maintenance.  For this experiment, the GCN5-B DN protein 
should be turned on after the parasites have converted to bradyzoites cysts.  Then not 
only can the viability of the bradyzoites be examined, but it can also be determined if 
bradyzoites expressing GCN5-B DN protein are able to convert back into tachyzoites.  If 
the expression of the GCN5-B DN protein hinders either process, this further validates 
the utility of TgGCN5-B as a novel therapeutic target. 
 Although microarray analysis of the TgGCN5-B dominant-negative mutant would 
provide insight into the genes regulated by this HAT, the utility of a large study must be 
considered.  The cost-benefit ratio of performing this microarray analysis might not be 
ideal since it is likely that a large number of transcripts are going to be dysregulated, 
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given the severe phenotype.  A more cost-effective approach would be to study the 
transcript levels of select cell-cycle and cell division genes at given time-points after the 
addition of Shld through real-time PCR analysis.  This is a direct approach and might 
initially be more beneficial than a global analysis.  Additionally, to obtain information of 
the gene network regulated by TgGCN5-B, chromatin immunoprecipitation followed by 
either microarray analysis or high-throughput sequencing (ChIP-chip or ChIP-seq) can 
be performed using parasites expressing HA-MYCGCN5-BFLAG
 Additionally, studies are currently being initiated to examine the loss of native 
endogenous TgGCN5-B.  This effect is being examined by tagging the C-terminus of the 
genomic locus of TgGCN5-B with a 2xHA epitope tag followed by the DD domain [187].  
When endogenous TgGCN5-B is tagged in this manner, the parasites must be kept on 
Shld in order for TgGCN5-B to be expressed.  The removal of Shld should cause 
degradation of TgGCN5-B and should mimic a KO.  Repetition of the growth assays and 
IFAs with cell-cycle markers should produce a similar phenotype as the dominant-
negative TgGCN5-B mutant.  The confirmation of this phenotype through an 
independent method will further validate that TgGCN5-B is critical for Toxoplasma 
tachyzoite proliferation. 
. 
 Finally, given the severe phenotype of the TgGCN5-B dominant-negative 
mutants, a small molecule inhibitor screen should be initiated.  To screen the inhibitors, 
a high-throughput assay could be designed utilizing the recombinant and catalytically 
active MBP-GCN5-B protein (Aim 2).  Even if an inhibitor is not clinically applicable, it 
could prove to be a useful laboratory tool. 
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Chapter 5:  Summary 
 
 This dissertation has characterized TgGCN5-B, one of two GCN5-family 
homologues in Toxoplasma.  It was discovered that TgGCN5-B harbors a unique NLS 
within its N-terminal extension, associates with several proteins including novel 
Apicomplexa transcription factors, and is critical for tachyzoite viability because parasites 
expressing a dominant-negative TgGCN5-B displayed a severe growth phenotype.  The 
decreased viability seen in the dominant-negative TgGCN5-B mutants suggests that 
TgGCN5-B is a novel therapeutic target.  Pharmacological inhibition of this enzyme 
should hinder Toxoplasma tachyzoite proliferation.  However, since inhibition of the 
catalytic activity of TgGCN5-B could also affect GCN5 homologues in the host, it was 
suggested that peptide aptamer inhibitors also be considered.  Specifically designed 
peptide aptamer inhibitors could disrupt the interaction of TgGCN5-B with its associating 
proteins (AP2-domain proteins) or block its NLS.  However, little is known about the role 
of TgGCN5-B in Toxoplasma bradyzoite differentiation and development.  Therefore, 
studies of the associating proteins of TgGCN5-B within bradyzoites as well as the affect 
of the dominant-negative on bradyzoites should be commenced.  In conclusion, the 
histone acetyltransferase TgGCN5-B plays an important role in Toxoplasma proliferation 
in vitro. 
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Appendices 
 
Appendix A:  Parasite counting 
 
To count parasites, 10 μl freshly lysed or filter-purified parasites was loaded into each 
side of a hemocytometer.  For each individual side of the hemocytometer, all the 
parasites within 5 squares of the 25 squares of the main grid were counted (see diagram 
below).  Two replicate counts could be obtained from one hemocytometer.  Typically, 
four replicate counts were required, so the hemocytometer was cleaned, and fresh 
parasites were loaded to obtain an additional set of replicate counts. 
 
 
Figure A1:  Counting grid of hemocytometer.  The highlighted numbers represent the 
5 individual squares counted for each replicate. 
 
After obtaining all replicates of parasite counts, calculation could be performed.  In 
general, the total mean was obtained (Ave. of Averages), representing the average 
number of parasites per square.  The total mean was multiplied by 25 since the counting 
grid has 25 squares.  The product is always multiplied by 1X104
  
 due to the amount 
placed in the hemocytometer.  This gives the concentration of parasites/ml.  
1 
2 
3 
4 
5 
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EXAMPLE 
 A B C D 
Box 1 30 35 37 19 
Box 2 24 21 29 25 
Box 3 26 26 15 27 
Box 4 35 32 24 20 
Box 5 20 27 21 31 
Totals 164 141 126 122 
Average 32.8 28.2 25.2 24.4 
 
1)  Concentration of parasites 
Ave. of Averages = 27.65 X 25 = 691.25X104 parasite/ml OR 6.9X106 parasite/ml 
 
2)  For cloning by limiting dilution into 96-well plate 
Ave. of Averages = 27.65 X 25 = 691.25X104 parasite/ml OR 6.9X106 parasite/ml 
6.9 X106 parasites/ml / 1000 = 6.9 X103 parasites/ml OR 6.9 parasites/μl 
100 wells/6.9 parasites/µl = 14.5uL X 2 = 29 µl + 20ml  Media 
After determining the concentration of parasites, a 1:1000 dilution is ALWAYS made 
(second line of calculation).  The concentration of this dilution can also be written to 
correspond to parasites/μl.  The third line of the calculation determines the 
approximately amount of the 1:1000 dilution needed to have roughly 1 parasite per well 
in the 96-well plates.  For this calculation, 100 wells is use for simplification.  The answer 
is double to account for any errors in counting.  The final answer is the volume from the 
1:1000 that should be added to 20 ml media for dispersion into the plate. 
 
3) For growth assays 
Ave. of Averages = 27.65 X 25 = 691.25X104 parasite/ml OR 6.9X106 parasite/ml 
(1.0X105 parasite/ml)(1.0 ml) = (6.9X106 parasite/ml)V; solve for V 
V = 0.0145 ml or 14.5 μl + 985.5 μl media for concentration of 1.0X105 parasite/ml 
At a concentration of 1.0X105
  
 parasite/ml, 10 µl corresponds to 1000 parasites, and 5 µl 
corresponds to 500 parasites. 
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Appendix B:  Details regarding mass spectrometry for affinity chromatography 
 
Mass spectrometry analysis performed in collaboration with Dr. W. Andy Tao (Purdue 
University) 
 
• Samples from affinity chromatography were denatured, reduced, and alkylated 
• Mixture was then injected into an Agilent 1100 HPLC using micro capilliaries to a 
C18 pre-packed column with a 0.1% formic acid solvent 
• Elution of peptide was with an acetonitrile gradient running from 0 – 80% for 90 
minutes. 
• Peptides were ionized using a nano spray tip and delivered into the mass 
spectrometry machine, an Orbitrap linear iontrap hybrid 
• Mass spectrometry data was searched using Sorcerer Software and ToxoDB 
 
Mass spectrometry details from personal communication with Jacob Galan, researcher 
in the lab of Dr. W. Andy Tao. 
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Appendix C:  Additional affinity chromatography data 
 
Table AI:  Proteins associating with MBP-GCN5-B from affinity chromatography #1 
Entry # Protein Description Accession Number 
1 protein arginine N-methyltransferase, putative 33.m01376 
2 small heat shock protein, putative \ bradyzoite-specific protein, 
putative 
44.m02755 
3 caltractin (centrin), putative 50.m03356 
4 eukaryotic translation initiation factor 3 subunit 9, putative 41.m00006 
5 60S ribosomal protein L18a, putative 55.m05004 
6 TCP-1\cpn60 family chaperonin, putative 49.m00030 
7 chorismate synthase, putative 20.m00001 
8 mitotic checkpoint protein BUB3, putative 50.m03067 
9 ribosomal protein L21, putative 50.m00012 
10 hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate 
synthase 
55.m00011 
11 hypothetical protein 41.m01274 
12 28 kDa antigen 42.m00015 
13 membrane skeletal protein IMC1, putative 44.m00031 
14 prohibitin, putative 49.m00051 
15 nucleoside-triphosphatase I 65.m00001 
16 ATP synthase, putative 42.m00065 
17 elongation factor 1-beta, putative 42.m00069 
18 ATP synthase, putative 76.m01572 
19 40s ribosomal protein S6, putative 27.m00119 
20 60S acidic ribosomal protein P2, putative 583.m00610 
21 fibrillarin, putative 583.m00637 
22 hypothetical protein 44.m06355 
23 protein transport protein Sec23, putative 80.m00011 
24 calmodulin, putative 541.m01151 
25 histone H2A, putative 55.m04926 
26 lysophospholipase, putative 76.m01665 
27 hypothetical protein 31.m00869 
28 hypothetical protein 583.m05696 
29 hypothetical protein 583.m11414 
30 conserved hypothetical protein 55.m00224 
31 eukaryotic translation initiation factor 3 subunit 3, putative 50.m03396 
32 ubiquinol-cytochrome C reductase complex 14 kDa protein-related 80.m00018 
33 hypothetical protein 583.m05375 
34 hypothetical protein 42.m03493 
35 eukaryotic translation initiation factor 3 delta subunit, putative 80.m02245 
36 tubulin beta chain 57.m00003 
37 malate:quinone oxidoreductase, putative 80.m00006 
38 GTP-binding nuclear protein RAN\TC4, putative 50.m00042 
39 transketolase, putative 59.m03618 
40 sec23\Sec24 domain-containing protein 65.m01096 
41 60s ribosomal protein L31, putative 57.m01771 
42 adenylate kinase, putative 42.m00116 
43 hypothetical protein 55.m10265 
44 eukaryotic translation initiation factor 3, putative 83.m01278 
45 histone H2A 145.m00002 
46 histone H4, putative 49.m03134 
47 hypothetical protein 583.m05686 
48 hypothetical protein 37.m00747 
49 hypothetical protein 83.m00011 
50 thioredoxin, putative 50.m00069 
51 u1 small nuclear ribonucleoprotein 70 kda-related protein 20.m03892 
52 conserved hypothetical protein 113.m00798 
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53 membrane skeletal protein IMC1 44.m00004 
54 40S ribosomal protein S12, putative 20.m03903 
55 zinc finger (C2H2 type) protein, putative 76.m00006 
56 gbp1p protein (RNA bindiong protein), putative 55.m00241 
57 conserved hypothetical protein 583.m00682 
58 ubiquinol-cytochrome c reductase, putative \ Rieske iron-sulfur protein, 
putative 
641.m00178 
59 hypothetical protein 55.m00144 
60 hypothetical protein 583.m00707 
61 40S ribosomal protein S26, putative 49.m03356 
62 60S acidic ribosomal protein P0 38.m00002 
63 Sec61beta family protein 27.m01477 
64 hypothetical protein 42.m03397 
65 subtilase family serine protease, putative 20.m00387 
66 U1 small nuclear ribonucleoprotein, putative 541.m01233 
67 ribosomal protein L5, putative 641.m00186 
68 hypothetical protein 57.m03130 
69 60s ribosomal protein L36, putative 49.m03096 
70 40S ribosomal protein S24, putative 33.m01367 
71 articulin 4 41.m00021 
72 hypothetical protein 23.m00237 
73 serine\threonine protein phosphatase, putative 42.m00006 
74 inner membrane complex protein (IMC3) 35.m01595 
75 hypothetical protein 44.m02644 
76 outer membrane protein romA 641.m01580 
77 myosin regulatory light chain, putative 583.m05709 
78 hypothetical protein 55.m05032 
79 histone H2A, putative 55.m04942 
80 40S ribosomal protein S3, putative 44.m04669 
81 protease-related 59.m03479 
82 14-3-3 protein, putative 55.m00015 
83 KH domain containing protein 72.m00843 
84 surface protein rhoptry, putative 583.m00003 
85 hypothetical protein 541.m01172 
86 heat shock protein 60 50.m00006 
87 hypothetical protein 42.m07426 
88 hypothetical protein 583.m00606 
89 chaperone protein dnaK, putative \ heat shock protein 70, putative 50.m00085 
90 developmentally regulated GTP-binding protein 1, putative 49.m00057 
91 hypothetical protein 50.m05687 
92 conserved hypothetical protein 33.m01321 
93 ROP8, putative 80.m02343 
94 myosin light chain TgMLC1-related 583.m05420 
95 hypothetical protein 55.m05095 
96 60S ribosomal protein L7a, putative 46.m00028 
97 ADP\ATP carrier, putative 50.m00009 
98 transcription regulatory protein SNF2, putative 641.m01573 
99 vacuolar ATP synthase subunit B, putative 38.m01889 
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Table A2:  Proteins associating with MBP-GCN5-B from affinity chromatography #2 
Entry # Protein Description Accession Number 
1 conserved hypothetical protein 50.m03254 
2 60s ribosomal protein L4, putative 583.m00619 
3 small heat shock protein, putative \ bradyzoite-specific protein, 
putative 
44.m02755 
4 membrane skeletal protein IMC1 44.m00004 
5 heat shock protein 70, putative 59.m00003 
6 ATP synthase beta chain, putative 55.m00168 
7 dense granule protein 3 42.m00013 
8 gbp1p protein (RNA bindiong protein), putative 55.m00241 
9 60S ribosomal protein L18a, putative 55.m05004 
10 RNA recognition motif. (a.k.a. RRM, RBD, or RNP domain)-
containing protein 
46.m01699 
11 histone H2B, putative 50.m03422 
12 conserved hypothetical protein 583.m00682 
13 WD-40 repeat protein, putative 641.m01564 
14 ribosomal protein L21, putative 50.m00012 
15 nucleolar protein family A, putative 59.m00071 
16 hypothetical protein 44.m02723 
17 ribosomal protein L11, putative 583.m00014 
18 hypothetical protein 583.m00707 
19 60s ribosomal protein L13a, putative 80.m00062 
20 hypothetical protein 41.m01274 
21 calmodulin 50.m03285 
22 28 kDa antigen 42.m00015 
23 ATP synthase alpha chain, putative 20.m00382 
24 membrane skeletal protein IMC1, putative 44.m00031 
25 prohibitin, putative 49.m00051 
26 ATP synthase, putative 42.m00065 
27 hypothetical protein 76.m01605 
28 rhoptry antigen, putative 551.m00238 
29 conserved hypothetical protein 33.m01321 
30 elongation factor 1-beta, putative 42.m00069 
31 splicing factor 3b subunit 10, putative 583.m05642 
32 ATP synthase, putative 76.m01572 
33 major surface antigen p30 44.m00009 
34 translation initiation factor 2 beta, putative 46.m00016 
35 40s ribosomal protein S6, putative 27.m00119 
36 histone H2B variant 1 25.m00008 
37 riboxomal protein L30\L7e, putative \ wx protein 583.m00012 
38 60S acidic ribosomal protein P2, putative 583.m00610 
39 fibrillarin, putative 583.m00637 
40 60S ribosomal protein L22, putative 49.m05661 
41 histone acetyltransferase GCN5, putative 49.m03346 
42 hypothetical protein 44.m06355 
43 thioredoxin, putative 25.m00203 
44 nucleolar RNA-binding domain-containing protein 65.m02513 
45 40s ribosomal protein S14, putative 55.m00221 
46 calmodulin, putative 541.m01151 
47 histone H2A, putative 55.m04926 
48 conserved hypothetical protein 113.m00780 
49 40S ribosomal protein S17, putative 25.m00216 
50 60S ribosomal protein L30, putative 44.m00044 
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51 40S ribosomal protein S7, putative 49.m00013 
52 microneme protein 4 (MIC4) 25.m00006 
53 hypothetical protein 583.m05696 
54 40S ribosomal protein S13, putative 59.m03516 
55 hypothetical protein 583.m11414 
56 40s ribosomal protein S20, putative 41.m01387 
57 conserved hypothetical protein 55.m00224 
58 tubulin alpha chain 583.m00022 
59 myosin A, putative 46.m00001 
60 L12 ribosomal protein 52.m00028 
61 rhoptry antigen, putative 83.m02145 
62 eukaryotic translation initiation factor 3 delta subunit, putative 80.m02245 
63 conserved hypothetical protein 113.m00009 
64 zinc finger (CCCH type) protein, putative 59.m00013 
65 hypothetical protein 44.m04681 
66 tubulin beta chain 57.m00003 
67 U1 small nuclear ribonucleoprotein, putative 541.m01233 
68 malate:quinone oxidoreductase, putative 80.m00006 
69 major sperm protein domain-containing protein 641.m01460 
70 ribosomal protein L5, putative 641.m00186 
71 40S ribosomal protein S28, putative 25.m02955 
72 small nuclear ribonucleoprotein (snRNP), putative 583.m00614 
73 ribosomal protein L34, putative 42.m03575 
74 60s ribosomal protein L31, putative 57.m01771 
75 adenylate kinase, putative 42.m00116 
76 tubulin beta chain, putative 41.m00036 
77 hypothetical protein 55.m10265 
78 heat shock protein 70, putative 583.m00009 
79 eukaryotic translation initiation factor 3, putative 83.m01278 
80 histone H2A 145.m00002 
81 calmodulin-related 50.m03141 
82 40S ribosomal protein S24, putative 33.m01367 
83 trypsin, putative 55.m05020 
84 histone H4, putative 49.m03134 
85 hypothetical protein 83.m01280 
86 articulin 4 41.m00021 
87 RNA recognition motif domain-containing protein 645.m00319 
88 hypothetical protein 80.m02161 
89 dense granule protein 7 20.m00005 
90 hypothetical protein 55.m05052 
91 hypothetical protein 583.m05686 
92 hypothetical protein 39.m00367 
93 myosin light chain (TgMLC1) 55.m00021 
94 60S ribosomal protein L10, putative 80.m00017 
95 hypothetical protein 83.m00011 
96 microneme protein 3 (MIC3) 641.m00002 
97 phosphatidylinositol-4-phosphate 5-kinase, putative 583.m05359 
98 60s ribosomal protein l6, putative 583.m05552 
99 DnaJ domain-containing protein 55.m00016 
100 hypothetical protein 49.m05663 
101 40s ribosomal protein s19, putative 28.m00306 
102 hypothetical protein 80.m03946 
103 ribosomal protein S10, putative 64.m00338 
104 inner membrane complex protein (IMC3) 35.m01595 
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105 calmodulin, putative 59.m03455 
106 surface protein rhoptry, putative 583.m00003 
107 conserved hypothetical protein 55.m00267 
108 elongation factor 1-alpha, putative,coding) elongation factor 1-
alpha, putative 
3.m00013 
109 hypothetical protein 44.m04616 
110 40S ribosomal protein S4, putative 25.m00221 
111 u1 small nuclear ribonucleoprotein 70 kda-related protein 20.m03892 
112 hypothetical protein 67.m00007 
113 pfs77-related 44.m00020 
114 acid phosphatase, putative 38.m01061 
115 delta-aminolevulinic acid dehydratase, putative 52.m01619 
116 high mobility group protein 26.m00246 
117 ribosomal protein L32, putative 57.m00005 
118 ATP synthase gama chain, putative 44.m02684 
119 40S ribosomal protein S5, putative 49.m00006 
120 60S ribosomal protein L7a, putative 55.m00280 
121 60S ribosomal protein L7a, putative 583.m05562 
122 hypothetical protein 20.m03934 
123 hypothetical protein 41.m03144 
124 prohibitin-related 44.m00051 
125 caltractin (centrin), putative 50.m03356 
126 DnaJ domain-containing protein 44.m02699 
127 porin, putative 55.m08198 
128 hypothetical protein 583.m05356 
129 ribosomal protein L37a 145.m00001 
130 actin 25.m00007 
131 small nuclear ribonucleoprotein, putative 57.m01848 
132 nucleolar phosphoprotein (nucleolin), putative 80.m02340 
133 EGF-like domain-containing protein 83.m01260 
134 protein kinase domain-containing protein 55.m08191 
135 fas apoptotic inhibitory molecule-related \ lifeguard protein-
related 
583.m00591 
136 hypothetical protein 44.m02570 
137 myosin light chain TgMLC1-related 583.m05420 
138 40S ribosomal protein S26, putative 49.m03356 
139 60s ribosomal protein L33-A, putative 50.m03286 
140 40S ribosomal protein S8, putative 50.m00067 
141 60S acidic ribosomal protein P0 38.m00002 
142 hypothetical protein 44.m02826 
143 protease-related 59.m03479 
144 40S ribosomal protein S11, putative 42.m00125 
145 lysophospholipase, putative 76.m01665 
146 rhoptry antigen, putative,coding) rhoptry antigen ROP8 33.m01398 
147 microneme protein 6 (MIC6) 38.m00003 
148 ribosomal protein S23, putative 44.m02556 
149 RNA recognition motif domain-containing protein 59.m03367 
150 hypothetical protein 31.m00869 
151 hypothetical protein 33.m01359 
152 40S ribosomal protein S21, putative 55.m00116 
153 RNA-binding protein, putative 20.m05985 
154 hypothetical protein 28.m00303 
155 DNA-binding protein HU, putative 42.m00103 
156 ubiquinol-cytochrome C reductase complex 14 kDa protein- 80.m00018 
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related 
157 60S acidic ribosomal protein P1, putative 55.m04872 
158 endonuclease\exonuclease\phosphatase domain-containing 
protein 
50.m03277 
159 DnaJ domain-containing protein 583.m05418 
160 nucleolar phosphoprotein p130, putative 25.m00202 
161 hypothetical protein 583.m05525 
162 conserved hypothetical protein 20.m08222 
163 ras-GTPase-activating protein binding protein, putative 49.m05723 
164 enhancer of rudimentary, putative 72.m00406 
165 phosphoribosylpyrophosphate synthetase, putative 39.m00330 
166 hypothetical protein 57.m03085 
167 conserved hypothetical protein 583.m00625 
168 ribosomal protein L23a, putative 49.m00008 
169 eukaryotic translation initiation factor 3 subunit 7, putative 611.m00038 
170 hypothetical protein 55.m05032 
171 acetyl-coenzyme A synthetase, putative 57.m03124 
172 conserved hypothetical protein 55.m00279 
173 polypyrimidine track-binding protein, putative 80.m00057 
174 centromere\microtubule binding protein, putative 33.m02213 
175 hypothetical protein 46.m01721 
176 eukaryotic translation initiation factor 4E, putative 42.m03276 
177 RNA-binding protein, putative 27.m00080 
178 40S ribosomal protein S15, putative 31.m00922 
179 40S ribosomal protein S15a, putative 46.m00005 
180 conserved hypothetical protein 38.m01082 
181 calcium-dependent protein kinase, putative \ calmodulin-
domain protein kinase, putative 
20.m00372 
182 splicing factor 3A subunit 2, putative 42.m00102 
183 proliferation-associated protein 2G4, putative 69.m00140 
184 60S ribosomal protein L24, putative 49.m00058 
185 histone H3 55.m00013 
186 thioredoxin, putative 50.m00069 
187 hypothetical protein 42.m03543 
188 ubiquitin \ ribosomal protein CEP52 fusion protein, putative 80.m02240 
189 peroxiredoxin family protein\glutaredoxin, putative 76.m01670 
190 hypothetical protein 44.m02644 
191 60S ribosomal protein L18, putative 145.m00327 
192 60S ribosomal protein L10a, putative 33.m01368 
193 retinitis pigmentosa GTPase regulator-related 49.m03185 
194 hypothetical protein 86.m00371 
195 mitochondria-associated granulocyte macrophage CSF 
signaling molecule, putative 
50.m03345 
196 hypothetical protein 25.m02941 
197 60S ribosomal protein L13, putative 55.m00189 
198 conserved hypothetical protein 50.m03340 
199 KH domain-containing protein 35.m00901 
200 60S ribosomal protein L28, putative 44.m04692 
201 hypothetical protein 72.m00399 
202 OTU-like cysteine protease domain-containing protein 44.m02558 
203 60S ribosomal protein L14, putative 57.m01833 
204 ribosomal protein L27, putative 55.m05006 
205 60S ribosomal protein L9, putative 76.m00009 
206 hypothetical protein 583.m05370 
139 
207 hypothetical protein 33.m01384 
208 eukaryotic translation initiation factor 2 alpha subunit, putative 583.m00670 
209 40S ribosomal protein S2, putative 541.m00133 
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Appendix D:  Monitoring parasite cell cycle stages via IFA 
 
For IFA, use antibodies to TgIMC1, TgPCNA, and stain with DAPI 
 
Description of parasite cell stages 
 
Early G1:  small parasites; small, single nuclei with dull DAPI staining 
 
Mid to late G1:  longer parasites; single, central nuclei with dull DAPI staining 
 
S phase:  large parasites; expanded nuclei with bright DAPI staining 
 
Late S phase:  large nuclei shifted to posterior; first indication of internal daughter cells 
development 
 
Mitotic:  posterior nuclei; 10 – 20 % daughter cell development 
 
Late mitotic (telophase):  U-shaped nuclei; 20 – 30% daughter cell development 
 
Cytokinetic:  divided nuclei; single parasite with two nuclei; 30 – 70% daughter cell 
development 
 
Information from personal communication with Dr. Michael White (University South 
Florida) 
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